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Abstract 
 
Many cancers, such as breast cancer, lung cancer, and head and neck cancer, 
preferentially metastasize via the lymphatic system prior to their systemic invasion. 
Conventional chemotherapy has limited penetration into the lymphatics due to its anatomy, 
because drug molecules have to diffuse from the blood capillaries into the surrounding tissues 
and further enter the lymph vessels to reach the diseased lymph nodes. Therefore, chemotherapy 
can be of limited benefit in treating lymph node disease. In addition, due to the systemic 
administration and wide distribution, conventional intravenous chemotherapy causes a variety of 
organ toxicities, including but not limited to:  renal toxicity, cardiotoxicity, and hepatic toxicity. 
This limits its use in the clinic, expecially for the elderly or late-stage patients who cannot 
tolerate systemic toxicities. Therefore, there is a critical need to develop of a localized drug 
delivery platform that confines the anti-cancer drugs to the site of the disease.  
This dissertation focuses on the development of subcutaneously delivered drug  
platforms for the treatment of cancers that are known to be lymphatically metastatic. The goal is 
to improve the anti-cancer efficacy and reduce the non-specific organ toxicities of small 
molecule chemotherapeutic agents. To achieve this goal, three polymer-based anti-cancer 
conjugates:  hyaluronan-cisplatin (HA-Pt), hyaluronan-doxorubicin (HA-DOX), and sugar star 
polymer-nitric oxide prodrug 1 (sugar-NO1), were synthesized, characterized, and evaluated in 
preclinical rodent models.  
The route of drug administration along with the controlled release of the drug from the 
platforms, both play an important role in improving the biopharmaceutical properties of these 
conjugates. This is demonstrated by the extended systemic rentention, as well as the elevated 
local accumulation of the drug in the draining lymph nodes of the tumor, when compared to 
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standard intravenous chemotherapy. The HA-Pt and HA-DOX conjugates exhibited reduced 
renal toxicity and cardiotoxicity, respectively, relative to the conventional intravenous 
chemotherapy in rats. Because of the improved pharmarcokinetic and toxicological profiles of 
the polymer-drug conjugates, animals that were treated with the subcutaneous conjugates 
demonstrated enhanced inhibition of the tumor progression and increased survival rates. To 
understand the increased anti-cancer activity of the conjugates on a cellular level, the interaction 
and internalization of the nanocarriers into tumor cells was also investigated using a gold 
nanoparticle tagged HA-Pt conjugate and a fluorescently labeled HA-DOX conjugate. 
In the clinic, cisplatin and doxorubicin are often administered in combination with other 
anti-tumor agents as a “chemo cocktail” to prevent chemoresistance. Additionally, nitric oxide 
has been shown to improve the cytotoxicity of cisplatin therapy via a synergistic effect. 
Therefore, the development of a nitric oxide prodrug cisplatin combinational therapy, with 
increased anti-proliferative activity against cancer cells, was investigated; and it is also presented 
in this disssertation and compared to cisplatin treatment alone. 
In conclusion, this thesis work has led to the successful preclinical development of two 
localized drug delivery platforms and one promising candidate for the treatment of metastatic 
carcinomas. The motivation for drug delivery scientists to develop more efficacious and less 
toxic chemotherapies will be presented.    
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1. Objectives 
The overall purpose of this study was to develop localized intralymphatic chemotherapy 
methods using polymer-based nanocarriers for the treatment of metastatic cancers, such as breast 
cancer and head and neck cancer. This thesis work can be divided into four parts:  1) 
Development of nanoconjugates for the delivery of cisplatin and nitric oxide prodrugs to the 
head and neck lymphatics of rodents, and the evaluation of the in vitro efficacy of the 
nanoconjugates in head and neck squamous cell carcinoma (HNSCC) cell lines; 2) Development 
of nanoconjugates for doxorubicin delivery to the breast lymphatics of rodents and the evaluation 
of the in vitro efficacy of doxorubicin nanoconjugates in breast cancer cell lines; 3) Examination 
of the safety, long-term toxicity, and efficacy, of lymphatic nanoconjugate chemotherapy in 
rodents and compare these to intravenous delivery; and 4) Assessment of the internalization of 
the carrier and cisplatin/doxorubicin in  cancer cells and murine tumors.  
In this chapter, a series of clinical and investigational applications of localized 
chemotherapy will be presented, with the goal of emphasizing their improvements compared to 
the conventional intravenous chemotherapy. In the following chapters, the development, 
characterization, in vitro and in vivo evaluation, of three polymer-based chemotherapeutic 
conjugates will be described. 
 
2. Localized chemotherapy 
The most common types of cancer therapies include surgery, radiation, chemotherapy, 
and their combinations. In the past decades, new treatment regimens have been discovered and 
implemented in the clinic, to concurrently or successively complement the standard procedures 
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in cancer therapy, and provide patients with improved treatment outcomes and fewer side effects. 
Some of these clinical and investigational treatment methods include antiangiogenesis therapy 
[1-3], immunotherapy [4-6], gene therapy [7-9], bone marrow transplantation, and peripheral 
blood stem cell transplantation [10-12]. Due to the complex nature of the molecular targets of 
these newer therapies and the relatively short history since their clinical introduction, they are 
not as widely used as conventional chemotherapy.  
Most cancer patients will receive some type of chemotherapy during their treatments in 
the form of adjuvant, neoadjuvant, or palliative therapy. Although the first line chemotherapies 
have provided lifesaving treatments for numerous cancer patients, their potential life-threatening 
side effects should not be overlooked. The most severe side effects of chemotherapy are mainly 
caused by the systemic toxicities of the anti-cancer drugs. Because the conventional 
chemotherapy is administered intravenously via a catheter, the cytotoxic drugs travel throughout 
the systemic circulation of the patient and accumulate in his or her healthy organs, such as the 
kidneys, heart, and liver, which eventually cause organ toxicities over time. 
One of the issues with infusion chemotherapy is that the effective dose of conventional 
cytotoxic agents is often greater than or close to the maximum tolerable dose in the patient, 
depending on his or her disease stage and health condition. Therefore, to minimize the systemic 
exposure of the highly toxic chemotherapeutic agents, alternative locoregional drug delivery 
routes have been explored in both preclinical investigations and clinical trials. To date, several 
localized chemotherapies have been adapted into clinical practices, providing cancer patients 
with additional options of therapy with fewer side effects. In this section, six types of localized 
chemotherapy will be described, which include:  isolated limb perfusion (ILP), heated 
intraperitoneal chemotherapy (HIPEC), intrapleural perfusion hyperthermo-chemotherapy 
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(IPPHC), isolated hepatic perfusion chemotherapy (IHP), transarterial chemoembolization 
(TACE), and lymphatic chemotherapy. 
 
2.1 Isolated limb perfusion chemotherapy (ILP) 
Isolated limb perfusion was initially introduced in the clinic in 1958 by the American 
surgeons, Creech and Krementz, as regional chemotherapy, using an extracorporeal circuit for 
the treatment of extremity melanoma [13]. Initially, the ILP procedure was performed at room 
temperature, but this procedure was later modified by Stehlin to be performed as a hyperthermic 
perfusion at 41-43 ˚C [14]. ILP works by temporarily isolating the arm or leg of the patient from 
the circulatory system using a tourniquet, and perfusing a highly concentrated anti-cancer agent, 
such as melphalan, for a short period of time. Typically several temperature probes are inserted 
into the subcutaneous tissue of the patient to monitor his/her body temperature. For example, ILP 
of the leg is performed by making a small incision close to the iliac vein of the patient; a catheter 
is then inserted into the iliac vein where the anti-cancer drug melphalan is perfused (Figure 1). 
Meanwhile another catheter is inserted into the draining artery, where the blood is collected and 
the melphalan solution is allowed to circulate for 1-2 hours. During the perfusion, a tourniquet is 
secured at the base of the leg, preventing the highly concentrated anti-cancer agent from entering 
the systemic circulation and reaching the healthy organs, such as the liver and kidneys. The ILP 
allows 10 to 20-fold higher regional drug concentrations to be administered compared to 
intravenous melphalan chemotherapy; therefore, it often leads to improved disease control, 
especially the malignancy is confined to the limbs. 
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Figure 1. Schematic representation of isolated limb perfusion. Figure originally published on the 
internet. See reference [15]. 
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Koops and Vaglini reported the impact of ILP in a multicenter randomized phase III 
clinical trial, as a preventive chemotherapy for melanoma patients who have a high risk of 
developing regional micrometastases [16]. A total of 832 patients were enrolled in the trial; 53% 
had a primary tumor with a thickness of 1.5-3 mm, and the remainder had a primary tumor 
thicker than 3 mm. The control group had 412 patients, who received a complete excision of the 
primary tumors without chemotherapy. The second group had a total of 420 patients, who were 
treated with hyperthermic ILP of melphalan after the initial resection. At the end of the follow-up 
period (median duration of 6.4 years), it was found that patients who received ILP exhibited 
reduced occurrence of in-transit metastases (control: 6.6% vs. ILP: 3.3%) and regional lymph 
node involvement (control: 16.7% vs. ILP: 1.6%). However, the rate of the occurrence of distant 
metastasis or overall survival was not statistically altered.  
Melphalan was the first and most effective anti-cancer agent utilized in ILP. Due to the 
short half life (tdegradation=50 min) and the severe toxicity of melphalan in local limb tissues, there 
have been a number of clinical trials investigating alternative chemotherapeutic agents. One of 
the agents was cisplatin, which appeared to be effective for the treatment of melanoma in 
preclinical studies. Thompson and Gianoutsos conducted a cisplatin pilot trial in patients with 
recurrent melanoma [17]. Unfortunately, cisplatin ILP failed to demonstrate either disease 
inhibition or improved tissue toxicity, compared to melphalan therapy, in the majority of the 
patients. Another platinum-based cytotoxic agent, carboplatin, was also investigated in clinical 
trials. Even though partial response was observed in some patients, severe local toxicities such as 
motor-sensory neuropathy and oedema, were reported in all patients. The pharmacokinetic data 
demonstrated extremely high drug concentration in the regional skin; hence, further evaluation of 
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carboplatin-related treatment regimens was not warranted [18]. To date, melphalan remains to be 
the most successful anti-cancer drug for ILP in the treatment of localized melanomas. 
Since melphalan became a commonly accepted treatment strategy, combination therapies 
using melphalan and other anti-cancer agents were extensively investigated in the 1990s, with 
the goal of further improving the rate of response and survival. Of these clinical investigations, 
the most successful regimen introduced tumor necrosis factor alpha (TNF-α) into the standard 
melphalan treatment. Eggermont and Lienard simultaneously reported the improved efficacy of 
melphalan and TNF-α combination chemotherapy in multicenter trials for the treatment of both 
melanoma and soft-tissue sarcoma [19-20]. To explore the underlying mechanism that leads to 
the synergistic effect between melphalan and TNF-α, a number of studies were conducted using 
animal xenograft models. Among the hypotheses of the synergism, de Wilt’s explanation was 
widely accepted, in which he and his coworkers discovered that the addition of TNF-α resulted 
in a six-fold increase of melphalan tumor accumulation in a rat model. Hence, it was not 
surprising that the combination therapy increased the inhibition of tumor progression relative to 
melphalan treatment alone [21]. 
Strategies for localized chemotherapy, such as ILP, greatly reduce the systemic side 
effects of anti-cancer agents by confining the drug to the blood capillaries of the tumor-bearing 
limb. Systemic toxicities of melphalan ILP were only observed when systemic leakage had 
occurred due to the incomplete isolation of the perfused artery. A clinical study of 438 melphalan 
ILPs was conducted by Klaase et al. to determine the incidence of systemic leakage and the 
significant factors that caused the leakage [22]. Of all patients who received melphalan ILP, 
12.6% exhibited systemic drug leakage ≥ 1% of the administered drug; additionally, 6.2% and 
1.4% of the patients had 5% and 10% systemic drug leakage, respectively. Since > 90% of the 
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melphalan was confined to limb, the low amount of melphalan that leaked to the systemic 
circulation lead to relatively mild side-effect compare to systemic regimens, for example, 
transient bone marrow depression. The most significant factors associated with systemic leakage 
were determined to be the level of isolation, the diameter of the venous cannula, and the extent 
of the ligation of the perfused iliac vein. 
The emergence of melphalan and TNF-α combination in ILP led to the clinical evaluation 
of the side effects caused by TNF-α systemic leakage. In a trial in the Netherlands, patients with 
recurrent melanoma received ILP of the combination of the two anti-cancer agents [23]. The 
pharmacokinetic data reported a 11.4 to 31.5-fold increase in the systemic TNF-α concentration 
in patients who had drug leakage compared to patients without systemic leakage. Even though 
the systemic concentration of TNF-α was greatly altered, only mild side effects manifested, 
including:  fever, nausea, and grade I/II hepatotoxicity, which represented the common 
toxicities of ILP using melphalan alone. Their findings suggested that the combination of 
melphalan and TNF-α did not cause increased systemic toxicities relative to melphalan treatment 
alone; thus, the combination regimen was recommended for ILP procedures considering its 
improved efficacy. 
Although ILP demonstrated improved efficacy and survival rate in patients with 
melanoma, it is still a complex and invasive procedure. To develop a simpler yet effective 
alternative, Thompson and coworkers at the Sydney Melanoma Unit introduced isolated limb 
infusion (ILI) technique to the clinic in the 1990s [24]. ILI is a low-flow ILP, in which catheters 
are percutaneously inserted into the axial artery and vein of the diseased limb. The solution of a 
cytotoxic agent, such as melphalan, is infused and circulated for 15 to 60 minutes. A tourniquet 
is applied at the base of the limb to prevent systemic drug leakage. Unlike ILP, surgery is no 
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longer necessary for this procedure; thus, the patient recovers quickly after the treatment. A 
number of clinical trials were conducted to evaluate the feasibility and efficacy of this newer 
procedure and compared it to ILP [24-27]. Lindner et al. reported a satisfactory response rate of 
85% for patients with melanoma who were treated with ILI [28]. Of these patients, 41% had 
complete response and 44% had partial response. The response rate is comparable to the reported 
effectiveness of ILP. Another ILI trial conducted by Thompson et al. also demonstrated similar 
results, suggesting that ILI is a less invasive but equivalently effective alternative of ILP [24]. 
Fewer patients (32%) developed severe limb and systemic toxicities compared to the ones treated 
with ILP [29]. This is especially beneficial for elderly patients who cannot tolerate the surgery 
involved in ILP or its associated side effects. In conclusion, ILI appears to demonstrate similar 
effectiveness and a lower morbidity rate compared to ILP.  
 
2.2 Heated intraperitoneal chemotherapy (HIPEC)     
Intraperitoneal chemotherapy was developed by Sugarbaker et al. in the 1980s to treat 
peritoneal carcinomas, including gastric and colorectal cancers, as well as cancers that originated 
elsewhere in the body but have metastasized to the surface or interior of the peritoneal cavity. In 
HIPEC, a heated, high-dose of an anti-cancer drug is circulated for a short period of time through 
the peritoneal cavity (Figure 2). HIPEC is often used as an adjuvant therapy after complete 
resection of the primary malignancies, to eradicate the residue disease at the site of the tumor. A 
clinical trial of patients with gastrointestinal carcinoma reported the advantageous 
pharmacokinetics of HIPEC, in which the median area-under-the-curve ratios of i.p./i.v. were 
determined to be 117 and 22 for 5-FU and mitomycin C chemotherapy, respectively [30].  
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Figure 2. Schematic representation of heated intraperitoneal chemotherapy. Figure originally 
published on the internet. See reference [31]. 
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To justify the addition of HIPEC to the standard procedures of peritoneal cancer therapy, 
clinical trials were conducted to compare the treatment outcome of surgery alone to the 
combination regiment of HIPEC and complete resection in patients with advanced gastric 
carcinomas. In a clinical trial in Japan, 141 patients with advanced gastric cancer along with 
invasion were registered, seventy-one were treated with HIPEC using 5-FU after the complete 
gastric resection, and the remainder received surgery alone [32]. The results revealed greatly 
reduced peritoneal recurrence rate over 7-year follow-up period (27% vs. 47%, p=0.0000847), 
and improved 2, 4, and 8-year survival rates in the HIPEC cohort. 
Besides 5-FU and mitomycin C, other anti-cancer agents have been investigated for 
HIPEC. One of these investigational candidates for HIPEC is oxaliplatin, which is a 
platinum-based anti-cancer agent often used in the intravenous treatment of colorectal cancer. 
Elias et al. conducted a phase II study of oxaliplatin in patients with advanced colorectal cancer 
in France [33]. They reported a prolonged 3-year survival rate of 65%, and 68% of the living 
patients were free of peritoneal recurrence at the conclusion of the follow-up period (18.3 to 49.6 
months). 
Many late-stage cancer patients with unresectable tumors that cannot be effectively 
treated with available therapies receive palliative surgery preceding systemic chemotherapy to 
relieve disease-associated pain and improve their quality-of-life. Verwaal et al. conducted a 
randomized trial in the Netherlands to compare HIPEC of 5-FU-leucovorin in combination with 
aggressive cytoreduction surgery, with the standard treatment regimen of palliative surgery 
followed by systemic chemotherapy, in patients with peritoneal carcinomatosis from colorectal 
cancer [34]. Aggressive cytoreduction is the surgical removal of any detectable microscopic 
tumors or metastases, often by debriding of the intestine and other tissue surfaces within the 
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peritoneal cavity, after the complete excision of the primary tumor. Verwaal et al. reported a 
prolonged median survival period of 22.3 months for patients who received the experimental 
therapy with HIPEC, compared to 12.6 months for patients who received the standard treatment. 
Further, a significant improvement in survival was observed for patients with five or less 
metastatic lesions in the peritoneal cavity, relative to patients who had seven or more metastases 
at the time of the surgery.  
Cytoreduction, also known as debulking, may reduce the rate of recurrence for some 
patient populations. It is not always recommended, because the aggressive resection may result 
in the removal of surrounding non-cancerous tissues, causing severe complications and increased 
mortality. A clinical trial, conducted by Jacquet et al., evaluated the post-treatment complications 
and the major risk factors of the HIPEC-cytoreduction combination procedure in patients with 
peritoneal carcinomatosis from adenocarcinoma of the colon or appendix [35]. The major 
complications included:  anastomotic leaks, bowel perforations, bile leaks, and pancreatitis, 
which resulted in a 35% morbidity rate and 5% mortality rate. The complications were believed 
to be associated with the extent of the surgery, the length of the operation, and the temperature of 
the perfused chemotherapeutic agents [35-36]. To investigate the role of hyperthermia in 
localized chemotherapy, a trial was conducted in patients with colon cancer. The authors 
reported that both normothermic and hyperthermic intraperitoneal chemotherapies were 
clinically safe and feasible. Even though the patients who received the heated chemotherapy 
showed a higher incidence of anastomotic leakage, it was caused by the extensive resection of 
the colon, as opposed to the hyperthermic conditions of the perfusate [37]. 
 
2.3 Intrapleural perfusion hyperthermo-chemotherapy (IPPHC) 
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Since the clinical success of melphalan ILP was recognized, other localized treatment 
strategies have been investigated over the past decades. Intrapleural perfusion chemotherapy, a 
localized therapy for the treatment of pleural disseminated malignancies in the body cavity that 
surrounds the lungs, is one of these newer therapies developed in the 1990s. Pre-surgery, several 
temperature probes are inserted into the intercostal pleura to monitor the temperature of the 
pleural cavity (Figure 3). During the IPPHC procedure, the primary malignancy is first excised. 
Subsequently, an irrigation inlet catheter and a drainage outlet catheter are inserted into the 
pulmonary artery, and a highly concentrated anti-cancer drug, such as cisplatin, is perfused for 
one to two hours. 
To determine the efficacy of IPPHC, a number of clinical trials were undertaken in 
patients with metastatic cancers that had spread to the pleura [38-41]. Matsuzaki et al. reported a 
trial conducted in Japan in which one cohort of patients received intrapleural perfusion of 
cisplatin after the removal of the malignancies, and the other cohort was treated with surgery 
alone [38]. The median survival of the experimental group was 2.3-fold longer than the standard 
surgery treated group (20 months vs. 6 months). Additionally, advantageous pharmacokinetic 
profiles were seen, demonstrated by the increased local concentration of cisplatin in the pleural 
cavity, along with minimal observed clinical complications. A similar clinical study was 
conducted a few years later by the same institution to compare the apoptotic status of the tumor 
tissue, pre- and post-IPPHC with cisplatin. An 8-fold increase in the number of the apoptotic 
cancer cells was detected immunochemically in the post-perfusion tissues compared to the 
untreated tumor tissues pre-treatment [39]. 
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Figure 3. Schematic representation of intrapleural perfusion hyperthermo-chemotherapy.  
Reused with permission from [42]. 
 
 
 
 
 
15 
 
Although intrapleural perfusion is often utilized as adjuvant chemotherapy after tumor 
excision, there is a possibility that a new modality consisting of presurgical IPPHC may provide 
better control of the tumor progression before the surgery is performed. Shigemura and 
coworkers evaluated this new modality in a 2003 pilot study for the treatment of lung cancer 
with carcinomatous pleuritis. A mean survival time of 19 months was reported for patients in the 
IPPHC and panpleuropneumonectomy combination arm [40]. No severe complications were 
observed in the study. Future trials with more patients and a longer follow-up time may be 
warranted to determine whether the new modality is superior to the previous regimen. 
Cisplatin is the most commonly used anti-cancer agent for IPPHC, but mitomycin C is 
also a candidate for this procedure. To evaluate the effectiveness of IPPHC using cisplatin and 
mitomycin C combination treatment, a clinical trial was undertaken in patients with malignant 
pleural disease in France in 2003 [41]. The 1-year and 5-year survival rates of 74% and 27%, 
respectively, were reported, over a follow-up period of approximately 7.5 years. This 
combination regimen appeared to be especially effective for patients with T1 (“Tumor involves 
same side pleura of the chest wall, with or without focal involvement of the pleura on the outer 
side of lung.”) or T2 (“Tumor involves same side pleura of the chest wall with at least one of the 
following features:  confluent tumor on the outer surface of the lung, involvement of the 
muscles of the diaphragm, or involvement of the lung tissue deeper to the mesothum covering 
the lung.”) mesothelioma [43], indicated by a median survival of 41.3 months. Therefore, patient 
staging and selection play a significant role in the design of a successful clinical trial for 
locoregional therapy. 
 
2.4 Isolated hepatic perfusion chemotherapy (IHP) 
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Locoregional chemotherapy for the treatment of unresectable liver cancers was first 
developed by Ausman in 1961 as an isolated hepatic perfusion technique [44]; which isolates the 
hepatic blood flow from the systemic circulation and directs anti-cancer drugs through the 
hepatic artery and vein. Unresectable liver carcinoma and hepatic metastases disseminated from 
colorectal cancer and ocular melanoma are lethal diseases with a survival time of merely several 
months despite aggressive treatment. IHP offers the advantage of circulating a highly 
concentrated anti-cancer drug solution through the tumor-bearing liver. Because the maximum 
delivered dose is limited by the tolerance of only the liver, as opposed to the whole body, usually 
a much higher concentration of perfusate can be administered compared to intravenous 
chemotherapy. The most commonly used anti-cancer drugs for IHP consists of melphalan alone, 
melphalan TNF-α combination, or mitomycin C. At the beginning of an IHP procedure, a 
laparotomy is performed to locate the hepatic artery and vein for the insertion of the irrigation 
inlet catheter and the drainage outlet catheter. The gastroduodenal artery is cannulated for the 
insertion of the inlet catheter, and the retrohepatic inferior vena cava is dissected to position the 
outlet catheter. A perfusion circuit with a roller pump, a heat exchanger, and an oxygenator, is 
secured to perfuse the anti-cancer drug through the liver for an hour [45]. 
To examine the efficacy of this new procedure, Alexander et al. conducted a clinical trial 
of IHP using the melphalan and TNF-α combination in patients with unresectable primary or 
metastatic secondary liver cancers [46]. The patients received a one-hour hyperthermic perfusion 
of melphalan and TNF-α combination. Post treatment, 75% of the patients developed reversible 
hepatic toxicities. At the end of the follow-up period, 3% of the patients showed a complete 
response to the therapy, and 72% of the patients exhibited a partial response. The findings 
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suggested that the melphalan and TNF-α combination therapy might be an effective and safe 
treatment regimen for patients with unresectable liver cancers. 
Whereas ILP requires only a small incision in the tumor-bearing limb, IHP for veinal and 
arterial access requires a laparotomy, thus it is a highly invasive and risky procedure in spite of 
the other advantages offered. To minimize the surgical invasion and reduce complication, the 
IHP technique was modified and adapted to a non-surgical procedure known as percutaneous 
hepatic perfusion (PHP). PHP is a non-invasive alternative to IHP, which delivers an anti-cancer 
drug to the liver at dramatically increased concentrations, with minimum systemic side effects. 
Because of the greatly reduced side effects and elimination of surgery, this procedure can be 
performed repeatedly four to six times within a month interval. During a PHP, an infusion 
catheter is inserted into the femoral artery through the skin and guided to the hepatic artery, and 
then a second catheter is inserted into the femoral artery on the other leg and guided to the 
inferior vena cava (Figure 4). After insertion, double balloons on the catheters are inflated to 
block the normal blood flow to complete the organ isolation. Subsequently, an anti-cancer drug 
is perfused through the liver for 30 minutes. At the end of the procedure, the two balloons are 
deflated and the catheters removed. To evaluate the feasibility and procedure-associated side 
effects of PHP, Ravikumar et al. carried out a pilot study in patients with advanced primary or 
metastatic liver cancers [47]. Patients were treated with percutaneous hepatic perfusion of either 
doxorubicin or 5-FU. In the dose escalation study, the dose-limiting toxicity was determined to 
be leucopenia in patients who received the highest dosage of doxorubicin or 5-FU. One of the 
benefits of PHP is that the procedure only requires an overnight hospital stay, and patients 
recovered quickly after the perfusion. A significant tumor response (> 95% reduction of tumor 
size) was observed in 9.5% of the patients. Because the size of the patient population was small  
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Figure 4. Schematic representation of percutaneous hepatic perfusion. Reused with  
permission from [48]. 
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(23 patients), further randomized trials will have to be conducted to evaluate the efficacy and 
safety of PHO compared to IHP. 
 
2.5 Transarterial chemoembolization (TACE)       
TACE is a localized chemotherapy strategy used for the treatment of unresectable 
primary or metastatic liver carcinomas. It was developed by French surgeons Doyon and 
coworkers in 1974 [49]. Similar to PHP, TACE is another non-surgical approach to deliver 
anti-cancer agents to the liver via catheters that are inserted into the femoral veins. Unlike PHP, a 
TACE procedure does not require the double-balloon catheters. In a TACE procedure, 
drug-encapsulated degradable starch microspheres, liposomes, or other drug particle matrix are 
administered to the liver, to deliver the anti-cancer drug in a sustained release pattern (Figure 5). 
In the meanwhile, these particulates embolize the branches of the hepatic artery; thus, tumor 
deposits are deprived of nutrients and oxygen. Similar to the other locoregional therapies, TACE 
is confined to the tumor-bearing liver; hence, the systemic toxicities of the anti-cancer drug may 
be greatly reduced. 
A nationwide clinical trial of TACE was undertaken in Japan to elucidate the impact of 
TACE on the survival of patients with unresectable hepatocellular carcinoma, which is the most 
common type of liver malignancy [50]. A total of 8510 patients were enrolled in the study, who 
received an emulsion of lipiodol, a contrast agent for in vivo imaging, and chemotherapeutic 
agents, such as cisplatin and doxorubicin, preceding the administration of gelatin sponge 
particles. Gelatin sponge particles were resorbable materials first introduced to the clinic in the 
mid 1960s in interventional radiology. The optimal size of gelatin sponge particle is believed to  
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Figure 5. Drug releasing microspheres. Figure originally published on the internet. See reference 
[51]. 
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be 500-1000 microns. After administration, they induce the formation of thrombus, causing 
occluding of the small end-arteries. In this trial, the median survival, 1-year, and 3-year survival 
rates were determined to be 34 months, 82%, and 47%, respectively. The mortality rate of 
treatment-related complications was determined to be 0.5%. Their results suggested that TACE 
may be a safe and feasible treatment modality, laying the foundation for further development to 
improve treatment effectiveness. However, the superiority of TACE over conventional 
intravenous chemotherapy remains controversial due to the mixed clinical results of its efficacy 
in treating liver cancers [52-54]. 
Although TACE is an independent procedure, it can be performed in combination with 
other procedures, such as a percutaneous ethanol injection (PEI), to improve the treatment 
efficacy and overall survival. Allgaier et al. conducted a trial of TACE and PEI combination 
therapy, and they compared it with TACE or PEI alone in patients with inoperable hepatocellular 
carcinoma [55]. The TACE and PEI combination cohort had a median survival of 25 months; 
whereas, TACE and PEI monotherapy cohorts had median survival times of 8 and 18 months, 
respectively. Although TACE-involved treatment modalities have shown some advantages over 
standard intravenous chemotherapy, the rate of procedure-related morbidity and mortality remain 
major issues. A clinical trial conducted by Poon et al. revealed overall treatment morbidities and 
mortalities of 23% and 4.3%, respectively, for patients with inoperable hepatocellular carcinoma 
[56]. The mortality rate was as high as 20% for patients with tumors greater than 10 cm at the 
time of the procedure or serum albumin concentrations lower than or equal to 35 g/L before the 
surgery. Therefore, careful evaluation of prognostic factors and patient selection are key factors 
in the design of successful TACE protocols. 
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In 2002, Camma et al. conducted a computerized meta-analysis of randomized controlled 
trials of TACE conducted between 1980 and 2000 for unresectable hepatocellular carcinomas, to 
evaluate whether the previously reported superiority of TACE is significant relative to other 
conservative modalities [57]. The survival data from the trials involving three intrahepatic 
procedures:  TACE, TAC (transarterial chemotherapy), and TAE (transarterial embolization), 
were compared to the conventional intravenous chemotherapies. TAC and TAE are modified 
TACE procedures. In TAC chemotherapeutic agents are administered without embolizing 
particles, and in TAE particle-based artery-blocking embolizing materials are given without 
chemotherapeutic agents. The authors reported that TACE significantly prolonged the 2-year 
survival rate compared to standard intravenous chemotherapy for patients with unresectable 
hepatocellular carcinoma. However, TACE did not demonstrate significant benefits, in terms of 
efficacy, relative to TAE. Their findings were consistent with the controversial role of 
chemotherapeutic agents in TACE, considering the additional side effects that were caused by an 
anti-cancer drug. The data involved in the meta-analysis was generated from the trials of TACE 
using 5-FU as the anti-cancer drug. Further analysis using data from trials involving other 
chemotherapeutic agents may be informative in elucidating the impact of TACE over other 
therapy modalities. 
 
2.6 Lymphatic chemotherapy 
 
2.6.1 Overview of lymphatic drug delivery 
The lymphatic system is a part of our immune system. The immune system is responsible 
for collecting and removing interstitial fluid from tissues; transporting fatty acids and vitamins to 
23 
 
the circulatory system; and carrying antigen-presenting cells to the lymph nodes via the lymph 
fluid, when an immune response is simulated by an invading microorganism. The lymphatic 
system is a unidirectional network that is comprised of lymph, lymph capillaries that carry the 
lymph, and connecting lymph nodes. The lymph fluid originates from the interstitial fluid, travels 
through the lymph vessels, and is filtered by the lymph nodes, before it ultimately returns to the 
circulatory system via the right or the left subclavian veins. Unlike the circulatory system, 
lymphatic system is unidirectional, and is regulated by a valve mechanism (Figure 6). The 
one-way valves are located in both afferent and efferent lymph vessels, and they move the lymph 
from one segment to another segment due to segmental contractions. Additionally, lymph flows 
slowly, because the lymphatic system lacks a “pump”, such as the heart, to force the fluids to 
circulate. Similar to blood capillaries, lymph capillaries branch into every part of our body 
except for the brain; therefore, tumor cells may use the lymphatic system in their initial 
non-hematological spread.  
When a primary tumor mass develops, it secretes lymphangiogenic cytokines that induce 
the formation of new lymph vessels [58]. The tumor cells invade the new lymph vessels and 
follow the lymph until entering the nearest draining lymph node, the sentinel lymph node, via the 
subcapsular sinus. The sentinel lymph node can trap the cancer cells, but if it does not 
successfully destroy the cancer cells, it may become the site of a secondary tumor and pass the 
tumor cells to the next draining lymph node. Ultimately, tumor cells may travel to the circulatory 
system and deposit in healthy organs resulting in the formation of distant metastases (Figure 7) 
[59]. Because lymphatic system plays a critical role in cancer metastasis, it has been recognized 
as a target for localized approaches to treat cancers that spread via the lymphatics, such as breast 
cancer, lung cancer, ovarian cancer, and head and neck cancer. 
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Figure 6. Open and closed valves. Figure originally published on the internet. See reference 
[60]. 
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Figure 7. Cancer spread from primary tumor to draining lymph nodes. Figure originally 
published in [59]. Reused with permission. 
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The subcutaneous tissues contain a rich supply of lymph vessels, so they have become 
the most widely route used for delivering lymphatic-targeted chemotherapeutic agents in 
preclinical trials. The fate of subcutaneously injected materials depends on a variety of factors, 
including the size, charge, and immunogenicity. The optimal size range for lymphatic drainage is 
believed to be 10 to 100 nm. Molecules smaller than 10 nm mainly enter the systemic circulation 
through blood capillaries via diffusion; whereas, molecules larger than 100 nm have substantial 
local retention at the injection site. Therefore, molecules of 10 to 100 nm may be good 
candidates for subcutaneous injections for lymphatic drug delivery. Further, neutral or anionic 
materials were shown to demonstrate better lymphatic uptake compared to cationic materials 
[61]. This is likely due to the enhanced macrophage uptake and the subsequent lymphatic 
drainage of the neutrally or negatively charged particles. The interior wall of the lymphatic 
lumen bears negative charges; thus, the charge repulsion between the wall of the lymph vessel 
and the surface of the subcutaneously injected materials causes them to move faster towards the 
draining lymph nodes. Because most of the first-line cytotoxic drugs are small molecules, 
carriers that can deliver small-molecule drug cargo to target the lymphatics are of great interest 
to drug delivery scientists. The candidates in this category include a variety of biodegradable 
polymers [62-64], liposomes [65-67], micelles [68-69], and nanoparticles [61, 70] (reviewed in 
section 2.6.2 “Lymphatic drug delivery using engineered liposomes and solid lipid 
nanoparticles”). Anionic particles move faster in the interstitium because the internal wall of 
lymphatic lumen is slightly negatively charged. Charge repulsion makes it move faster. Charge 
may trigger macrophage uptake and drainage 
Subcutaneous administration of these drug-loaded nanoformulations usually leads to 
enhanced accumulation and retention of the drug in the draining lymph nodes, in preclinical 
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animal models. These conjugates also take advantage of their controlled drug release properties 
to alter the pharmacokinetics of the anti-cancer drugs, by reducing the peak plasma 
concentration, as well as prolonging the systemic retention. The modified pharmacokinetics may 
further translate into an improved safety profile, by reducing the Cmax-associated systemic side 
effects of the drug. In addition, a number of xenograft models suggest that subcutaneously 
injected carrier-based drug conjugates resulted in better treatment efficacy and survival 
compared to the conventional intravenous chemotherapy.  
To demonstrate the previous statements in detail, the development, characterization and 
evaluation of such polymer-based drug conjugates will be presented in chapters two through five 
of this dissertation.  
 
2.6.2 Lymphatic drug delivery and imaging using engineered liposomes 
A wide spectrum of cancers, including breast, lung, and head and neck squamous cell 
cancers, metastasize through lymphatics to enter systemic circulation and develop secondary 
tumors.  The lymphatics and sentinel lymph node, the first tumor draining lymph node, play a 
significant role in early stage diagnostics and subsequent therapies. Lymphatic delivery of drug 
encapsulated liposomal formulations has been investigated extensively in the past decade. A 
liposome is a vesicle containing lipid bilayer, composed of unimers which usually have a 
hydrophilic head and a hydrophobic tail and oriented so that the hydrophobic headgroups are 
inside the bilayer. Hydrophilic, lipid-insoluble drugs, or DNA can be encapsulated in the 
aqueous core within the liposome to improve their stability or bioavailability, compared to the 
free drugs or DNA. Current research on the lymphatic retention and imaging of subcutaneously, 
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intestinally, and pulmonary administration of engineered liposomes is discussed in this section. 
The primary improvements over conventional therapy are summarized in Table 1. 
Traditional liposomal formulations utilize the encapsulation of anti-cancer drugs into 
liposomes for intravenous infusion for the treatment of various types of cancers. Doxil, a 
pegylated liposomal doxorubicin chemotherapy formulation, is widely used as first-line therapy 
of AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors [71-75]. 
The primary advantages of systemic liposomal chemotherapy encompass reduced side effects 
compared to the standard therapy, and prevention of the anti-cancer drug from enzymatic 
digestion in the systemic circulation. Another characteristic of pegylated liposomes is that their 
size can be adjusted through the modification of the PEG chains or lipid bilayer core of the 
carrier, promoting its potential use as a drug delivery vehicle to the lymphatics after 
subcutaneous injection [76].  
In 2007, Moghimi et al. proposed that subcutaneously injected pentameric IgM may 
facilitate the lymphatic drainage and enhance lymphatic retention of IgG1-PEG-liposome 
conjugates; presumably attributed to the binding between IgM and macrophage Fc receptors in 
the draining lymph node sinuses, promoting the effective trapping of the therapeutic peptide or 
protein bound immune-PEG-liposomes [77]. In their previous study, they reported that pegylated 
immune-liposomes had more rapid lymphatic drainage from the injection site to the surrounding 
lymphatics due to the hydrophilic nature of the PEG moieties [78]. In their later study, they 
proved that concomitant administration of monoclonal IgM against rat IgG1 adjacent to the 
injection site of IgG1-PEG-liposomes could further enhance the lymphatic retention of the 
liposomal conjugates. It may be ascribed to the formation of IgM antibody-mediated vesicular 
aggregates in the lymphatic vessels. Harrington et al. reported improved delivery of anticancer 
drugs to tumors using pegylated liposomes as vehicles for intratumoral and subcutaneous  
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Route of administration Improvement over standard therapy References 
Subcutaneous Enhanced lymphatic retention [76-79] 
Intestinal Increased bioavailability and stability [80-81] 
Pulmonary Improved lymphatic penetration [82-83] 
 
Table 1. Summary of primary improvements of engineered liposomes over conventional therapy 
in vivo. 
 
 
 
 
 
 
 
 
 
30 
 
injection [76]. The authors compared the pharmacokinetics and tissue distribution, of 
subcutaneously or intratumorally injected pegylated liposome-encapsulated 
111
In-labeled 
diethylenetriaminepentaacetic acid (IDLPL) with the unencapsulated IDLPL. The encapsulated 
form increased the carrier residence time and concentration in the head and neck tumors and 
their nodal metastases (both inguinal and axillary lymph nodes) in a nude mouse xerograph 
model, yielding a 11.6-fold increase in the area-under-the-curve (AUC) (96 hours). 
A major issue of conventional liposomal formulations is that liposomes are poorly 
retained in the draining lymph nodes following injection (<2% injected dose). In order to 
enhance the retention of liposomes to lymph nodes, Phillips et al. developed an avidin activated 
biotin-coated liposome, resulting in prolonged lymphatic retention and extended lymph node 
localization, in an experimental rabbit model [79].  Biotin-coated liposomes were injected 
subcutaneously into both hind feet of rabbits, followed by an adjacent subcutaneous injection of 
avidin, causing the formation of liposomal aggregates in the lymphatic vessels. Twenty-four 
hours post injection, the retention of the liposomes was increased by 7.1 and 6.7-fold in the 
popliteal nodes and iliac nodes, respectively.  
Intravenous liposomal doxorubicin (i.e. Doxil) has substantially improved 
pharmacokinetics compared to doxorubicin via the intravenous route, including improved AUC 
and half life. Ling et al. compared subcutaneous administration of liposomal doxorubicin with 
the standard intravenous doxorubicin treatment in a rabbit breast cancer model [84]. Female New 
Zealand rabbits were inoculated with VX2 carcinomas and treated three times with 1-mg/kg 
(doxorubicin equivalent) of subcutaneous liposomal doxorubicin, intravenous adriamycin, or 
saline, once the axillary lymph nodes reached 5 mm in diameter. Two days after the completion 
of the treatment, the nodal volume was measured and compared between different treatment 
groups. Data revealed that the liposomal doxorubicin treatment and intravenous doxorubicin 
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decreased the nodal volume by 57% and 27%, respectively, and increased the number of 
apoptotic cells by 3.2- and 2.0-fold, respectively, compared to the saline control. The 
subcutaneous administration of doxorubicin demonstrated a more robust inhibitory effect in 
relative to systemic doxorubicin, with a p value equals to 0.002 between the two treatment 
groups. Site inflammation including allergy and skin ulceration was not observed, likely due to 
the low dose of the drug administered, as well as the relatively short treatment period. In 
summary, the liposomal doxorubicin treatment exhibited effective inhibition of tumor 
progression and induction of apoptosis of metastatic cells, which may be a promising method for 
the treatment of node-positive advanced breast cancer.  
The lymphatic administration route can also improve access to the systemic space and 
improve plasma pharmacokinetics compared to intravenous formuations. Trubetskoy et al. 
showed that subcutaneously injected liposome-encapsulated drugs can be absorbed into systemic 
circulation in response to manual massage of the injection site [85]. A five minute manual 
massage could induce release of up to 40% of the subcutaneously injected 200-nm 
111
In-angiotensin II incorporated PEG-liposomes (made with egg phosphatidyl choline). In 
addition, when compared to the unmodified liposomes, the PEG-shielded liposomes had 
increased blood localization due to the reduced uptake by the lymph node macrophages. During 
the observation period of 45 minutes, the blood concentrations of the radioisotope-labeled, and 
drug-incorporated PEGylated liposomes remained constant, whereas the concentration of the 
plain liposomes decreased shortly post massage. The authors also suggested that the drug release 
pattern and the pharmacokinetic profile of the formulation could be modulated though the 
modification of the liposomal surface structure.  
Oral delivery of therapeutics is the most convenient and widely employed route of drug 
delivery. However, a number of drugs exhibit poor oral bioavailability due to the degradation of 
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the active drugs in the gastrointestinal tract. The pH of stomach fluid may go as low as 1.0 in the 
fasted state and increase to 3.0 to 4.0 in the fed state. The extremely acidic environment 
facilitates the degradation of orally administered drugs. In the 1970s, liposomal formulations 
were developed as oral drug delivery carriers, shielding the labile drugs from the acidic 
environment via reduced rate of degradation and increased extent of uptake. Orally administered 
drug-incorporated liposomes enter the systemic circulation via the portal vein and intestinal 
lymphatics. Drugs entering the portal vein pass through the liver and undergo first-pass 
metabolism. However, drugs entering the intestinal lymphatic through the intestinal lumen first 
migrate to the lymphatic vessels and draining lymph nodes before entering systemic circulation; 
therefore, avoiding the liver and first-pass metabolism. Lymphatic uptake of therapeutics via the 
intestinal route plays a role in the increased bioavailability of a number of drugs [86].  
Intestinal absorbability and stability are the primary formulation concerns when 
delivering drug-encapsulated liposomal formulations orally. In the 1980s, Hashida et al. studied 
the in vivo absorption characteristics of liposome-encapsulated carboxyfluorescein as a model 
liposomal drug and compared the plasma and lymph concentration profiles of the released 
carboxyfluorescein to that of the free dye [80]. There were no statistically significant differences 
in both the plasma and lymph between the two formulations, suggesting drug-encapsulated 
liposomes exhibited poor absorption across the intestinal mucosa. However, co-administration of 
lipid-surfactant mixed micelles greatly enhanced the permeability of the drug-trapped liposomes. 
This inductive effect was likely due to the interaction between the lipid-surfactant micelle and 
the lipid bilayer of the intestinal cell membrane. 
A number of hydrophilic drugs exert poor lymphatic transport due to their low intestinal 
bioavailability, limiting their use in the clinic. In 2006, Ling et al. evaluated a liposome system 
for oral delivery of a poorly bioavailable hydrophilic drug, cefotaxime, in a rat model by 
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comparing three forms of the drug:  liposomal formulation, aqueous free drug, and a physical 
mixture of the drug and liposomes [86]. The data revealed that the liposomal formulation of the 
drug exhibited a 2.7-fold increase in its oral bioavailability compared to the aqueous dosage, and 
a 2.3-fold increase for the physical mixture. In addition, they also reported that the liposomal 
formulation lead to a significant enhancement of the lymphatic localization of the drug relative to 
the other two formulations. Therefore, liposome systems may be useful carriers for poorly 
bioavailable hydrophilic drugs, promoting their lymphatic transport in the intestinal lymph as 
well as their systemic bioavailability. 
Oral delivery of DNA vaccination remains a challenge due to the unsatisfactory stability 
of DNA vaccines and the need to induce an immunological response after immunization. Perrie 
et al. reported a novel liposome-mediated DNA vaccination using a dehydration-rehydration 
method, encapsulating plasmid DNA encoded for an enhanced green fluorescent protein into the 
liposomes [81]. Stability studies in a simulated intestinal media suggested the dehydration- 
rehydration vesicles incorporating the DNA (DRV-DNA) had a greater intestinal stability 
compared to the small unilamellar vesicles (SUV-DNA). In addition, the DRV-DNA, when 
administered orally in a mouse model, invoked a greater and longer IgA response compared to 
the naked DNA, suggesting a prolonged DNA retention and improved DNA protection of the 
DRV-DNA formulation. 
The respiratory system consists of an upper respiratory tract, including the nose, nasal 
cavity, and pharynx; and a lower respiratory tract, including the lungs and trachea. The lungs are 
rich in lymphatic vessels, and a series of lymph nodes encompassing the hilar, mediastinal, 
carinal, and aortic nodes. Therefore, the lymphatics and lymph nodes can be readily accessed by 
pulmonary delivered aerosolized formulations [87]. 
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Chemotherapy delivered by the pulmonary route could concentrate anticancer drugs in 
the lungs and draining lymph, while avoiding significant issues associated with systemic 
chemotherapy including serious non-target toxicities, poor drug penetration into the lymphatic 
vessels and surrounding lymph nodes, and first pass clearance in the case of orals. Latimer et al. 
investigated the feasibility of delivering liposomal formulation of paclitaxel and a vitamin E 
analog (α-TEA) in an aerosol for treatment of murine mammary tumors and metastases [82]. The 
pulmonary delivery of sequential combination treatments significantly decreased the mammary 
tumor burden compared to controls as well as the individually administered liposomal drugs. In 
addition, the aerosolized combination regimen reduced the total number of cells staining positive 
for cell markers CD31 and Ki67, suggesting an improved inhibition of lymphatic and pulmonary 
metastases. In a similar study, Lawson et al. compared the anti-proliferative efficacy of a 
dilauroylphosphatidylcholine liposome delivered 9-nitro-camptothecin (9-NC), α-TEA, and a 
combination therapy of 9-NC and α-TEA in a metastatic murine mammary tumor model. Each 
individual treatment and the combination treatment was encapsulated in liposomes and delivered 
via an aerosol to treat lung and the surrounding lymph node metastases. The Ki-67 
immunostaining results revealed that there were less proliferative cells present in the animals 
treated with the combination therapy compared to the animals treated with 9-NC alone. 
However, there were no statistically significant differences between the 9-NC + α-TEA group 
and α-TEA group alone. All three treatments (9-NC alone, α-TEA alone, and 9-NC + α-TEA) 
showed elevated number of apoptotic cells by TUNNEL assay, when compared to the empty 
liposome control group. In addition, the in vivo anti-cancer efficacy studies demonstrated the 
combination treatment greatly hindered the tumor progression compared to each treatment alone, 
leading to the prolonged survival rate. [88].  
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Another application of pulmonary delivered liposomal formulations is to visualize deep 
lung lymphatic drainage after incorporating radioactive markers such as 
99m
Tc into liposomes. 
Botelho et al. administered an aerosolized formulation of nanoradioliposomes to wild boars, and 
successfully visualized their deep lymphatic lung network and surrounding lymph nodes (Figure 
8) [83]. The technique provided new information into the complex structure of the lymphatic 
network, which was not available through the use of conventional CT. In addition, it has become 
a new and non-invasive molecular imaging technique for the diagnosis of early dissemination of 
lung cancers.  
Twenty-one therapeutic monoclonal antibodies have been approved by the FDA for 
immunological and oncological targeting since 1994, most of which belong to the IgG1 family. 
Lymphatic delivery of liposomal antibody formulations offers advantages over other routes due 
to the enhanced cellular uptake of the antibodies and the prolonged localization of the liposomal 
conjugates, resulting in improved efficacy. In 2004, Cui et al. developed a mannan-coated 
liposome protamine-DNA (LPD) nanoparticle formulation based on their previous studies of 
LPD nanoparticles [89]. The in vitro uptake of the mannan-coated LPD by antigen-presenting 
cells, DC2.4, was evaluated and compared to non-coated LDP. The data revealed that the 
mannan coating significantly enhanced cellular uptake of the nanoparticles by targeting the 
antigen-presenting cells; therefore, it may be a potential carrier for the delivery of 
biopharmaceuticals. In a separate experiment, they investigated the in vivo immunity of 
mannan-coated LPD against HPV-positive TC-1 lung cancer in C57BL/6 mice, by incorporating 
the major histocompatibility complex class-I (MHC class-I) restricted peptide antigen from HPV 
16 E7 protein. It was reported that both preventive and therapeutic efficacy of the LPD/E7 
formulation was greatly enhanced due to the mannan coating. 
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Figure 8. Thoracic images in posterior view obtained after 
99
mTc-Liposome aerosol inhalation, 
in the pig nº 18. a) 5 min after the inhalation – visualization of hilar draining chains; b) 10 min 
after the inhalation – individualization of hilar draining chains; c) 13 min after the inhalation – 
transdiaphragmatic drainage; d) 30 min after the inhalation – initial visualization of the aortic 
chain ganglia.Figure originally published in [83]. Reused with permission.  
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HIV is life-threatening disease worldwide. Approximately forty-two million people live 
with HIV worldwide, half of which are in African countries. HIV infection in humans causes 
immune system failure, resulting in millions of deaths due to pathogen infections. Therefore, 
anti-HIV treatment regimens are in great need worldwide. Desormeaux et al. described a method 
for the synthesis of PEG stabilized immunoliposomes conjugated to anti-HLA-DR antibodies, 
that effectively delivered indinavir to the lymphoid tissues of female C3H mice for the treatment 
of HIV-1 [90]. The subcutaneous administration of anti-HLA-DR immunoliposomes 
demonstrated a 2.9-fold greater accumulation in the cervical lymph nodes of C3H mice 
compared to the standard liposome formulation. In addition, the PEG stabilized 
immunoliposomes delivered high concentration of indinavir to the lymphoid tissues for at least 
15 days post-injection. A single subcutaneous dose (2 µmol lipids/g tissue) of the sterically 
stabilized immunoliposomes demonstrated a 0.9 to 1.9-fold greater AUC in the cervical, 
brachial, mesenteric, inguinal, and popliteal lymph nodes of C3H mice compared to the 
conventional immunoliposomal formulation. The encapsulation of anti-viral drugs into sterically 
stabilized immunoliposomes introduced a novel drug delivery approach for the treatment of 
life-threatening HIV-1 disease by greatly increasing the drug concentration in the diseased lymph 
nodes. In 2000, Bestman-Smith et al. optimized the anti-HIV liposomal formulations for 
accumulation in lymphoid organs by targeting the primary HLA-DR expressing cellular 
reservoirs of HIV-1. The liposomal formulations of interest were made from a combination of 
dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, distearoylphosphatidylethanol 
amine-N-[poly(ethyleneglycol)-2000], and dipalmitoylphosphatidylethanolamine-N-(4-(p- 
maleimidophenyl)butyryl). They compared four types of liposomal formulations, including:  
conventional liposomes, sterically stabilized liposomes, conventional immunoliposomes bearing 
anti-HLA-DR, and sterically stabilized immunoliposomes bearing anti-HLA-DR Fab’ fragments 
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at the end termini of PEG chains [91]. Greater accumulation of liposomes were observed for the 
PEGylated immunoliposomes compared to the other three treatments in most of the evaluated 
lymph nodes and the spleen in female C3H mouse model; introducing a novel approach to 
concentrate drugs in HIV-1 reservoirs and improve their efficacy. 
Another potential clinical application of liposomal formulations is cancer vaccination. 
Although cancer diagnostic and therapeutic technologies have been greatly improved in the past 
two decades, there is still a critical need for cancer prevention medications, such as effective and 
safe cancer vaccinations. In 2001, Mui et al. reported their study of a liposomal 
nanoparticle-encapsulated oligodeoxynucleotides (ODN)-cytosine-guanine (CpG) formulation 
(LN-ODN-CpG); which demonstrated enhanced stimulatory activity of LN-ODN-CpG against 
the immune response, by triggering the Toll-like receptor 9 in an ICR mouse model. The lipid 
particle carriers were synthesized using distearoylphosphatidylcholine /cholesterol/ dioleoyl-3-N, 
N-dimethylammoniumpropane/1-O-(2’-(ω-methoxypolyethyleneglycol)succinoyl-2-N-myristoyl 
sphingosine with a molar ratio of 20:45:25:10 [92]. In a following study from their group in 
2007, they explored the feasibility of using subcutaneously injected LN-ODN-CpG formulation 
as a cancer vaccine adjuvant along with co-administration of tumor-associated antigens to induce 
antigen specific adaptive immune response in murine cancer models of thymoma and melanoma. 
They also compared the lymphatic uptake of fluorescently labeled free and 
liposome-encapsulated ODN-CpG conjugates. Post subcutaneous injection of either free 
ODN-CpG or LN-ODN-CpG (5 mg/kg on an ODN-CpG basis), mice were sacrificed and their 
draining lymph nodes were excised at pre-determined time intervals. The results revealed that the 
LN-ODN-CpG treatment demonstrated a two to nine-fold increase in lymph node uptake of the 
ODN-CpG compared to the free ODN-CpG, suggesting the possibility of using the liposomal 
nanoparticles as a cancer vaccination for lymphatically metastatic cancers [93].  
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A similar study was conducted by Kojima et al in 2008 using an ovalbumin (OVA) 
-encapsulated oligomannose-coated liposomal (OML) vaccination against OVA-expressing 
E.G7-OVA tumor in a C57BL/6 mouse model. All of the mice previously immunized with the 
OVA-OMLs developed effective anti-cancer immunity and completely rejected the tumor. In 
addition, a single subcutaneous injection of the OVA-OML treatment led to significantly reduced 
tumor progression in tumor-bearing mice [94]. 
There has been a series of clinical trials to evaluate the efficacy and safety of liposomal 
cancer vaccinations [95-96]. A phase IIB trial of the L-BLP25 liposome vaccine was conducted 
in patients with stage IIIB and IV non-small cell lung cancer. The L-BLP25 liposome vaccine is 
a liposome-based peptide vaccine derived from the mucin 1 antigen. In the trial, patients were 
randomly divided into two groups:  the L-BLP25 group, in which patients were treated with 
weekly immunizations of the liposomal vaccine following a single intravenous dose of 
cyclophosphamide; or the control group, in which patients were treated with cyclophosphamide 
alone. Although the results demonstrated a 4.4-month increase in survival for the patients that 
were treated with the vaccination, the difference was not statistically significant [95]. 
Nevertheless, no vaccine-related toxicities were observed in the patients in the L-BLP25 
treatment group. 
Lymphatic system is a complex network, consisting of lymph vessels and lymph nodes, 
which are connected by the lymph vessels. Imaging of the lymphatics plays a role in disease 
discovery and diagnosis. In addition to the conventional computed tomography (CT) technique, 
newer tools such as scintigraphy and lymphography have also been widely utilized in the past 
two decades. Scintigraphy, a valuable tool to capture two-dimensional images of a body 
radiation source after intravenous injection of a readily cleared radioactive chemical into the 
patient, has been used extensively in the past decade for the development and evaluation of 
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gamma-emitting radionuclide labeled liposomal formulations. Pillips et al. reported a series of 
applications of scintigraphic imaging using technetium-99m (
99m
Tc) labeled liposomes [97], 
including examination of bone fracture healing, detection of viral infection, and intraarticular and 
intralymphatic delivery of liposomal formulations. In addition, Phillips et al. also compared a 
series of 
99m
Tc labeled liposomes, including:  
99m
Tc sulfur colloid, filtered 
99m
Tc sulfur colloid, 
filtered 
99m
Tc sulfur colloid with reduced heating time, and 
99m
Tc human serum albumin, in 
rabbits for optimal detection of the sentinel lymph nodes (Figure 9) [98]. Similar radioactive 
imaging techniques may be used for the evaluation and optimization of new radioactive 
liposomes for improved sentinel lymph node diagnostics. 
Lymphoscintigraphy is a relatively new technology, which is only been widely used 
clinically since the 1990s. It is a type of nuclear medicine imaging, generating two-dimensional 
scintigrams of the lymphatic system including lymph nodes and vessels. A radioactive substance 
is administered as an intravenous injection, oral, or pulmonary dosage. The radioactive material 
is taken up by the draining lymph nodes after passing through lymph ducts; in the meantime, it 
generates gamma rays that can be detected by a gamma camera or positron emission tomography 
scanner. It is commonly used as a tool to identify sentinel lymph nodes [99] and diagnose disease 
conditions such as lymphoma [100] and lymphedema [101-102]. In 2002, Plut et al. developed a 
formulation kit by chemically combining a pyrogen-free low molecular weight isosulfan blue 
dye solution and 
99m
Tc labeled liposomes, producing a radioactive blue liposomal formulation 
for pre-surgical injections clinically [103]. This formulation avoids the non-synchronized 
distribution and clearance kinetics of the small molecular weight dye and the radioactive 
liposomes when they are administered separately. In the clinic, patients usually receive an 
injection of a colored dye solution before operation, providing visualization of the lymphatic 
network, followed by another injection of a radioactive formulation. The radiotracer can be  
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Figure 9. Gamma camera images of the lower portion of rabbits following subcutaneous 
injection (0.3 ml) of various [99mTc] liposomes in each hind foot at either 30 minutes, 60 
minutes or 24 hours post injection. The images show the injection site in the hind feet, the 
popliteal node region and iliac node region. (C) 124 nm PEG-liposomes (both feet); (D) 124 nm 
Negative-liposomes (both feet). Figure originally published in reference [98]. Reused with 
permission. 
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detected using lymphoscintigraphy, leading to the identification of draining lymph nodes, 
including the sentinel lymph node. However, the two injections do not occur simultaneously, 
thus causing the differing distribution and clearance kinetics of the two substances. In order to 
overcome this issue and simplify the pre-surgical injection procedure, the kit was developed by 
combining the isosulfan blue dye with the 
99m
Tc labeled liposomes. 
Magnetic resonance imaging (MRI) could become another useful tool for imaging the 
lymphatic system. MRI has the potential to overcome the poor resolution of 
99m
Tc, but 
lymphcentric contrast agents are required to provide clinically useful imaging of the lymphatic 
system. Fujimoto et al. developed gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) 
labeled liposomes using long-circulating palmityl-D-glucuronide liposomes. After a 
subcutaneous injection of the liposomal formulation into the hind feet of rabbits, the popliteal 
lymph nodes as well as the deep retroperitoneal lymph node were detected. The enhanced 
lymphatic liposomal accumulation was likely due to the trapping of liposomes by the 
macrophages [104-106].  
Rapid clearance post injection is the major drawback of liposomal formulations; 
therefore, a liposomal drug delivery system with prolonged retention is of high interest to 
physicians. Avidin/biotin-liposome systems overcome this limitation by forming avidin 
biotin-liposome aggregates after subsequent injections into the primary intraperitoneal of biotin 
coated liposomes followed by avidin [107-108]; thus, retaining the liposomes in the diseased 
tissues and the draining lymph nodes. Zavaleta et al. compared three avidin/biotin-liposome 
systems with different dosing sequences of avidin and biotin-liposomes in a rodent ovarian 
cancer xenograft model [107]. Lymphatic uptake of the liposomes was significantly enhanced in 
the rats treated with the subcutaneous injection of biotin-liposomes 2 hours post avidin injection. 
A similar study was conducted using a slightly modified avdin/
99m
Tc-blue-biotin-liposome 
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system by Medina et al. to target the mediastinal node, and to determine the most effective 
injection site and tissue biodistribution of 
99m
Tc-labeled liposomal formulations in rats [109]. 
The pharmacokinetics and movement pattern of the avdin/
99m
Tc-blue-biotin-liposome 
formulation post intraperitoneal injected was evaluated using scintigraphic imaging. Their results 
suggested that lymph node targeting effect was independent of the cavity in which the 
formulation was inected, however, was closely related to the dosage administered. 
 
2.6.3 Lymphatic drug delivery and imaging using solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are a class of particulate drug carriers [110] made from 
lipids that remain in the solid state at room and body temperatures. Lipids utilized for SLN are 
typically physiological lipids, including: fatty acids, steroids, waxes, mono-, di-, or triglyceride 
mixtures. A wide variety of biocompatible surfactants are used to stabilize SLN; therefore, SLN 
have the advantage of physical stability with low toxicity. SLN are becoming increasingly used 
for the protection of labile drugs from degradation in the body and for controlled sustained 
release [111]. 
The application of SLN formulations for anticancer drug delivery has overcome many 
obstacles commonly seen in conventional cancer chemotherapy, such as limited specificity, high 
toxicity and tendency of drug resistance [112]. Various anticancer drugs, including:  etoposide 
[113], methotrexate [114], and idarubicin [115] have been incorporated into SLN by different 
research groups and evaluated. Conventional administration routes (e.g. intravenous route) have 
shown relatively low tumor uptake [113], due to the hindrance of drug-loaded SLN to access the 
solid tumor [116], and reduced circulation time, due to the fast clearance by mononuclear 
phagocyte system, which in turn decrease the specific targeting effect. For this reason, various 
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alternative application routes, such as duodenal [115, 117-119], subcutaneous [113] and 
pulmonary [120] routes have been studied.  
Drugs with poor oral bioavailability due to low solubility in GI tract or pre-systemic 
hepatic metabolism (first-pass effect) can be incorporated into SLN; allowing transported into 
systemic circulation via the intestinal lymphatics and bypassing first-pass metabolism, enhancing 
the drug bioavailability. A series of studies related to the absorption and distribution of SLN after 
duodenal administration has been carried out by Bargoni, Cavalli, and their colleagues [115, 
117-119]. In one of the above studies [117], 
131
I-17-iodoheptadecanoic acid labeled drug-free 
SLN were administered into the duodenal lumen of fed rats. Transmission electron microscopy 
and photon correlation spectroscopy analysis of the lymph and blood samples indicated that SLN 
were taken up and transported predominantly by the lymphatics rather than by systemic 
circulation, confirming the transmucosal transport of SLN. However, the author suggested that 
the significant difference in the SLN uptake between the lymphatic system and blood was 
probably the result of the totally blocked passage of the SLN from the lymph to the blood, 
because of the designed experimental conditions for sample collection and the physiologically 
impaired transportation and absorption of SLN caused by surgery-related paralysis of the 
intestine of the animals. A later comparison study [118] of the drug release, absorption, and 
distribution, of tobramycin-loaded SLN (tobra-SLN), prepared from stearic acid, 
phosphatidylcholine, and taurocholate, in the plasma and lymph after duodenal administration, 
revealed that the AUC for tobra-SLN was 24-fold higher than intravenous administration of the 
same SLN formulation and 120-fold higher than free tobramycin solution after intravenous 
injection. In addition, this study suggested the potential of SLN as sustained release system, as 
the half-life of tobramycin increased from 57 min (tobramycin solution) to 283 min (tobra-SLN 
45 
 
intravenously administered) to 1371 min (tobra-SLN duodenally administered). The 
enhancement of drug absorption and bioavailability for tobra-SLN after duodenal administration 
was ascribed mostly to the preferred transmucosal transport of tobramycin SLN to the lymph 
compared to the blood.  In a similar study applying idarubicin loaded SLN (IDA-SLN) 
conducted by the same group, the enhancement in drug bioavailability was observed also when 
the IDA-SLN was administered through the duodenal route when compared to the intravenous 
route [115].  
The influence of the subcutaneous route on the tumor uptake and biodistribution of 
drug-loaded SLN was evaluated by Reddy et al [113]. They prepared etoposide -loaded 
tripalmitin (ETPL) SLN radiolabeled with 
99m
Tc, and the ETPL nanoparticles were administered 
subcutaneously, intraperitoneally, and intravenously, to mice bearing Dalton’s lymphoma 
tumors. Gamma scintigraphy and the radioactivity measurements were used to determine 
biodistribution and tumor uptake of the ETPL SLN in the blood and organs. The data 24 hours 
after subcutaneous administration indicated that the ETPL SLN exhibited a noticeably higher 
degree of tumor uptake (8 and 59 fold higher than that of the intraperitoneal and intravenous 
routes, respectively) and reduced build-up in RES organs (i.e. liver, lung and spleen) compared 
to the other two routes.  The tumor concentration of the ETPL SLN one hour after subcutaneous 
injection was 23.3% of that at 24 hours post injection, showing a lower extent of initial uptake 
compared to intraperitoneal and intravenous routes, whose initial uptake ratios were 29.7% and 
48.1%, respectively. The gradual increase in tumor uptake of the drug from the subcutaneous 
injection site after the low initial uptake indicated that the drug-loaded SLN could be used for 
sustained drug release therapy. Therefore, a proximal subcutaneous injection could be proposed 
as the optimal route for lymphatic chemotherapy over intraperitoneal and intravenous routes.  
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Small cell lung cancer represents about 15% of all lung cancer cases, and it can spread 
through the lymphatic system, with intrathoracic lymph node metastasis to about 70% of the 
limited stage patients and to nearly 80% of the extensive stage patients [121]. In the case of the 
other more common type of lung cancer- non small cell lung cancer, greater than 80% of stage 
IV patients showing extensive metastasis to the lymphatics [122]. Since lymphatic drainage takes 
great part in alveolar clearance of foreign materials with submicron size, targeted delivery of 
anticancer drug to the lymphatic from the pulmonary route could be developed. 
Videira et al. [120] evaluated the bio-distribution of inhaled  
99m
Tc-HMPAO- 
radiolabelled SLN (rl-SLN) with an average size of 200 nm, and compared the results with the 
distribution of the free tracer (
99m
Tc-HMPAO) administered via the same route. The gamma 
scintigraphic images showed significant accumulation of the rl-SLN in the lungs followed by a 
high distribution rate into lymphatic tissues and inguinal lymph nodes, through alveolar 
clearance, which indicated that the rl-SLN were mainly cleared from lungs via the lymphatics. 
However, in the case of the free tracer, it was quickly cleared from lungs by the systemic 
circulation. In addition, about 24% of the 
99m
Tc-HMPAO activities still remained in the lungs 
four hours after administration of the rt-SLN, demonstrating a significant degree of retention of 
the intact SLN. This is consistent with the proposed sustained release effect of SLN by Müller et 
al. [110]; who proposed that during the production of SLN, drug molecules were dispersed into 
the solid lipid matrix. Due to the reduced mobility of the drug moiety in the lipid crystal lattice, 
prolonged drug release from SLN can be achieved.   
Although the uptake of SLN into the lymphatic system and the distribution within the 
lymphatics varies with the different administration routes, they are largely determined by the 
physicochemical characteristics of the SLN [123-124], including:  particle size, surface charge, 
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and hydrophobicity of the particles.  When the SLN are injected subcutaneously, the particle 
size becomes the major determinant of lymphatic uptake from interstitial fluid [123, 125]. Due to 
the structure of interstitium, with narrow aqueous channels of about 100 nm in diameter, SLN 
need to be sized between 10 to 100 nm to easily travel through these channels into lymph from 
the injection site. In comparison, particles larger than 100 nm will be retained at the injection 
site, and those smaller than 10 nm tend to undergo re-absorption back into the blood capillaries. 
Support for this size dependency on the lymphatic uptake of colloids was observed in a 
lymphatic uptake and distribution study by Oussoren et al [125] using liposomes. In addition to 
the proper particle size, negative surface charge and hydrophobicity of the SLN have been shown 
to facilitate the lymphatic drainage from the injection site and localization in the lymph nodes 
[123]. 
Solid lipid nanoparticles are complicated colloidal particle systems; the physicochemical 
characteristics of SLN are impacted by the components and the composition, along with the 
intermolecular interactions between the drug loaded and SLN components.  In a study of 
methotrexate (MTX) SLN formulation for oral lymphatic delivery, Paliwal et al. [114] assessed 
the influence of the lipid on the characteristics of the SLN. The SLN were prepared using four 
different lipids (stearic acid, monostearin, tristearin and Compritol 888 ATO) by the solvent 
diffusion method; particle size, zeta potential, shape, drug entrapment efficiency, in vitro release 
profile, and pharmacokinetics characteristics, of the four MTX SLNs were compared. The MTX 
SLN prepared from Compritol 888 ATO, a highly lipophilic atomized mixture of mono-, di-, 
tri-behenates of glycerol, generated the smallest, most uniform SLN with the highest entrapment 
efficiency. The Compritol 888 ATO based SLN (MTX-CA) yielded a 10% higher MTX loading; 
the longer chain length of glyceryl behenate in the Compritol 888 ATO could enhance the 
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intermolecular entrapment of the MTX by interchain intercalation. In addition, the crystal lattice 
of SLN prepared from Compritol 888 is less perfect in comparison with those made from 
relatively pure lipids, thus leaving more space for the drug to be loaded. The bioavailability and 
intestinal lymphatic uptake of MTX SLNs were evaluated after intraduodenal administration to 
albino rats. While all four of the MTX formulations exhibited a significant increase in the AUC 
and lymphatic drug concentration compared to the free drug solution, with MTX-CA having the 
highest bioavailability and lymphatic absorption. The author ascribed these results to the 
MTX-CA having the smallest size and the solubilization characteristics of the mono-glyceryl 
behenate in Compritol 888 ATO. Therefore, the Compritol 888 ATO SLN formulation was 
proposed to be the preferred carrier for oral lymphatic delivery.  However, it is noteworthy that 
the Compritol 888 ATO formulation showed a relatively low negative value for the zeta potential 
(-12mV). A similar finding was observed in the study of  
99m
Tc-radiolabelled SLN [120] using 
the same lipid.  Low zeta potential is an indicator of reduced storage stability, due to the 
possible conversion of the SLN dispersion into a viscous gel; this transformation could be related 
to a change in the lipid crystals [111]. However, this phenomenon could be hindered by addition 
of the proper surfactant and optimizing the lipid concentration.  
The emulsifier composition and concentration influence the partitioning of the drug 
between the oil and aqueous phases during the SLN formation, which has direct effects on the 
SLN quality. For this reason Sanjula et al. [126] compared the physiochemical characteristics, in 
vitro release, and in vivo absorption, of Carvedilol-loaded SLN with varied ratios of poloxamer 
188, a water soluble nonionic emulsifier. They demonstrated that a high concentration of 
poloxamer 188 resulted in reduced drug entrapment efficiency and aggregation of the SLN, 
which in turn decreased the amount of drug that could be released from the SLN, thus lowering 
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the bioavailability. This observation was consistent with a study by the Paliwal et al., who used 
soya lecithin as an emulsifier in Methotrexate SLN [114]. In the latter study, as the amount of 
soya lecithin increased from 1.0% to 1.5%, the drug entrapment efficiency and the percentage 
release of drug decreased. A possible explanation is that when the concentration of the emulsifier 
is above a certain value at which it can sufficiently cover the lipid core, the SLN dispersion is 
stabilized; above this value, the extra surfactant tends to form micelles that entrap the 
hydrophobic drug within their cores. Therefore, the portion of drug that partitioned into the lipid 
matrix decreased, resulting in the reduced entrapment efficiency of the SLN formulation. 
Further, the increased size and aggregation, introduced by the additional surfactant, reduced the 
hydrophobicity of the SLN, thus decreasing the lymphatic uptake [123-124].  
  Adjusting the amount of drug loaded in the SLN can change the physicochemical 
characteristics of SLN, including:  particle size, total particle number, and surface area in SLN 
dispersion. These variations could impact the in vitro release behavior and in vivo 
pharmacokinetic parameters. In a comparative study [119] using three tobramycin loaded SLN 
formulations with different percentages of drug (1.25%, 2.50% and 5.00%), Cavalli et al. found 
that after duodenal administration, the lower the percentage of tobramycin loaded into the SLN, 
the slower the  drug was released, the higher the bioavailability, and the longer residence time. 
The SLN with 1.25% drug loading yielded the smallest particle sizes (less than 100 nm); hence, 
this SLN dispersion had the largest total number of particles in the given volume of SLN 
dispersion. These factors contributed to the prolonged drug circulation. Tobramycin-SLN has 
been reported to be successfully transported by the transmucosal pathway to lymphatic system 
after duodenal administration [117]. In this study, analysis of the lymph and lymph nodes 
showed that the tobramycin concentration was significantly higher in lymph nodes than in lymph 
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after duodenal administration; indicating that the drug retention in the lymph nodes was followed 
by slow drug release to the lymphatic system.   
Lymphatic chemotherapy holds great promise as an alternate therapy for patients with 
metastatic cancers. Despite the advances in cancer prevention and treatment in the past decades, 
recurrence still often occurs after treatment is completed, due to the inability to eradicate disease 
residing in the deep tissues and distant lymph nodes or dose-limiting toxicity of existing 
protocols that prevent patients from receiving full recommended regimens. Lymphatic therapy 
using drug-encapsulated liposomes and solid lipid nanoparticles emerges as a new technology to 
provide better penetration into the lymphatics where residual disease exists. It can be used in the 
clinic either as a neoadjuvant to achieve early disease control, or be administered post primary 
treatment to serve as a cleanup therapy to eradicate micro-metastases and nano-metastases, 
preventing cancer recurrence. In addition, solid lipid nanoparticle formulations provide a number 
of advantages for delivery of poorly water-soluble, unstable, and cytotoxic drugs, to the 
lymphatic system. By optimizing the preparation procedure and choosing the proper 
administration route, significant enhancements in bioavailability and lymphatic uptake can be 
achieved.  
 
3. Overview of thesis 
In section 2 of this introduction, the therapeutic improvements of localized 
chemotherapies have been discussed and compared to the conventional systemic chemotherapy, 
laying the foundation of the following chapters. The hypothesis of this thesis work is that 
locoregional lymphatic delivery of small-molecule chemotherapeutic agents will increase drug 
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concentrations in the tumors and lymph nodes, reducing the progression rate of distant 
metastases, and the overall drug-induced toxicity, compared to the standard intravenous therapy. 
The hypothesis will be evaluated against two types of cancers using two model drug delivery 
platforms in chapters two through five. In the section, the contents of each chapter are described. 
 
3.1 Intralymphatic delivery of hyaluronic acid-cisplatin conjugates for the treatment of 
breast cancer and head and neck cancer 
Chapter two describes the synthesis and characterization of a hyaluronic acid-cisplatin 
conjugate for the subcutaneous delivery of cisplatin to the rodent lymphatics. The in vitro drug 
release kinetics, anti-proliferative activity, pharmacokinetics, and safety of the conjugate, are 
presented. In addition, murine xenograft models of Part A) breast cancer, and Part B) head and 
neck cancer are described for the evaluation of the anti-cancer efficacy of the hyaluronic 
acid-cisplatin conjugate. 
  
3.2 Intralymphatic delivery of hyaluronic acid-doxorubicin conjugates for the 
treatment of breast cancer 
Chapter three provides information on the development and evaluation of a hyaluronic 
acid-doxorubicin conjugate for the localized, controlled delivery of doxorubicin to the breast 
lymphatics. The stability, toxicity, pharmacokinetics, and in vivo anti-cancer efficacy, of the 
conjugate are also discussed. 
 
3.3 Combination chemotherapy 
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Chapter four discusses the development and in vitro optimization of combination 
chemotherapy using cisplatin and nitric oxide releasing prodrugs. To determine the optimal 
dosage and dosing schedule of the combinational treatment, a series of cell-based assays were 
performed in head and neck cancer and breast cancer cell lines. The mechanism that leads to the 
enhanced cytotoxicity of the combination regimens is presented. 
 
3.4 Internalization of nanocarriers into tumor cells 
Built upon the previous three chapters, chapter five focuses on the investigation of how 
carrier-based chemotherapies internalize into tumor cells. The synthesis of a gold tagged 
hyaluronic acid-cisplatin conjugate and a near-IR dye labeled hyaluronic acid-doxorubicin 
conjugate, are described. In addition, this chapter discusses findings regarding the internalization 
and cellular distribution of the carriers using transmission electron microscopy and fluorescence 
microscopy techniques. 
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1. Introduction 
Since the FDA’s approval of cisplatin in 1977 for the treatment of metastatic ovarian 
cancer [1], cisplatin (cis-diamminedichloroplatinum or CDDP) has emerged as the principal 
chemotherapeutic agent for many solid tumors, despite newer platinum drugs with fewer side-
effects. CDDP has a high initial response rate in many cancers including head and neck 
squamous sarcomas, lymphomas, small cell and non-small cell lung, testicular, ovarian, gastric, 
esophagus, and pancreatic cancers [2]. Although not clinically employed as a single agent, 
CDDP is highly active in combination chemotherapeutic regimens for breast cancer [3], but the 
significant dose-limiting toxicity of CDDP has hampered its use in many patients.  
Nephrotoxicity is the most dangerous and insidious of CDDP’s side-effects, exhibited by 
renal tubular inflammation and necrosis, as CDDP is filtered by the kidneys [4]. After 
intravenous administration, CDDP tightly binds to plasma proteins and becomes highly 
concentrated in the plasma compared to other organs [5]. CDDP efficacy is well-correlated with 
the area-under-the-curve (AUC), but not with the maximum plasma concentration (Cmax) [6]; 
however, toxicity is increased by high peak drug concentrations, as seen immediately after bolus 
injection or during short i.v. infusions, further increasing the risk of nephrotoxicity [2]. 
Fractional or metronomic dosing schedules that divide the same total dose of CDDP over several, 
e.g. daily, smaller injections, have been shown to significantly reduce nephrotoxicity and 
ototoxicity [6-7] due to lower peak plasma concentrations. However, metronomic dosing 
requires a more frequent dosing schedule, longer in-hospital stays, and increased care costs 
thereby limiting its use.  
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Locally advanced breast cancer in women remains a challenge for treatment, with current 
multimodality therapy resulting in moderate toxicity both locoregionally and systemically. 
Locoregional relapse of breast cancer can occur in up to 13% of patients, and a complete axillary 
lymphadenectomy can reduce this risk to less than 2% but carries its own surgical risks and 
morbidity including numbness in the upper medial arm, axilla and chest wall; increased 
incidence of skin and wound infections; and painful lymphedema in up to 30% to 50% of 
patients [8-9]. Cytotoxic chemotherapies also have poor penetration to the locoregional 
lymphatics in the breast because of separation of the lymphatics from the systemic vasculature as 
well as lymphatic mono-directional flow [10]. Platinum-based chemotherapy is the most 
commonly used chemotherapeutic in the United States but carries its own morbidity including 
dose-limiting nephrotoxicity and neurotoxicity. CDDP is not commonly used as a single-agent 
treatment for breast cancer although it is a part of several combination regimens, but CDDP may 
have a place in patient populations that have failed to respond to anthracyclines and taxanes. 
Triple-negative breast cancers are commonly resistant to standard regimens, but there is 
increasing evidence that these patients may have increased platinum sensitivity [11]. Recent 
studies report that BRCA1 breast cancers are highly sensitive to platinum regimens because of 
the role BRCA1 plays in DNA double-strand repair [12-13]. Herein, we sought to investigate the 
feasibility of developing a lymphatic drug delivery system to maximize the efficacy and long-
term survival rate of cisplatin-based chemotherapy in treating locally advanced breast cancer and 
to reduce its dosing frequency and the associated patient hospital-stay. The development and in 
vivo evaluation of this cisplatin-based locoregional chemotherapy will be discussed in Part A of 
this chapter.  
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Cisplatin is commonly used as the first-line chemotherapy for head and neck squamous 
cell carcinoma (HNSCC). HNSCC is the sixth most common cancer worldwide, encompassing 
epithelial carcinomas and squamous cell carcinomas, which are characterized by their 
pathological characteristics [14]. Cancer in the head and neck region can arise from soft tissues, 
bones, and a variety of glands in the upper aerodigestive tracts, including:  the oral cavity, 
oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses and salivary glands [15]. 
Approximately 60,000 Americans are diagnosed with head and neck cancer each year. It has 
been noted that according to the  statistics, that the largest group is  head and neck squamous cell 
carcinoma, where malignancies originate in the most superficial layer of the tissues or organs in 
the head and neck region. Early stage (Stage I and II) localized HNSCC has good disease 
prognosis and local tumor control, yielding a stable survival rate of approximately 81% in the 
past decade. In contrast, patients with regional or metastatic disease have a poor survival rate, as 
low as 52% and 26%, respectively, which has improved only slightly in the past twenty years 
[14]. Late stage (Stage III or IV) patients are usually diagnosed with the involvement of multiple 
lymph nodes or distant metastasis. In most cases, the patients have to undergo neck dissection to 
examine the area of tumor lymphatic drainage and excise the diseased cervical lymph nodes in 
the lymphatic basin, preventing further disease recurrence. 
Historically, patients with unresectable HNSCC have been treated with radiation therapy. 
Unfortunately, the five-year survival was unsatisfactory and disease recurrence usually occurred 
within two years after the radiation therapy. For HNSCC patients, there was an imperative need 
for a more effective, and less invasive regimen after ablation of the primary tumor. Therefore, 
concurrent chemoradiotherapy has been readily accepted as a neoadjuvant, as well as an adjuvant 
therapy for better local and regional control of the disease. Platinum-based chemotherapy 
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administered concomitant with radiation therapy has now become the first-line therapeutic 
strategy in the clinic due to the radiosensitizing properties and cytotoxic efficacy of cisplatin [16]. 
Several Phase III clinical trials in locally advanced HNSCC exhibited promising results of a 
three-drug chemotherapy regimen with cisplatin, taxane, and 5-fluorouracil, with improved 
overall survival, particularly for patients with unresectable tumors [17]. However, some clinical 
trials with cisplatin and 5-fluorouracil combinational adjuvant chemotherapy followed by 
radiotherapy, showed only minimal improvements in the disease-free survival and locoregional 
control, in comparison with patients who received radiation therapy alone [16]. In addition, most 
chemotherapeutics, including cisplatin, have poor penetration to the lymphatic basin due to its 
anatomy and mono-directional flow, limiting their efficacy in treating late stage patients. Hence, 
we sought to develop a lymphatic carrier-based platinum chemotherapy for the treatment of 
locally advanced head and neck squamous cell cancer. The development and in vivo evaluation 
of hyaluronan-cisplatin conjugates will be presented in Part B of this chapter. 
 
2. Synthesis and characterization of hyaluronan-cisplatin (HA-Pt) conjugates 
Cisplatin (CDDP) was conjugated to hyaluronan (HA, 35,000 Da) with and without the 
addition of silver nitrate (26 mg) as an activating agent. Typically, HA (100 mg) and CDDP (45 
mg) were dissolved in H2O (20 mL) and stirred in the dark for three days under argon at ambient 
temperature (ca. 25 ºC). The reaction mixture was filtered (0.2-μm nylon membrane) and 
dialyzed against ddH2O (10,000 MWCO; Pierce, Rockford, IL) for 48 h at 4 ºC protected from 
light. Following dialysis, the crude product was concentrated and stored at 4 ºC. 
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The degree of CDDP substitution was determined by atomic absorption spectroscopy 
(AAS) (Varian SpectrAA GTA-110 with graphite furnace). The furnace program was as follows: 
ramp 25 to 80 °C, hold 2 s, ramp to 120 °C, hold 10 s, ramp to 1000 °C, hold 5 s, ramp to 
2700 °C, hold 2 s, cool to 25 °C over 20 s. The graphite partition tube was cleaned every 100 
samples by baking at 2800 °C for 7 s. Argon was used as the injection and carrier gas. 
Cisplatin was highly conjugated to HA, with typical conjugations of 0.25 w/w 
cisplatin/complex using a starting ratio of 0.5 w/w cisplatin/HA. Up to 0.75 w/w 
cisplatin/complex was attempted with decreasing efficiency (Table 1). The conjugation 
efficiency remained the same both in the presence or absence of the activating agent, silver 
nitrate. The AAS produced a linear concentration curve from 10 to 450 ng/mL (R
2
=0.9998), with 
a limit of detection of 5 ng/mL and a limit of quantification of 10 ng/mL (5% standard deviation). 
 
3. In vitro release 
The in vitro release rate of the active hydrated form of the cisplatin (cis-[Pt(NH3)2 
(H2O)2]
+
) from the HA-Pt conjugate was determined in both water and phosphate buffered saline 
(PBS, pH 7.4, 140 mM NaCl) solution. HA-Pt was added to a 10,000 MWCO dialysis bag 
(Pierce, Rockford, IL) and placed in a water or PBS bath and stirred at 37 ˚C. The bath volume 
(3 L) was replaced every 4 h to maintain sink conditions. Samples were taken from the dialysis 
bag at predetermined time points, and the remaining Pt concentration was determined by AAS. 
The release rate of cisplatin from complexes was determined in both phosphate buffered 
saline and water. The Cl
-
 in saline was expected to more rapidly displace cisplatin, increasing the  
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Cisplatin added 
w/w cisplatin/HA 
Conjugated 
w/w cisplatin/HA 
Conjugation 
Efficiency, % 
0.03 0.022 73 % 
0.08 0.040 50 % 
0.15 0.086 57 % 
0.20 0.119 60 % 
0.30 0.149 50 % 
0.40 0.210 53 % 
0.50 0.254 51 % 
0.60 0.263 44 % 
0.70 0.241 34 % 
 
Table 1. Conjugation efficiency of cisplatin to HA. Efficiency calculated as (cisplatin 
added/cisplatin incorporated) × 100%. 
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release rate. The release of drug showed pseudo first order release kinetics with a release half-life 
of 42 h in water and 10 h in physiological saline (Figure 1). 
 
4. Cytotoxicity 
The metastatic human breast cancer cell line MDA-MB-468LN (isolated from patient’s 
lymph nodes), was maintained in modified Eagle’s medium alpha (MEMα) supplemented with 
10% fetal bovine serum, 1% L-glutamine, and 0.4 mg/mL G418 (geneticin). The lymphatically 
metastatic head and neck cancer cell line MDA1986, was maintained in Dulbecco's modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% L-glutamine. 
Additional cell lines included MDA-MB-231, MCF-7 and JMAR, which were maintained in 
DMEM with 10% fetal bovine serum and 1% L-glutamine. Preceding proliferation studies, cells 
were trypsinized and seeded into 96-well plates (5,000 cells/well). After 24 h, CDDP, HA-Pt, or 
HA was added (n=12; 6 or 7 concentrations), and 72 h post-addition, resazurin blue in 10 μl of 
phosphate-buffered saline was added to each well (final concentration of 5 µM). After 4 h, well 
fluorescence was measured (λex 560 nm, λem 590 nm) using a spectroflurometer (SpectraMax 
Gemini; Molecular Devices, Sunnyvale, CA). IC50 was determined as the midpoint between 
untreated (positive) and cell-free (negative) controls for each plate. 
HA-Pt conjugates had similar anti-proliferative activity to free cisplatin in cell culture. 
Toxicity was evaluated in the human breast cancer cell lines MDA-MB-468LN, MDA-MB-231 
and MCF-7 and human head and neck cancer cell line MDA-1986 (Table 2). Two types of HA-
Pt conjugates were evaluated, including HA-Pt formulation with sliver and silver-free HA-Pt  
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Figure 1. In vitro drug release in water and physiological PBS at 37 °C. 
 
 
 
 
 
 
83 
 
 
 
 
 
Treatment/IC50 MDA-MB-468LN MDA-MB-231 MCF-7 MDA-1986 JMAR 
HA > 10 mg/mL > 10 mg/mL > 10 mg/mL > 10 mg/mL Not tested 
CDDP 5 µg/mL 6 µg/mL 6 µg/mL 2 µg/mL 2 µg/mL 
HA-Pt (Ag free) 10 µg/mL 10 µg/mL 11 µg/mL 2 µg/mL 2 µg/mL 
HA-Pt (w/ Ag) 9 µg/mL 4 µg/mL 6 µg/mL Not tested Not tested 
 
Table 2. IC50 values of HA-Pt and CDDP in various human cancer cell lines. 
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conjugates. In all cell lines, there was no significant difference in toxicity between HA-Pt and 
cisplatin. Carrier HA had no toxicity to human cells over the concentration range examined (up 
to 10 mg/mL).  
 
5. Pharmacokinetics and tissue distribution 
Sprague-Dawley rats (female, 200-250 g) were cannulated in the left jugular vein under 
isoflurane anesthesia and were allowed to recover overnight. Animals were then administered i.v. 
CDDP, i.v. HA-Pt, s.c. HA-Pt, or s.c. CDDP (1.0 or 3.3 mg/kg equivalent cisplatin; n=5 for each 
group) under isoflurane anesthesia. Subcutaneous injections were given in the uppermost right 
mammary fat pad of the animal. Whole blood was withdrawn (200 μl) from the cannula at 0, 5, 
30 min, 1, 2, 4, 6, 12, 24, 48 and 96 h, after dosing and was placed into 2-ml centrifuge tubes 
pretreated with heparin. The cannula was washed before and after withdrawal with saline and 
then heparin locked. The whole blood was centrifuged at 17,000 × g for 5 mins, and the plasma 
was frozen at -80 ºC until analysis.  
In the tissue distribution studies, age and weight matched animals were administered the 
drugs and euthanized at the previously stated time-points. The right ipsilateral axilla nodes 
(treated side) (Figure 2), left contralateral axilla nodes (control side), and major organs (liver, 
kidneys, heart, spleen, lungs, brain, muscle, and bladder) were excised; washed with 0.9% saline; 
and stored at -80 ºC until analysis. Typically, a 50 mg tissue sample was digested using 1.5 ml of 
6.7% nitric acid for 2 hours at 80 ºC. After digestion, samples were homogenized (Tissue Tearor; 
BioSpec Products Inc., Bartlesville, OK) and centrifuged. The supernatant and plasma samples  
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Figure 2.  The axial lymph node package was excised after euthanizing animals (white arrows). 
In order to identify draining lymph nodes, 100 uL of patent blue was injected subcutaneously 
into the fatpad and the animal euthanized after 5 min (patent blue was not used in distribution 
studies). 
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were analyzed by AAS as described in the Synthesis section.   
The pharmacokinetics parameters of HA-Pt and CDDP were determined by fitting 
individual animals’ data to a two-compartment model with SAAM II (version 1.2, University of 
Washington) (Table 3). The area under the curve (AUC) of s.c. HA-Pt was 660% greater than i.v. 
CDDP. The plasma half life (t½) of s.c. HA-Pt was 200% greater than i.v. CDDP and 490% 
greater than i.v. HA-Pt. Clearance rates (Cl) of s.c. HA-Pt and i.v. HA-Pt were not significantly 
different, but the total body clearance (Cl) of i.v. CDDP was 590% greater than s.c. HA-Pt. The 
steady-state volume of distribution (Vss) of platinum was greater for the i.v. CDDP than s.c. or 
i.v. HA-Pt. 
The s.c. HA-Pt preferentially accumulated in the draining ipsilateral axillary lymph nodes 
as compared to the i.v. CDDP control (Figure 3); preferential accumulation was still evident at 
48 h post-injection despite an in vitro disassociation half-life of Pt from HA of 10 h. The 
ipsilateral axillary node AUC of HA-Pt when injected locally was 279% greater than i.v. CDDP 
node levels (p<0.001), and the peak node concentration (Cmax) of HA-Pt was 520% greater than 
i.v. CDDP. The relative organ AUCs for i.v. CDDP were kidneys > axilla nodes > spleen > 
liver > bladder > brain > muscle > lungs > heart; for s.c. HA-Pt, ipsilateral axilla nodes > 
kidneys > liver > heart > contralateral axilla nodes > spleen > lungs > brain > muscle > bladder 
(Table 4). CDDP was injected s.c. as a comparision to the nanocarrier HA-Pt. There was no 
apparent increase in concentration in the draining lymph nodes, but the muscle tissue near the 
injection site had the highest platinum concentrate relative to the other tissues. 
The pharmacokinetics of s.c. HA-Pt was greatly altered compared to the same carrier 
administered i.v. or the standard i.v. CDDP formulation. The greatly increased AUC of HA-Pt  
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Parameters Unit CDDP i.v. HA-Pt i.v. HA-Pt s.c. CDDP s.c. 
Vss l/kg 8.310±3.508 0.154±0.038 3.628±0.760 3.585±2.420 
AUC0-inf (µg·h)/ml 14.104±4.570 141.176±38.878 107.122±59.062 56.707±27.102 
Cl l/(kg·h) 0.257±0.097 0.030±0.007 0.037±0.028 21.790±13.749 
Cmax µg/ml 4.025±0.265 59.864±5.504 1.035±0.688 2.713±0.381 
MRT h 5.148±2.510 2.640±1.153 15.497±4.943 15.263±7.554 
t1/2 (β) h 3.568±1.740 1.830±0.800 10.742±3.426 10.580±5.236 
 
Table 3. Pharmacokinetics of formulations. Data were modeled using a two-compartment model 
for individual animals and then averaged for each group (n = 5, average ± STD). 
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Figure 3. Plasma concentration of Pt after i.v. or s.c. injection of CDDP or HA-Pt (3.3 mg/kg Pt-
basis) (Top panel). Concentration of Pt in ipsilateral (right) axillary nodes and contralateral (left) 
axillary nodes after i.v. or s.c. injection of CDDP or s.c. HA-Pt nanoconjugates (3.3 mg/kg Pt-
basis) into the right mammary fatpad (Bottom panel). 
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Tissue AUC0-96 h, μg/g·h Cmax, μg/g (Tmax) 
CDDP  
i.v. 
HA-Pt s.c. CDDP s.c. CDDP i.v.* HA-Pt s.c. CDDP s.c. 
Heart 128 ±8 465 ±23 422±120 1.7±0.1 
(1 h) 
14.7±1.1 
(1 h) 
13.6±8.5 
(4 h) 
Lungs 139 ±7 347 ±13 170±92 2.2±0.1 
(1 h) 
7.5±0.7 
(1 h) 
9.0±6.7 
(4 h) 
Kidneys 291±8 669±28 517±76 4.6±0.4 
(1 h) 
12.3±2.5 
(4 h) 
10.5±3.1 
(4 h) 
Brain 152±11 344±22 341±57 2.3±0.1 
(1 h) 
7.5±2.0 
(4 h) 
9.4±4.2 
(4 h) 
Liver 178±5 495±20 359±33 2.9±0.2 
(4 h) 
10.6±2.2 
(4 h) 
10.8±2.5 
(12 h) 
Spleen 201±7 384±15 299±34 3.0±0.4 
(1 h) 
6.6±0.6 
(4 h) 
8.9±1.6 
(4 h) 
Muscle 151±9 262±15 367±27 2.2±0.2 
(1 h) 
8.5±2.1 
(4 h) 
11.9±5.9 
(4 h) 
Bladder 162±10 194±6 50±38 3.1±0.4 
(1 h) 
2.9±0.4 
(4 h) 
2.0±1.1 
(1 h) 
Ipsilateral axilla  
nodes 
205±12 ** 776±9 312±19 3.3±0.3 
(1 h) 
20.4±1.4 
(1 h) 
1.7±1.0 
(4 h) 
Contralateral  
axilla nodes 
205±12 ** 413±17 60±41 3.3±0.3 
(1 h) 
4.6±0.3 
(4 h) 
5.7±1.3 
(12 h) 
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Table 4. Tissue AUC (average ± STD) and Cmax (average ± STD) of 3.3 mg/kg i.v. CDDP and 
s.c. HA-Pt study groups. Two-way ANOVA analysis revealed study groups (CDDP and HA-Pt) 
differed significantly for all tissues, p<0.001 (n=5). * The first tissue sampling was at 1 hr so a 
Cmax prior to this would not be detected. The first plasma sampling was at 5 mins. ** For i.v. 
CDDP, the bilateral axilla nodes were assayed together. 
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s.c. is consistent with sustained release of platinum by the nanocarrier. This effect may be due 
both to the delayed diffusion of platinum from the s.c. injection site and the slow release of 
conjugated platinum from the carrier as i.v. administration of HA-Pt also resulted in relatively 
large AUC. In a previous study, it was determined that CDDP administered s.c. gives rise to a 
comparable AUC (15), although this known vesicant can be highly inflammatory to tissues, 
which may alter the diffusion rate.  The relatively small Vss and Cl and large AUC of i.v. HA-Pt 
indicates platinum release from the carrier may be slow. CDDP is readily eliminated renally but 
the highly molecular weight of HA-Pt precludes rapid renal clearance. Pharmacokinetic 
modeling suggests the nanocarrier also slowed the rate constant of distribution transfer of 
platinum from the plasma compartment to the tissues, which was approximately 10-fold slower 
for i.v. HA-Pt compared to i.v. CDDP. This was possible due to the ionization state and high 
molecular weight of hyaluronan, which is naturally cleared from the body by lymphatic transport 
into the systemic circulation followed by enzymatic degradation in the liver. CDDP administered 
s.c. did not significantly improve node concentrations, giving slightly lower exposure than i.v. 
CDDP. Indeed, the majority of CDDP administered s.c. was retained in the surrounding muscle 
tissue. Since CDDP is a known vesicant, subcutaneous administration is not a safe and feasible 
option in the absence of a drug carrier such as the hyaluronan nanoconjugate. 
Clinical studies have indicated that CDDP’s severe dose-limiting side-effects are likely 
due to the high peak plasma levels (Cmax) experienced immediately after i.v. administration. 
Recent applications of metronomic dosing regimens have been shown to decrease toxicity 
although they are clinically cumbersome and inconvenient and resulted in increased costs to 
patients [6-7]. Based on our preliminary experience with this delivery system, locally 
administered nanocarrier chemotherapeutics may avoid high peak concentrations due to slow 
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release of platinum from the carrier, with a half-life in saline of around 11 h compared to 4 h for 
the standard CDDP formulation [18], and also as a result of  slow platinum diffusion from the 
tissues or lymph into the systemic circulation after release from the carrier. 
The increased tissue concentrations of platinum achieved with s.c. HA-Pt compared to i.v. 
CDDP carries two potential advantages: (1) This could result in a lower dose of platinum being 
required to achieve the same tissue effect such that the HA-Pt dose may be reduced by several 
fold and still maintain equivalent tissue levels; and (2) maintaining therapeutic systemic 
concentrations of drug is important for utilizing this drug as an adjuvant therapy since it is well 
known that most patients with cancers which have metastasized to the locoregional lymph nodes 
likely have micro in addition to systemic macrometastases. Therefore, this treatment if 
extendable to the clinical situation could potentially replace daily systemic intravenous therapy 
utilizing a less invasive and less-frequent dosing schedule, e.g. weekly subcutaneous dosing as 
compared to current therapy which is daily intravenous infusion, while simultaneously providing 
augmented local drug delivery and exposure over time to the locoregional tumor basin and 
lymphatics. The larger tissue AUC of s.c. HA-Pt may also increase rates of tumor apoptosis since 
a recent study found that a prolonged subtoxic level of CDDP can substantial improve tumor cell 
apoptosis compared to a single high dose [19]. Overall, assuming linear pharmacokinetics, the 
total platinum dose for local HA-Pt therapy could be reduced by 75% while maintaining the 
same systemic and node concentrations of platinum as i.v. CDDP, possibly with lower 
concentrations in the other tissues with the exception of the heart.  
 
6. Toxicology analysis: renal toxicity and ototoxicity 
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Sprague-Dawley rats (35 females) were randomly divided into study groups of 5 animals 
each and dosed: 1.0 mg/kg s.c. HA-Pt (with and without silver; platinum equivalent to 1.0 mg/kg 
CDDP), 3.3 mg/kg s.c. HA-Pt (with and without silver), i.v. CDDP at 1.0 and 3.3 mg/kg, and s.c. 
HA (control; HA equivalent to 3.3 mg/kg HA-Pt). Each animal was administered a single bolus 
dose at the beginning of the 30-day study period. Urine samples were collected every day during 
the first two weeks of the study and every four days during third and fourth week of the studies 
except for the 3.3 mg/kg HA-Pt with silver group, which will be discussed later. In order to 
reduce the morbidity to animals, subjects were housed in metabolic cages for 12 h to collect 
approximately 5 ml of urine and then returned to cages with bedding until the next collection 
period. Urine samples were centrifuged at 17,000 x g for 5 mins and stored in -80 ºC freezer until 
creatinine analysis.  
Urine creatinine was analyzed using the QuantiChrom™ Creatinine Assay Kit according 
to the manufacturer’s instructions (BioAssay Systems, Hayward, CA). The values of the optical 
density were measured using a UV plate reader. Creatinine concentration of the sample was 
calculated as (ODSAMPLE 5 – ODSAMPLE 1) / (ODSTD 5 – ODSTD 1) x [STD] (mg/dL). ODSAMPLE5, 
ODSAMPLE1, ODSTD5, and ODSTD1 are OD510nm values of sample and standard at 5 min and 1 min, 
respectively. [STD] is 50 mg/dl for the urine assay. 
Urine creatinine levels are an indirect indicator of glomerular filtration rate, which can 
indicate changes in renal function and renal toxicity. A decrease in creatinine excretion 
corresponds to decreased renal function and possible renal toxicity or damage. Significant renal 
toxicity was observed in animals that received silver activated HA-Pt nanoconjugate (3.3 mg/kg), 
with a 30% decrease in creatinine excretion apparent at 3 days and a 70% decrease at 4 days 
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(Figure 4). All animals in this group died within one week of treatment due to drug-related 
cachexia. In contrast, the silver-free HA-Pt did not demonstrate significant toxicity, and 
creatinine levels remained near pre-dosing levels throughout the study’s duration. Toxicity as 
measured by creatinine excretion was compared to the previous silver formulation, which had 
not been previously assessed. The silver-free formulations reported here demonstrate 
significantly less renal toxicity. 
It was expected that lymphatic delivery of platinum would reduce systemic tissue 
exposure compared to i.v. CDDP, but s.c. HA-Pt had a much greater AUC than i.v. CDDP in 
most tissues including the kidneys (Table 4). The Vd is affected by the partition coefficient along 
with the tissue and plasma protein binding, which may be different between the parent CDDP 
and the nanoconjugate HA-Pt. However, the urine creatinine studies did not indicate an increase 
in toxicity. The reduction in toxicity could be due to protection of tissues by the nanocarrier; 
hyaluronan is frequently used in the clinic as a rescue therapy after accidental venipuncture by 
intravenous lines. The predominant chemical form of platinum in the kidneys may differ 
significantly between the two formulations as AAS measures only total elemental platinum, so it 
is unknown if the platinum from HA-Pt was detoxified before renal uptake. This could provide 
an explanation as to why the higher accumulated AUC seen in the kidney with HA-Pt was not as 
destructive as i.v. CDDP. CDDP (Pt[(NH3)2Cl2]) is believed to become nephrotoxic after the 
displacement of a single chloride ion, which leads to the conjugation of a positively charged aqua 
ligand and glutathione, followed by a series of metabolic reactions ultimately leading to cysteine-
conjugates that can produce highly reactive thiol species in the proximal tubule cells [20]. Since 
the mechanism of platinum release and metabolism from HA is still under investigation, it is 
unknown if platinum reaching the kidneys from HA-Pt complexes is significantly detoxified  
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Figure 4.  Urine creatinine concentration of animals that received 3.3 mg/kg HA-Pt with or 
without silver or i.v. CDDP (n=5, p<0.05).  
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unlike the free drug in the i.v. CDDP treatment. Future work is to examine the distribution of 
nanocarrier-bound and free platinum at the cellular level in the tissues and tumors of xenografts 
by transmission electron microscopy.  
Cisplatin is known to induce dose-dependent ototoxicity, leading to mostly irreversible 
auditory impairment, primarily in the high frequencies, in both human and experimental animals 
[21-22]. Cisplatin is highly plasma protein bound after intravenous administration. 
Approximately 96% of the drug becomes biologically inactive after it binds to the plasma protein, 
principally serum albumin; whereas the monohydrated fraction of the free drug causes 
ototoxicity and injures the cochlea [22-23]. Cisplatin ototoxicity was likely due to the generation 
and release of reactive oxygen species post exposure of the mechanosensory hair cells to the 
active form of the drug [24]. The use of protective antioxidants was demonstrated to attenuate 
the injuries to the hair cells caused by cisplatin chemotherapy due to a free radical scavenging 
effect [25-27].  
In order to check for ototoxicity from the cisplatin tratments, mice were tested for hearing 
loss.  The hearing loss was measured in nude mice after three weekly doses of CDDP i.v. or HA-
Pt s.c. chemotherapy. Saline was injected via tail vein into a group of control animals. At the 
fourth week, a probe was placed inside the external auditory canal of anesthetized mice and an 
acoustic stimulus was delivered using Smart OAE (Intelligent Hearing Systems, Miami, FL). 
Distortion product otoacoustic emission (DPOAEs) was recorded and graphed. Frequencies 
tested range from 3,000 to 32,000 Hz. The amplitude was recorded in dB SPL (decibel sound 
pressure level). 
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In this study, mice in both the control and treated groups (saline i.v., CDDP i.v. and HA-
Pt s.c.) exhibited otoacoustic emission, which indicated that the cisplatin-targeted 
mechanosensory hair cells in the inner ear region remained functional. However, no statistically 
significant differences were observed between groups, which is likely due to the relatively low 
doses of cisplatin (3.5 mg/kg × 3 wks) that were administered. Zuur et al. reported that low-dose 
intravenous cisplatin chemotherapy caused less acute hearing loss, compared to high-dose 
therapy in a study of 60 patients [28]. Studies at a higher dose or more frequent dosing schedule 
may better reveal the influence of dosing to the degree of ototoxicity. 
 
7. Pathology 
Healthy Sprague-Dawley rats (250–300 g, Charles River) were randomly divided into 2 
groups and administered CDDP intravenously via the tail vein or HA-Pt subcutaneously into the 
mammary fat pad (1.0 mg/kg or 3.3 mg/kg platinum basis, n = 5/group). The animals were 
euthanized after 4 weeks, and the liver, bilateral kidneys, spleen, lungs, heart, right (ipsilateral) 
and left (contralateral) axillary nodes, and brain were excised intact and stored in 80% alcoholic 
formalin solution overnight for fixation before slide mounting. Mounting using hematoxylin and 
eosin (H&E) staining were conducted by Veterinary Laboratory Resources (Kansas City, KS). 
The pathological examination was performed by a blinded board-certified veterinarian 
pathologist (University of Kansas Medical Center, Kansas City, KS).  
At the conclusion of the 30-day toxicity study, animals were euthanized, and a full 
pathological examination was performed. Brain tissue and underlying tissue of the injection site 
were noted to be normal in appearance with no microscopic changes for all study groups. Very 
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mild changes in lymph nodes were detected for high-dose intravenous CDDP (3.3 mg/kg) and 
subcutaneous HA-Pt. Very mild morphological changes were observed in the livers for animals 
receiving both low-dose CDDP intravenously (1.0mg/kg) and low-dose HA-Pt subcutaneously as 
indicated by the presence of mild inflammation in the sinusoids (Figure 5). Mild degeneration 
with some sinusoidal necroses was observed for animals receiving high-dose intravenous CDDP 
and high-dose subcutaneous HA-Pt treatment. Necroses, however, were more severe in the 
intravenous CDDP group. In addition, 60% of animals receiving low-dose intravenous CDDP 
were observed to develop mild renal necrosis including hemorrhage into the renal tubules along 
with tubular edema. In contrast, none of the animals receiving low-dose subcutaneous HA-Pt had 
renal tubular necrosis. Similarly, 4 of 5 (80%) animals receiving high-dose intravenous CDDP 
compared with 1 of 5 (20%) animals receiving high-dose subcutaneous HA-Pt were diagnosed 
with mild renal tubular necrosis. Overall, the pathology studies showed that the HA-Pt 
conjugates had a lower incidence of both renal and hepatic toxicity compared with the 
conventional i.v. CDDP treatment at all dose ranges. Additionally, no neurotoxicity (in the brain 
tissue) or inflammation of injection site (in the underlying muscle tissue) was observed in the 
treated animals. A representative picture regarding the histological status of kidneys, liver, 
lymph nodes, brain and muscle tissue from each treatment group was collected, and diagnosed 
and classified into three categories (Grade 0, Grade 1 and Grade 2 with elevating severity of 
toxicity (Figure 6-10, Table 5).   
 
8. Development of mouse xenograft models for in vivo imaging and efficacy evaluation 
 
8.1 Part A:  development of a breast cancer model for in vivo imaging 
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Figure 5.  Kidneys of the subcutaneous HA-Pt group exhibited a normal appearance except for 
sparse minimal tubular cell necrosis, whereas the intravenous CDDP treatment group had 
pyknotic nuclei and apoptosis in the medullary tubular epithelia cells. Livers of the subcutaneous 
HA-Pt group showed very minor hepatitis, but otherwise appeared normal; whereas the 
intravenous CDDP treatment group had necrotizing lesions and hepatitis. Sprague-Dawley rats 
were injected subcutaneously into the mammary fat pad with HA-Pt or intravenously with CDDP 
(3.3mg/kg). Slides are typical of animals in each study group (n = 5). 
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Figure 6.  Kidney tissue analysis 30 days post injection. Tissues were stained with H&E. (A) 
Animals receiving s.c. injection of HA had normal findings; (B) animals receiving high dose i.v. 
CDDP had degenerative changes, such as pyknotic nuclei in corticomedullary tubular cells; (C) 
animals receiving SC high dose HA-Pt without silver had fairly a normal appearance, except for 
minor foci of the tubular cell necrosis at the corticomedullary junction; (D) animals receiving  
low dose s.c. HA-Pt with silver had widely spread pyknotic nuclei in medullary tubular epithelial 
cells; (E) animals receiving low dose i.v. CDDP had pyknotic nuclei in medullary tubular 
epithelial cells, an increase in dark purple staining suggesting nuclear staining and widespread 
apoptosis; (F)  animals receiving low dose s.c. HA-Pt without silver had normal appearance, 
except for minimal renal tubular cell swelling and degeneration. 
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Figure 7.  Liver tissue analysis 30 days post injection. Tissues were stained with H&E. (A) 
Animals receiving s.c. injection of HA had normal findings; (B) animals receiving high dose i.v. 
CDDP had moderate necrosis; (C) animals receiving high dose s.c. HA-Pt without silver had 
fairly normal appearance except for very mild degeneration; (D) animals receiving low dose s.c. 
HA-Pt with silver had fairly normal appearance except for very mild degeneration; (E) animals 
receiving low dose i.v. CDDP had fairly normal appearance except for very mild degeneration; 
(F)  animals receiving low dose s.c. HA-Pt without silver had normal appearance. 
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Figure 8.  Brain tissue analysis 30 days post injection. Tissues were stained with H&E. (A) 
Animals receiving s.c. injection of HA had normal findings; (B) animals receiving high dose i.v.  
CDDP had normal appearance; (C) animals receiving high dose s.c. HA-Pt without silver had 
normal appearance; (D) animals receiving low dose s.c. HA-Pt with silver had fairly normal 
appearance; (E) animals receiving low dose i.v. CDDP had normal appearance; (F) animals 
receiving low dose s.c. HA-Pt without silver had normal appearance. 
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Figure 9. Lymphoid tissue analysis 30 days post injection. Tissues were stained with H&E.  
Animals receiving (A) s.c. injection of HA; (B) high dose i.v. CDDP; (C) high dose s.c. HA-Pt 
without silver; (D) low dose s.c. HA-Pt with silver; (E) low dose i.v. CDDP; and (F) low dose s.c.  
HA-Pt without silver all had normal lymph node appearance. 
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Figure 10.  Analysis of underlying tissue at the injection site 30 days post injection. Tissues 
were stained with H&E. Animals receiving (A) s.c. injection of HA; (B) high dose s.c. HA-Pt 
without silver; (C) low dose s.c HA-Pt with silver; (D) low dose s.c HA-Pt without silver all had 
normal appearance. 
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Treatment Liver Kidney Lymph nodes 
Low Pt 40% Grade 0, 
40% Grade 1, 
20% Grade 2 
20% Grade 0, 
20% Grade 1, 
60% Grade 2 
100% Grade 0 
Low HA-Pt 20% Grade 0, 
60% Grade 1, 
20% Grade 2 
20% Grade 0, 
80% Grade 1 
60% Grade 0, 
40% Grade 1 
 
High Pt 60% Grade 1, 
40% Grade 2 
20% Grade 1, 
80% Grade 2 
80% Grade 0 
20% Grade 1, 
High HA-Pt 20% Grade 0, 
60% Grade 1, 
20% Grade 2 
20% Grade 0, 
60% Grade 1, 
20% Grade 2 
60% Grade 0 
40% Grade 1, 
 
 
Table 5.  Diagnostic grading of the severity of organ toxicities. 
 
For Kidneys: 
Grade 0: Normal (no symptoms) 
Grade 1: Minimal necrosis 
Grade 2: Mild necrosis (includes degeneration and nuclear pyknosis)  
For Livers: 
Grade 0: Normal (no symptoms) 
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Grade 1: Inflammation (includes granulomas, microranulomas and hepatitis) or inclusions 
-Hepatitis:  inflammation of the liver caused by a virus or a toxin 
-Granulomas: a tumor composed of granulation tissue resulting from injury or inflammation 
or infection. 
-Inclusions: any small intracellular body found within another (characteristic of certain 
diseases) 
Grade 2: Degeneration or necrosis 
For Lymph nodes: 
Grade 0: Normal (no symptoms) 
Grade 1: Mild lymphoid hyperplasia or depletion  
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The MDA-MB-468LN breast cancer cells were trypsinized (0.25% w/v trypsin) and 
prepared in 1X phosphate buffered saline solution at 3 different cell concentrations (10
5 
cells/mL,  
10
6
 cells/mL, and 10
7 
cells/mL). Cells (100 µL) were injected under pentobarbital sedation into 
the mammary fat pad of female nu/nu mice using a 27-G needle through a 5-mm incision (20–25 
g, Charles River). The incision was closed with sterilized wound clips and was removed one 
week later, when the incision had healed.  
Animals developed mammary tumors starting from the third week (Figure 11). The tumor 
size was measured twice a week with a digital caliper. Tumor volume was then calculated 
according to the following equation: tumor volume (mm
3
) = 0.52 × (width)
2
 × length (Figure 12). 
Animals were euthanized before the end of the study, when their tumor size reached 2,000 mm
3
 
or the body score index fell below 2.  
The MDA-MB-468LN cell line was transformed with a green fluorescent protein to allow 
for tumor growth monitoring by whole-body fluorescent imaging, using a CSI Maestro imaging 
system (Version 2.4, Woburn, MA) with a 445- to 490-nm filtered halogen excitation light and a 
515-nm longpass emission filter. The fluorescence was measured in 10-nm bandpass segments 
from 520 to 720 nm, using a cooled CCD camera using autoexposure. Images were then 
spectrally unmixed using the automatic deconvolution tools to limit skin and intestine 
autofluorescence resulting from the chlorophyll in the food (Figure 13). In addition, lymphatic 
metastases were observed after spectrum unmixing in the draining axillary lymph node package 
(Figure 14). 
The drainage and localization of the lymphatic carrier was verified using a HA-Texas 
Red dye conjugate. Before imaging, mice were anesthesized, under isoflurane, and HA-Texas 
Red (10 mg/mL in saline, 20 µL) was injected subcutaneously near the left mammary fatpad of  
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Figure 11.  A nude mouse with a mammary tumor (white arrows). 
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Figure 12. Measurement of tumor size from week 2 to 6. Nude mice were injected with 10
4
, 10
5
 
or 10
6
 cells/mouse (N=5). 
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GFP channel
 
 
Figure 13. Images of lymphatically metastatic breast cancer xenograft before (top panel) and 
after (bottom panel) spectrum deconvolution. Tumor develops 3-5 wks after mammary fatpad 
injection; a primary tumor formed in the draining sentinel node (green arrow) with early 
metastases invading adjacent axillary nodes (white arrows indicating tumor cell clusters in axilla 
region). 
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Figure 14.  A nude mouse with a primary tumor (red arrow) and multiple metastases (white 
arrows) in the draining axillary lymph node package. 
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tumor bearing mice (before injection, Figure 15A). The injection area was massaged gently for 5 
min and fluorescently imaged after 5 and 18 hrs (Figure 15B and 15C). Fluorescent conjugates of 
HA (1 dye/23 HA molecules) drained into the left lymphatic basins after a subcutaneous 
injection into the left mammary fatpad, with no observed bilateral drainage into the right basin. 
After 5 hrs, localization of HA in the nodes surrounding the tumor can be clearly observed 
(Figure 15B).  Most of the carrier has localized in the basin of the tumor at 18 hrs with a lesser 
amount remaining the adjacent axillary node basins (Figure 15C).  
 
8.2 Part A:  evaluation of anticancer efficacy in breast cancer bearing mice 
Three weeks after cancer cell injection, tumors of 50 mm
3
 to 100 mm
3 
were observed, 
and animals were randomly divided into 4 different treatment groups. Treatments including 
saline i.v., HA s.c., CDDP i.v. (3.3 mg/kg), and HA-Pt s.c. (3.3 mg/kg) were administered in the 
third and fourth weeks after tumor cells implantation. The tumor size was measured weekly and 
animal health was closely monitored. 
Control animals showed a standard tumor growth curve at 10
6
 cells/injection with tumor 
volumes exceeding 1,000 mm
3
 at 6 weeks post-inoculation (Figure 16). Animals dosed with the 
HA carrier-only showed no difference from the saline control, confirming the in vitro data that 
HA has no direct anticancer activity. The i.v. CDDP-treated animals showed a tumor growth 
delay of about 3 weeks compared with the controls (P < 0.05) with a median survival of 12 
weeks (compared with 7 weeks in the controls P < 0.01, Figure 16). HA-Pt treated animals had 
an initial delay in tumor growth of 5 weeks (P < 0.01 compared with controls), but this was not 
significant compared with intravenous CDDP; both curves intersected at the 11
th
 week  
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Figure 15.  Nude mice bearing MDA-MB-468 breast lymphatic tumors (expressing green 
fluorescent protein [GFP], panel A) were subcutaneously injected with HA-Texas Red in the left 
mammary fat pad. After 5 hrs and 18 hrs (B and C, respectively), significant HA localization in 
the draining nodes, and it was co-localized with the tumor (GFP-channel in green, Texas Red 
channel in red, blue arrow denotes the injection site). 
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Figure 16.  (A) Tumor volume and (B) survival rate. Treatments including saline i.v., HA s.c., 
CDDP i.v. (3.3 mg/kg), and HA-Pt s.c. (3.3 mg/kg) were administered in the third and fourth 
weeks after tumor cells implantation. 
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postinoculation, with a median survival of 12 weeks as well. However, there was one animal in 
the HA-Pt group who exhibited a complete response to treatment with no measurable tumor and 
survival well exceeding 24 weeks (upper limit of study). There were no complete responders in 
the intravenous CDDP group. 
Lymphatically delivered chemotherapy through a subcutaneous injection is a novel 
approach to drug delivery that has only recently been shown by Dr. Forrest’s group to be feasible 
with CDDP. Nanoconjugation of CDDP to hyaluronic acid not only allows for improved 
locoregional delivery of the drug to the site of greatest tumor burden in the breast and axillary 
tissues, but also decreases the level of renal toxicity associated with this drug. The toxicity data 
show that there is no significant injection site toxicity on pathological analysis, indicating that 
when bound to the carrier, CDDP does not lead to necrosis of the surrounding tissue. It is only 
after the carrier is cleaved from the conjugate by either hyaluronidase or receptor-mediated 
endocytosis (hyaluronan is a ligand for CD44, a receptor that is overexpressed on lymph nodes 
and many cancers including breast cancers and melanoma) that the drug becomes functionally 
active. In the tissue toxicology analysis, both renal and hepatic toxicity was significantly reduced 
in the HA-Pt–treated animals compared with the standard CDDP-treated group. 
The other benefit noted in the HA-Pt nanoconjugate group involved efficacy in tumor 
growth inhibition and response in vivo in breast cancer xenograft. The HA-Pt versus CDDP 
tumor growth curves in Figure 16 showed that both drugs effectively delayed the tumor growth 
in an orthotopic, lymph node metastatic model of breast cancer. The HA-Pt group had an 
improved although not statistically significant arrest in tumor growth (about 2–3 weeks of 
additional delay compared with CDDP and a 5- to 6-week delay compared with controls). What 
was significant was a complete response was seen in 20% of the HA-Pt–treated group and in 0% 
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of the CDDP-treated group (Figure 16). These data support that HA-Pt injected subcutaneously 
in the breast has mildly improved efficacy over standard CDDP injected intravenously.  
With improved efficacy and reduced toxicity with the nanoconjugate formulation in a 
metastatic breast cancer model in vivo, these data provide solid support for completing further 
preclinical proof of concept studies to advance this formulation into clinical applications. The 
benefits of a locally injectable chemotherapeutic over an intravenous infusion include potentially 
lower cost, because the patient does not have to be physically attached to an infusion pump with 
nurse or physician supervision, as well as the ability to deliver CDDP weekly with the sustained 
release properties of the nanoconjugate as opposed to daily administration, used most current 
intravenous protocols. The sustained-release properties of this nanoconjugate provide an 
excellent boost to locoregional tumor tissues, while maintaining therapeutic systemic levels and 
providing promise for potential future use in locally advanced breast cancer, in both the 
neoadjuvant and adjuvant setting. In addition, localized therapy may be an effective addition to 
systemic therapy in patients with metastatic disease; localized therapy can provide a higher dose 
of chemotherapeutic to the most vulnerable tissues than what is possible with systemic therapy 
alone.  
Other published and ongoing studies have shown that HA-Pt given locoregionally 
provides adequate systemic levels of CDDP, including serum area under the curve levels greater 
than intravenous CDDP, but without the high (toxic) peak serum concentrations of intravenous 
therapy. As a result, it was hypothesize that these nanoconjugates would have a useful role in the 
treatment of locally advanced breast cancer in the neoadjuvant setting, providing enhanced 
locoregional drug efficacy while maintaining or even enhancing systemic therapy to distant 
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disease. Further studies will be necessary to evaluate long-term efficacy and toxicity in animal 
models as well as the role of this nanoconjugate in combination chemotherapy regimens. 
 
 
8.3 Part B:  development of a head and neck cancer model for in vivo imaging 
The pCLNRX-turbo635 plasmid was constructed by inserting a 715-bp AfeI/HindIII 
fragment of the pTurboFP635C (Evrogen Inc, Moscow, Russia) into a 7675-bp AleI/HindIII 
fragment of the pCLNRX retrovirus expression vector (Imgenex, San Diego, CA). The 
incorporation of the insert was verified by sequencing. Packaging 293-GPG cells were used to 
generate retroviruses using CaCl2 precipitation method; followed by infecting MDA-1986 human 
head and neck squamous cell cancer cells, and selection with 0.8 mg/mL G418 for two weeks. 
Stable protein production and the resulting strong, near-infared cell fluorescence was verified by 
fluorescence microscopy with a Texas Red filter on an upright microscope.  
Stable MDA-1986/Turbo635 cells were prepared in 1×PBS solution at a cell 
concentration of 10
7
 cells/mL. One hundred microliters of the cell solution was injected under 
pentobarbital sedation into the oral mucosa layer of nude mice using 27-ga needles. The tumor 
size was measured twice a week using digital calipers on mice anesthetized with 1.5-2 % 
isoflurane in 50% oxygen-50% ambient air mixture. Tumor volume was calculated using the 
equation: Tumor volume (mm
3
) = 0.52 × (width)
2 
× length. 
Before imaging, mice were anesthetized, and Texas Red-HA (10 mg/mL in saline, 100 
µL) was injected subcutaneously near the neck of the animal. The injection area was massaged 
gently for 5 min and fluorescently imaged over 24 hours (CRI Maestro Flex, CRI Inc., Woburn, 
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MA) using a 445- to 490-nm filtered halogen excitation light and a 515-nm longpass emission 
filter. Fluorescence was measured in 10-nm bandpass segments from 520 to 720 nm, using a 
cooled CCD camera using autoexposure. Images were spectrally unmixed using the automatic 
deconvolution tools (Maestro ver. 2.10) to limit skin and intestine autofluorescence resulting 
from the chlorophyll in the food.  
In this study, an orthotopic murine tumor model of HNSCC was established by injecting 
human head and neck squamous cell cancer cells, MDA-1986, into the buccal mucosa of nude 
mice. The model exhibited rapid and sustained tumor growth, with average survival up to 12 
weeks after tumor cell implantation. The primary tumor proceeded similar to highly aggressive 
human HNSCC, invading the mandible and metastasizing to the cervical nodes. To validate the 
tumor model and verify the incidence of distant metastasis, the intact primary tumor and the 
draining lymph nodes were removed from the animal and stored in formalin solution overnight 
for fixation, before the tissues were biopsied. H&E staining tests were conducted, and the 
histology slides showed muscular (middle panel) and glandular (right panel) invasion of the 
cancer cells into the lymphatics (Figure 17).  
In order for the nanocarriers to deliver anticancer drugs to metastases in the head and 
neck locoregional lymphatics, the carriers should drain from the tumor area to the diseased 
lymph nodes. To verify the drainage into the diseased cervical lymph nodes, a HA-Texas Red 
conjugate was injected peritumorally, and the mouse was imaged 24 hours post injection (Figure 
18). The nanoconjugates slowly diffused from the injection site to the primary tumor and 
peripheral locoregional lymphatics, which harbored the metastases. The targeted drainage of the 
HA conjugates toward the neoplastic tissue takes advantages of lymphangiogenesis, leading to  
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Figure 17. (A) Orthotopic mouse model of HNSCC showing the primary tumor (blue arrow) and 
the lymphatic metastases (white arrow). Histology slides show (B) muscular and (C) glandular 
invasion. 
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Figure 18. HA-Texas Red to the surrounding lymphatics (24 hours post injection). Dashed circle 
and × indicated the location of the primary tumor and the nearby injection site, respectively. 
*
HNSCC: head and neck squamous cell cancer 
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the increased accumulation of the nanoconjugates adjacent to the tumor and the cervical lymph 
nodes. Other polymeric carriers, such as optically labeled dendrimers [29] or dextran [30-31] 
have also been used to enable visualization of the lymphatic drainage. 
In order to visualize tumor progression in the early stages, the MDA1986 cell line was 
developed to express a red fluorescent protein. Initially, Turbo635 was inserted into the pLNCX2 
vector (Clontech) under control of the CMV immediate promoter with a neomycin insert and the 
transfected cells were selected with G418. Although the resulting cells had strong fluorescence in 
vitro, the tumor implants resulted in no fluorescence; leading to the interpretation that the 
promoter was “shut off” in this cell line after implantation. Replacement of pLNCX2 with the 
Hsp70 promoter resulted in expression of the strong fluorescent reporter gene in vitro and in vivo. 
 
8.4 Part B:  evaluation of anticancer efficacy in head and neck cancer bearing mice 
Female nude mice were injected with MDA-1986 cells and randomly divided into five 
groups including saline i.v. group (N = 5), HA s.c. group (N = 6), CDDP i.v. group (N = 5), HA-
Pt s.c. group (N = 7), and HA-Pt i.v. group (N=6). Animals in each group were euthanized once 
their tumor size reached 1000 mm
3
 or 12 weeks after tumor cells were implanted.  In addition, 
animals were euthanized during the study if tumors became ulcerated or infections unrelated to 
tumor growth occurred. Facial tumors were observed two weeks after tumor cells were implanted. 
All treatments were administered on weeks 3, 4, and 5, after the tumor cell implantation. Three 
doses of 3.5 mg/kg CDDP, 3.5 mg/kg HA-Pt (on Pt basis), or physiological saline were 
administered intravenously via tail veins; or three doses of 3.5 mg/kg of HA-Pt (on Pt basis) or 
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HA were administered subcutaneously near the tumors. The size of the primary tumor was 
measured weekly. A similar study was conducted using male nude mice, which were treated with 
either CDDP i.v. (N = 4, 3.5 mg/kg × 3 wks) or HA-Pt s.c. (N = 4, equivalent dose on a platinum 
basis). 
In this anticancer efficacy study, two groups of female nude mice treated with saline i.v. 
or HA s.c. developed tumors of approximately 1000 mm
3
 on average after five weeks, which 
indicated that HA does not alter the natural progression of HNSCC. On the other hand, the 
female animals that were treated with three doses of either i.v. cisplatin or i.v. HA-Pt developed 
tumors of approximately 1000 mm
3
 eight weeks post tumor cell implantation. In contrast, 57% of 
the female animals bearing HNSCC xenografts in the HA-Pt s.c. treated group (three equivalent 
doses of HA-Pt) were cured within six weeks, with no disease recurrence by the end of the study 
(Figure 19). In addition, the survival rate was greatly improved for the animals treated with HA-
Pt s.c., when compared to either of the control groups (p<0.05 for both saline i.v. and HA s.c. 
groups) or CDDP i.v. (p<0.05) and HA-Pt i.v. (p<0.05) groups (Figure 19). No statistically 
significant differences were observed for intravenously treated CDDP and HA-Pt groups. Overall, 
the results of the tumor model suggests that HA-Pt conjugates achieved a higher anti-cancer 
efficacy relative to the conventional CDDP i.v. therapy, due to the route of drug administration, 
as well as the intrinsic properties of hyaluronan as a carrier for lymphatic drug delivery (Figure 
19). HA-Pt slowly released the active form of the drug, which subsequently drained to the 
adjacent cervical lymph nodes and the surrounding lymphatic regions. The gradual release of 
CDDP did not cause any skin or tissue reaction at the injection site, even though CDDP is a well 
known vesicant. This is likely due to the protective effect of HA, which has been used as a 
rescue medication to alleviate local toxicity effects of chemotherapeutics.  
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Figure 19. (A) Measurement of tumor sizes. Female animals were administered saline i.v., HA 
s.c., equivalent doses of CDDP i.v., HA-Pt s.c. and HA-Pt i.v. (3.5 mg/kg on Pt basis, 5≤ N ≤ 7). 
(B) Survival curves of female animals treated by saline, HA, CDDP or HA-Pt (5≤ N ≤ 7) (Top 
Right Panel). (C) Lymphatic HA-Pt chemotherapy at 12 weeks. (D) Intravenous CDDP 
chemotherapy at 8 weeks. 
*
HA-Pt: hyaluronan-cisplatin; CDDP: cisplatin; HA: hyaluronan; i.v.: 
intravenous; s.c.: subcutaneous. 
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Administration of anti-cancer drugs via polymeric delivery vehicles is a promising 
method for local delivery of concentrated chemotherapeutics, effectively treating lymphatically 
metastatic cancers. A study by Dunne et al. revealed that CDDP bound poly(ethylene oxide)-b- 
poly(lysine) block copolymers greatly hindered the tumor progression in a squamous cell cancer 
model of the upper aerodigestive tract in animals [32]. Another study done by Xie et al. reported 
an enhanced efficacy against laryngeal squamous cell carcinoma in rodents using paclitaxel-
loaded poly(lactic-co-glycolic acid) microspheres compared with conventional paclitaxel therapy 
[33]. 
Another interesting observation was that the tumor progression of HNSCC exhibited a 
more aggressive pattern in male nude mice compared to female nude mice. All the male animals 
in the CDDP i.v. group reached an average tumor size of approximately 1000 mm
3
 in two weeks 
(Figure 20) as opposed to eight weeks as seen in the previous female animals studies (Figure 19). 
On the other hand, 80% of the male animals in the HA-Pt s.c. group developed tumors of 
approximately 1000 mm
3
 in three weeks and 20% of the animals were able to live through the 
end of the fourth week (Figure 20). Therefore, gender differences, as well as weight loss and 
stress may be contributing factors that are responsible for the differentiated carcinoma 
progression. In human studies, tobacco and alcohol consumption was believed to be the major, 
but not only, factors inducing the occurrence and recurrence of HNSCC. Other factors, such as 
age, weight loss, nutritional status, and complications, may also play a role in the survival of 
patients [34]. Dahlstrom et al. conducted a demographic study, of 172 patients that never smoked 
and never drank, that described the age and sex distribution of HNSCC patients, and identified 
the specific types of the most commonly diagnosed HNSCCs [35]. A similar study was also 
performed by Onyango et al, showing an overall male preponderance in the occurrence of  
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Figure 20. (A) Measurement of tumor sizes. Male animals were administered equivalent doses 
of CDDP i.v. and HA-Pt s.c. (3.5 mg/kg on Pt basis, N = 4 for CDDP i.v., N = 6 for HA-Pt s.c.). 
(B) Survival curves of male animals treated by CDDP or HA-Pt (N = 4 for CDDP i.v., N = 6 for 
HA-Pt s.c.). 
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HNSCC among 793 patience [36]. Additional factors affecting the disease progression and 
metastasis are still under investigation.  
This study demonstrates that intralymphatic delivery of cisplatin may be a promising 
treatment regimen to deliver chemotherapeutics to the primary malignancy, locoregional 
lymphatics, and metastases, with greatly improved in vivo efficacy and survival compared with 
conventional cisplatin chemotherapy. Successful completion of this study may provide a 
platform for the development of other polymeric drug delivery models for the treatment of a 
wide spectrum of lymphatically metastic cancers. The platinum-based hyaluronan conjugates can 
either be administered as a neoadjuvant therapy prior to surgery to reduce tumor size and control 
cancer progression, or be given as an adjuvant therapy post surgery to reduce the risk of 
recurrence and eradicate cancer residuals, such as micrometastases. In addition, due to the 
sustained release characteristics of the conjugate, weekly or biweekly HA-Pt injections could 
replace the conventional daily infusion, leading to improved patient compliance and reduced 
healthcare costs. 
Despite major strides in cancer prevention and treatment during the past decades, there 
has been only a modest improvement on the overall survival. Over half of HNSCC patients will 
face recurrence at some point, and these cancers recur because current imaging tools fail to 
detect occult disease or therapies fail to completely eradicate resistant disease. More frequent and 
intense radioimaging, or stronger regimens of chemotherapy and radiation, would be detrimental 
in the long run to patients’ health, so new approaches are needed. 
Localized therapies stand a stronger chance of eradicating residual disease, since higher 
doses of chemotherapy can be administered without dose-limiting toxicity to the heart, kidneys, 
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and liver. Localized chemotherapy is already used to great success in the treatment of peritoneal 
disease in colon cancer using heated intraperitoneal chemotherapy, limb melanomas with heated 
isolated limb perfusions, and liver cancer using isolated hyperthermic liver perfusion. However, 
there is no way to isolate most organs and tissues for concentrated chemotherapy, such as the 
breasts, the neck, and the lungs. For most tissues, the lymphatics are an ideal pathway for local 
therapy due to their importance in early cancer metastasis. Localized chemotherapy may become 
an important component in the treatment of early stage cancers that are still confined to the 
primary tumor and local lymphatics; yet, to date, there are no tools in the clinic to localize 
chemotherapy to the lymphatic system. 
Localized delivery systems, such as the one described here can effectively treat these 
early stage diseases, and we believe that they will represent a new treatment option in the next 5 
to 10 years. Next generation systems will incorporate both imaging and diagnostic capabilities in 
the drug or drug carriers, so that the staging (or restaging) of the disease can be followed 
immediately by treatment:  to reduce treatment costs; limit the need for invasive surgeries and 
intravenous treatments; and increase the likelihood that all disease can be eliminated in the early, 
more controllable stages.   
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1. Introduction 
Doxorubicin (DOX) is among the most effective chemotherapeutics used for the 
treatment of cancers including breast, ovarian, sarcomas, pediatric solid tumors, Hodgkin’s 
disease, multiple myeloma, and non-Hodgkin’s lymphomas. Despite the success of DOX against 
many cancers, its use can be severely limited by its cardiac toxicity including development of a 
cardiomyopathy, often refractory to common medications, which can progress to biventricular 
failure and even death (reviewed in [1]). This damage is caused by the generation of reactive 
oxidative species, such as superoxide and hydrogen peroxide, upon the reduction of doxorubicin 
to form an election deficient semiquinone. In addition, doxorubicin is an iron chelator, chelating 
Fe(III) and perturbing the transportation of iron into cells. It causes iron-deficient cell death of 
myocytes [2]. Technologies such as polymeric micelles [3], synthetic polymer conjugates [4], 
and antibody targeted carriers [5], have demonstrated reduced or altered toxicity in Phase I trials, 
yet the therapeutic efficacy of these formulations has yet to be demonstrated. In the absence of 
safer, efficacious systemic formulations, localized delivery of DOX may improve tolerability and 
improve efficacy, especially in the treatment of early breast cancer. 
Early breast cancers typically spread, initially from the primary tumor site to the regional 
lymph nodes in the axilla prior to systemic dissemination. Surgery and radiation therapy can be 
effective, but result in significant side effects including painful lymphedema [6]. There is debate 
over the risks verses the benefits of aggressive therapy for patients with isolated tumor cells or 
nanometastases in the axillary lymph nodes; however, recent studies support that there is a strong 
risk factor for metastatic relapse in patients with nodal nano-metastases, with occult lymph node 
disease accounting for up to 50% of metastatic recurrences [7] and a hazard ratio of 1.5 for 
patients with isolated cancer cells who do not receive adjuvant systemic chemotherapy [8]. We 
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therefore sought to develop a formulation of DOX that could be given locally and concentrated 
in the draining lymphatic basin of the breast, where early metastases are more prevalent, while 
sparing normal tissues from many of the organ toxicities associated with systemic chemotherapy. 
DOX is a potent vesicant, so direct s.c. injection (leading to lymphatic drainage) is not viable; 
however, conjugates of DOX and a lymphatically targeted carrier may avoid severe tissue 
toxicity through improved localization to the lymphatic basin. For this purpose, hyaluronan may 
be an ideal carrier. 
Hyaluronan (HA) is a polysaccharide, of alternating D-glucuronic acid and N-acetyl D-
glucosamine, found in the connective tissues of the body, and it is cleared primarily by the 
lymphatic system (12 to 72 hrs turnover half-life [9]). After entering the lymphatic vessels, HA 
is transported to the nodes, where it is catabolized by receptor-mediated endocytosis and 
lysosomal degradation. Several studies have correlated an increase in HA synthesis and uptake 
with cancer progression and metastatic potential [10-11]. Breast cancer cells are known to have 
greater uptake of HA than normal tissues [12], requiring HA for high P-glycoprotein expression, 
the primary contributor to DOX resistance [13]. The knockout of HA receptors has been reported 
to prevent migration of cancers that initially spread intralymphatically [14]. Furthermore, 
invasive breast cancer cells overexpress CD44, the primary receptor for HA [15], and are 
dependent on high concentrations of CD44-internalized HA for proliferation (reviewed in [12]). 
Doxorubicin conjugated to HA may represent a natural lymphatic and breast-cancer-targeted 
delivery platform to improve efficacy against lymphatic metastases.  
Several HA-DOX conjugates have been reported which used irreversible or peptide 
linkers, which had considerable loss in anticancer activity [16-18]. We report herein a new pH-
sensitive, reversible hydrazone linked HA-DOX conjugate with potent anticancer activity against 
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breast cancer cells in vitro demonstrating excellent cellular uptake and retention. Furthermore, 
HA is shown to drain to the axilla basin of rats after s.c. injection into the mammary fatpad, 
laying the foundation for future studies of pharmacokinetics, and anti-tumor activity in rodent 
models.  
 
2. Synthesis and characterization of hyaluronan-doxorubicin (HA-DOX) conjugates 
Direct conjugation of drugs to HA is inefficient due to the steric hindrance of the 
polysaccaride backbone and low reactivity of the carboxylate group. HA was derivatized with 
adipic acid dihydrazide (ADH), according to the procedure of Luo et al. [19]. Briefly, HA (200 
mg, 35 kDa) was dissolved in 40 mL ddH2O with ADH (436 mg) and 1-ethyl-3-[3-
(dimethylamino)-propyl]carbodiimide (EDCI, 48 mg). The solution pH was adjusted to 4.75 with 
1 N HCl, and checked again after 10 min. The reaction was quenched by addition of 0.1 N 
NaOH to pH 7.0. The reaction scheme is shown in Figure 1. The resulting solution was dialyzed 
against ddH2O for two days with bath changes every 12 hrs. After dialysis, the product was 
filtered (0.2 µm polystyrene membrane, Millipore), and lyophilized. The degree of substitution 
was determined to be 33 % by 
1
H NMR in D2O using the ratio of ADH methylene protons to HA 
acetyl methyl protons.  
Conjugation of DOX to HA was accomplished by formation of a hydrazone bond 
between the ketone of DOX and the hydrazide side chain of HA-ADH [20]. HA-ADH (110 mg) 
was dissolved in 30 mL of 2 mM sodium phosphate buffer (pH 6.5). DOX·HCl (2 mL, 2 mg/mL) 
was added dropwise in the HA-ADH solution. The solution was adjusted to pH 6.5 with 0.1 N 
NaOH and after 12 hrs, it was dialyzed against 2 mM sodium phosphate buffer (pH 7.8), with  
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Figure 1. Synthesis of hyaluronan-doxorubicin (HA-DOX) conjugate.  
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twice daily changes until no further color change was observed (2 days). Solutions were 
protected from light at all times.  
Gel permeation chromatography (GPC; Shodex HQ-806M column, 0.8 mL/min, 20 mM 
HEPES, pH 7.2) with refractive index and fluorescent detection (ex/em 480/590 nm) was utilized 
to verify drug conjugation by equivalent elution times. The HA (green) and bound DOX (blue) 
both eluted at approximately 11 minutes (Figure 2). The degree of conjugation was determined 
by UV/Vis spectrophotometry at 480 nm using a standard calibration curve (1-100 µg/mL). A 
series of concentrations of DOX standard solution was prepared to generate a calibration curve. 
The concentrations of the standard solution were 1, 2, 5, 10, 25, 50 and 100 µg/mL (R
2
=0.99). 
Absorbance at 480 nm was measured and it was due to the UV absorbance of DOX; HA does not 
exhibit UV absorbance (data not shown). Specifically, the loading degree was calculated to be 
5.2 % (wt/wt). In general, the optimal loading degree of DOX was maintained to be in a range of 
5-15 % (wt/wt) to obtain the maximum solubility and the least volume of solution administered 
in the animal studies.  
Nanocarrier strategies for the delivery of drugs have been investigated extensively in the 
past decade. Among candidates of potential nanocarriers, hyaluronan represents a very promising 
substrate by being both a biocompatible and nonimmunogenic molecule. It has been used as a 
carrier for the delivery of a variety of chemotherapeutic agents, for instance, cisplatin [21], 
paclitaxel [22] and mitomycin C [23]. Strategies with different choices of spacers for the 
delivery of doxorubicin have been explored for optimal entrapment efficiency [24], specific 
tumor targeting [25] and higher cellular uptake [26].  A liposome-encapsulated formulation of 
doxorubicin (Doxil
TM
) is currently available in human chemotherapy and produces major 
benefits, including reduced acute cardiotoxicity compared to i.v. DOX·HCl and improved  
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Figure 2.  Chromatogram of HA-DOX (GPC). The HA (green) and bound DOX (blue) were 
both eluted at approximately 11 minutes. 
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biodistribution [27]. However, liposomal DOX can cause palmar plantar erythrodysesthesia, a 
dermatologic toxic reaction associated with the leakage of a small amount of the drug from the 
long-circulating liposomes into the cutaneous tissues of the palms and the soles of the feet [28].  
A trial of DOX and liposomal DOX in 509 patients with metastatic breast cancer demonstrated 
reduced toxicity of liposomal DOX, but no increase in survival [29]. In this chapter, the 
development of a controlled-release HA-DOX conjugate will be described. The HA-DOX 
conjugate demonstrated improved efficacy in locally advanced disease and reduced side effects 
compared to conventional DOX and liposomal DOX treatments. 
 
3. In vitro release 
In order to determine the release profile of DOX from HA-DOX, the release was studied 
at three different pHs mimicking the pHs of normal cells and cancer cells. HA-DOX (20 mg) 
was dissolved in PBS (10 mL) adjusted to pH 5.0, 6.0 or 7.4 and sealed in dialysis tubing 
(10,000 MWCO, Pierce, Rockford, IL). The dialysis tubings were placed in a PBS bath at pH 5.0, 
6.0 or 7.4; 100 µL aliquots were taken from the bags as predetermined time points, and were 
analyzed by GPC coupled with refractive index and fluorescence (ex/em 480/590) detectors. The 
PBS solution was changed 5 times daily, and the ratio of the peak areas of HA to DOX was 
calculated for up to 500 hrs. 
HA-DOX conjugates were synthesized using a pH sensitive linker, resulting in adipic 
dihydrazide functionalized nanoconjugates. The conjugate releases doxorubicin in a pH 
dependent fashion via a Schiff base mechanism, yielding free DOX and the polymer. The release 
half life of DOX was determined to be 172 hrs at pH 7.4, 110 hrs at pH 6.0 and 45 hrs at pH 5.0 
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(Figure 3). The ratio of the release half lives of DOX from the polymer backbone at pH 5.0, 6.0 
and 7.4, was determined to be approximately 1:2.4:3.8, clearly indicating the dependence of the 
hydrolysis of carbon-nitrogen double bond to pH changes. The extended half life at physiological 
pH was consistent with the sustained release characteristics of HA-DOX conjugates. Thus, the 
carrier releases the active form of the drug more rapidly in vivo in an acidic environment as in 
the hypoxic environment within solid tumor masses, which may preferentially concentrate drug 
near the primary tumor or distant metastases of breast cancer cells, compared to a relatively 
neutral environment that surrounds normal cells. 
 
4. In vitro imaging and cytotoxicity 
In order to confirm that the HA-DOX conjugate can enter cells, cancer cells were 
incubated with HA-DOX and imaged. Typically cell lines were seeded into 12-well plates 
(50,000 cells/well) containing a poly-L-lysine coated coverslip (Fisher Scientific). After 24 hrs, 
DOX, HA-DOX, or HA was applied, and after 6 hrs, the media was refreshed. After 12 hrs, cells 
were examined by fluorescent microscopy (ex/em 480/590). Images were adjusted for contrast 
and brightness with no further manipulation. Both free DOX and HA-DOX conjugate were taken 
up by MDA-MB-231 cells after 6 hours incubation (data not shown).  
Cell growth inhibition was determined in 96-well plates (3,000 cells/well in 100 µL) (n=3, 
12 wells/concentration). DOX or HA-DOX in PBS was applied after 24 hrs; 72 hrs post-addition, 
resazurin blue in 10 µL PBS was applied to each well (final 5 µM). After 4 hrs, well 
fluorescence was measured (ex/em 560/590) (SpectraMax Gemini, Molecular Devices), and the 
IC50 concentration determined as the midpoint between untreated (positive) and cell-free 
(negative) controls. 
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Figure 3. In vitro release of DOX from HA-DOX at pH 5.0, 6.0 and 7.4. 
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HA-DOX conjugates exhibit slightly lower toxicities than free doxorubicin in cell culture:  
MDA-MB-468LN, 221 and 515 nM (DOX and HA-DOX, respectively); MDA-MB-231, 147 
and 588 nM; and MCF-7, 221 and 1287 nM. However, the conjugate remains potent for all the 
breast cancer cell lines tested with IC50 values in the nanomolar range. HA exhibits no toxicity to 
human cells over the concentration range examined (up to 10 mg/mL, data not shown).  
 
5. Pharmacokinetics  
Sprague-Dawley rats (200-300 g females, Charles Rivers) were placed under isoflurane 
anesthesia and cannulated at the jugular veins. Animals were allowed to recover with access to 
food and water overnight. Then they were injected s.c. (100 µL) into the left mammary fat pad 
with HA-DOX (4 mg/kg DOX·HCl equivalent, n=4), i.v. into the jugular vein with 2 mg/mL 
DOX·HCl in 0.9 % saline (4 mg/kg DOX·HCl equivalent, n=4), or s.c. (100 µL) into the left 
mammary fat pad with DOX·HCl (4 mg/kg DOX·HCl equivalent, n=4). Blood was sampled 
from the jugular vein (200-300 μL) at 0 min, 5 min, 30 min, 1h, 2h, 4h, 6h, 12h and 24 h. Plasma 
was separated by centrifugation from whole blood and stored at -80 ºC freezer until analysis. At 
24 hours, the animals were euthanized by isoflurane overdose.  
The pharmacokinetic parameters were determined using SAAM II Version 1.2 software. 
A two compartmental model was utilized for i.v. DOX, s.c. DOX, and s.c. HA-DOX data. 
Pharmacokinetic data were collected from 0 to 24 hours and were analyzed, resulting in a series 
of biexponential plasma level-time curves.  Pharmacokinetic parameters such as volume of 
distribution, clearance, area under the curve, mean residence time and elimination half-time were 
determined as followed. 
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The pharmacokinetics of s.c. HA-DOX were compared to i.v. DOX and s.c. DOX in 
Sprague-Dawley rats. The peak plasma concentration of i.v. DOX was 18.8-fold greater than s.c. 
HA-DOX (Figure 4). The release of DOX from HA-DOX into the systemic circulation was slow, 
and the resulting plasma AUC of HA-DOX did not exhibit significant difference from i.v. 
therapy. The peak plasma concentration of s.c. DOX was 1.3 greater than s.c. HA-DOX and the 
AUC of s.c. DOX was slightly lower than s.c. HA-DOX. The serum DOX level measured in 
HA-DOX was associated with the free unbound drug instead of the sum of free drug and HA 
bound drug due to the difficulty cleaving DOX from the polymer backbone in serum samples. 
Thus, the actual total DOX level in the serum would be expected to be higher for s.c. HA-DOX, 
resulting in a greater AUC. 
A two-compartment model was selected to describe the biexponential nature of the 
pharmacokinetics of HA-DOX and DOX. The predicted volume of distribution of i.v. DOX was 
determined to be approximately 3.4-fold greater than HA-DOX. In addition, both routes of drug 
administration (i.v. DOX and s.c. HA-DOX) resulted in similar values of Area-under-the-curve 
(AUC0-24 h), clearance and elimination half life. However, s.c. HA-DOX exhibited a 2.2-fold 
increase in systemic mean residence time, which is consistent with the sustained release nature of 
the polymer drug conjugate. Finally, the observed peak plasma concentration of i.v. DOX is 
shown to be 18.8-fold higher than that of the s.c. HA-DOX, which may cause potential tissue 
toxicity, such as cardiac toxicity (dose-limiting) and hepatoxicity (the liver is the major organ of 
DOX metabolism) (Table 1).   
The previous study demonstrated that the intralymphatic delivery model using 
hyaluronan-cisplatin conjugate not only increases drug concentrations in loco-regional nodal 
tissues significantly compared to the standard cisplatin formulation, but it also exhibits sustained  
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Figure 4.  Serum concentration of doxorubicin. The animals were treated with i.v. DOX, s.c. 
HA-DOX and s.c. DOX. 
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Parameters Unit DOX (i.v.) HA-DOX (s.c.) 
Vd L/kg 0.430 ± 0.272 0.096 ± 0.084 
A µg/mL 4.415 ± 1.515 30.974 ± 29.980 
B µg/mL 0.078 ± 0.013 0.086 ± 0.012 
AUC0-24 h (µg·h)/mL 2.061 ± 0.824 2.201 ± 0.905 
Cl L/(kg·h) 1.283 ± 0.404 1.261 ± 0.564 
MRT (Syst) h 8.247 ± 4.944
*
 26.501 ± 10.703
*
 
t1/2 (β) h 0.226 ± 0.072 0.199 ± 0.293 
Cmax (t) µg/mL (min) 2.580 ± 0.670 (5)
*
 0.130 ± 0.020 (30)
*
 
 
Table 1.  The pharmacokinetic data were fitted using a two-compartmental model. Data are 
shown as means and standard deviation. *Study groups, i.v. DOX and s.c. HA-DOX, differed 
significantly for MRT(Syst) and Cmax(t). Significance defined as p<0.05 using student t-test 
(n=4). 
 
 
149 
 
release kinetics, allowing lower peak plasma concentration which could translate into lower 
organ toxicity over time [21]. In this study, the intralymphatic delivery strategy was successfully 
applied to the HA-DOX delivery system, reducing the Cmax by approximately 19-fold without 
compromising the plasma drug AUC. In addition, only the free DOX released from HA, as 
opposed to the sum of free and bound drug, was detected and analyzed for the calculation of the 
total drug AUC in the plasma. The actual total DOX concentration in the plasma may be higher, 
allowing a greater AUC compared to the standard DOX treatment. This may result in a lower 
dose of doxorubicin being required to achieve the same plasma and tissue drug level. HA-DOX 
injections therefore, could be considered for weekly or even biweekly injections, with great 
potential to replace daily conventional intravenous doxorubicin chemotherapy both from a 
standpoint of improved toxicity profiles, but also in terms of improvements in compliance and 
completion of chemotherapeutic regimens.   
In addition, the difference in the volume of distribution in the plasma compartment, Vd, 
between i.v. DOX group and s.c. HA-DOX group was possibly due to the easier access to the 
surrounding tissues for free doxorubicin molecules as opposed to polymer bound DOX 
conjugates. Doxorubicin with a log P value of 1.3, pKa of 8.4, and a molecular weight of 544 
g/mol, rapidly crosses lipid membranes and binds to tissues, resulting in a larger Vd [30]. Finally, 
HA-DOX conjugates exhibited a 2.2-fold increase in systemic mean residence time relative to 
unbound i.v. DOX. The extended residence time of HA-DOX conjugates may decrease the 
frequency of doxorubicin chemotherapy and have potential to improve patient compliance and 
quality of life in a clinical setting. The sustained release drug-carrier model avoids peak and 
trough of plasma drug concentration in both drug distribution and elimination, leading to a well 
controlled drug level profile corresponding to its therapeutic index. 
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6. Toxicology 
Renal toxicity is one of the side effects found with the administration of anthracycline 
antibiotics. The potential renal toxicity of DOX and HA-DOX was determined using lysosomal 
enzyme, β-N-Acetylglucosaminidase (NAG) (Sigma), which acts as an indicator of ongoing 
kidney damage. Two groups (n=3) of Sprague-Dawley rats were treated with 4 mg/kg of either 
i.v. DOX or s.c. HA-DOX. Animals were housed in metabolic cages and their urine was 
collected daily. The urine samples were centrifuged and stored at -80 ºC freezer until analysis. 
The animals were euthanized after 8-10 days. The urine samples were analyzed for the 
concentration of NAG upon hydrolyzing the NAG substrate, 4-nitrophenyl.  
NAG is a urinary enzyme that is sensitive to early renal tubular dysfunction. It is 
commonly and widely used as a biomarker for the early detection of renal tubular damage. NAG 
is expressed in normal kidney at a relatively constant level. However, elevated urinary NAG 
activity in chemotherapy treated animals may be associated with renal tubular dysfunction 
caused by the administered chemotherapeutic agent. The NAG activity in animals treated with 
s.c HA-DOX exhibited a relatively steady level during the study period of 9 days (Figure 5A). 
On the other hand, animals that were treated with i.v. DOX demonstrated a slight increase in 
NAG activity starting two days after drug administration (Figure 5B). A dose of 4 mg/kg DOX 
or HA-DOX may not be sufficient to induce significant renal tubular damage (Figure 5C).  
Furthermore, cardiotoxicity is also a dose-limiting toxicity associated with doxorubicin 
therapy. The cardiac toxicity of DOX and HA-DOX was determined using a rat cardiac 
Troponin-I (cTnI) ELISA kit (Life Diagnostic). Sprague-Dawley rats were cannulated in the  
 
151 
 
A 
 
B 
 
C 
 
Figure 5.  Urine NAG level of i.v. DOX or s.c. HA-DOX treated rats. 
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jugular vein and injected with 4 mg/kg DOX·HCl solution i.v. or HA-DOX s.c. into the 
mammary fat pad. Blood samples were collected at 0, 8, 16, 24 hrs and 2, 3, 4, 5 and 6 days from 
the jugular vein and centrifuged to obtain the plasma. Samples were stored at -80 ºC freezer until 
analysis. 
Doxorubicin-induced cardiomyopathy and congestive heart failure was believed to be 
dose-dependent. Troponin I is a cardio-specific protein that is released from injured myocytes. It 
is a highly sensitive and specific biomarker for cardiac damage. The cTnI levels, for i.v. DOX 
and s.c HA-DOX, were both below the detection limit of the commercial available cTnI assay kit 
(0.156 ng/mL); indicating that 4 mg/kg was a relatively low dose for an animal model of 
doxorubicin-induced cardiotoxicity. 
 
7. Pathology 
Sprague-Dawley rats were divided into two groups and treated with DOX s.c. or HA-
DOX s.c. (n=6/group) at either 2 or 4 mg/kg. Three rats from each group were euthanized 6 hrs 
after drug administration and the other three were euthanized 24 hrs after drug administration. 
The liver, bilateral kidneys, spleen, lungs, heart, right (ipsilateral) and left (contralateral) axillary 
nodes, and brain, were excised intact and stored in 80 % alcoholic formalin solution overnight 
for fixation before slide mounting. The H&E staining were conducted by Veterinary Lab 
Resources (Kansas City, KS). The pathological examination was performed by a blinded board-
certified veterinarian pathologist (University of Kansas Medical Center, Kansas City, KS). The 
heart, kidneys, liver, lymph nodes and underlying tissue of the injection site, were normal with 
no microscopic changes for all study groups. 
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In addition, the long term toxicity (8-10 days) of DOX and HA-DOX at 4 mg/kg was 
evaluated. The liver and lymph nodes were normal, with no microscopic changes for both study 
groups. The underlying tissue of the injection site was examined for the HA-DOX s.c. treated 
animals, and no microscopic changes were observed. Mild degeneration in the kidney was 
detected for both groups, indicated by sparse pyknotic nuclei and mild inflammation. In addition, 
83% of animals (n=6) receiving 4 mg/kg i.v. DOX were observed to have myocyte degeneration, 
including myofiber necrosis and myocarditis. In contrast, none of the animals (n=5) receiving s.c. 
HA-DOX exhibited cardiac damage. Overall, the pathology studies demonstrated that the HA-
DOX conjugates had a lower incidence of cardiac toxicity compared to the conventional 
intravenous DOX treatment (Figure 6). 
In spite of the high efficacy of DOX chemotherapy, its clinical use is limited due to its 
dose-limiting cardiac toxicity, along with its renal toxicity and hepatoxicity. Tissue toxicities 
from doxorubicin are typically caused by the generation of oxygen species from the conversion 
of DOX to the semiquinone, yielding very reactive hydroxyl radicals. The free radicals may also 
cause damage to various membrane lipids and other cellular components [31]. Pathological 
examination 10 days following a single dose of doxorubicin revealed significant cardiac 
differences between the s.c. HA-DOX and i.v. DOX formulations. Of the animals that received 
i.v. DOX, 83% developed myocarditis and cardiac myocyte degeneration. Other significant 
lesions included thrombosis and muscle inflammation around the thrombus. In contrast, only 
20 % of animals that received s.c. HA-DOX developed very subtle myocyte degeneration. No 
lesions or inflammation were observed for 80% of the animals in the s.c. HA-DOX group, which 
clearly demonstrates that the HA-DOX formulation greatly reduces the cardiac toxicity of 
doxorubicin in a rodent model.  Furthermore, the pathology studies demonstrated that the skin  
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Figure 6.  Heart tissues of (A) HA-DOX, (B) DOX and (C) underlying tissues of the HA-DOX 
injection site. 
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and cutaneous tissues at the injection site, were devoid of inflammation or necrosis at both 6 and 
24 hours after HA-DOX injection. This finding may be corroborated clinically with the use of 
hyaluronan as a rescue medication, to alleviate the local toxicity effects of doxorubicin that has 
extravasated into the subcutaneous tissues following dislodgement of an i.v. catheter during 
intravenous administration. This effect was confirmed in tissue biopsies at the conclusion of the 
study (10 days post injection), which demonstrated no substantial damage to the underlying 
tissue at the injection site. Therefore, HA-DOX conjugates have the potential to reduce the 
incidence of local skin and soft tissue toxicity from doxorubicin chemotherapy, which would 
improve patient tolerance and compliance in clinical application. 
Another strategy for reducing doxorubicin associated cardiac and liver toxicity is 
metronomic chemotherapy, which involves continuous administration of doxorubicin at regular 
short intervals, as opposed to bolus dosing with a higher concentration of the drug [32]. 
Metronomic dosing regimens decrease the non-specific toxicity of an anti-cancer drug in normal 
cells. In addition, in a study by Pastorino et al., a metronomic chemotherapy of a NGR peptide 
coupled liposomal doxorubicin formulation greatly hindered the progression of orthotopic 
neuroblastoma xenografts in immunodeficient mice [33]. This dosing regimen, however, has its 
own drawbacks clinically, in that more frequent intravenous doses are required, which adds to 
patient discomfort, time spent in infusions, and creates nursing as well as compliance issues.  
 
8. Tumor model and in vivo drug release 
MDA-MB-468LN human breast cancer cells (kind gift of Ann Chambers, London 
University) were implanted into the mammary fat pad of female nude mice from a small incision 
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using a 27-ga needle (100 μL, 10
6 
cells) under pentobarbital sedation. The incision was closed 
using sterilized staples, which were removed when the incision healed. The MDA-MB-468LN 
human breast cancer cell line can be transfected with a GFP-neomycin expression vector and 
selected with G418, to express green fluorescent protein (GFP) so that metastasis can be 
monitored by whole animal fluorescent imaging. The tumor growth was monitored by 
fluorescent imaging using the CSI Maestro imaging system, and the tumor size was measured 
twice a week using digital calipers on mice anesthetized with 1.5-2 % isoflurane in 50 % 
oxygen-50 % ambient air mixture. The tumor volume was calculated using the equation: Tumor 
Volume (mm
3
) = 0.52×(width)
2
×length. 
In order for the nanocarriers to deliver anticancer drugs to nano- and micrometastases in 
the breast locoregional lymphatics, carriers should drain from the injection site near the breast 
area to the diseased lymph nodes. The injected HA-DOX conjugates to verify drainage into the 
diseased lymph nodes, which were indicated by the dashed circle in the following figures. Nude 
mice with mammary tumors (approximately 500 mm
3
) were injected peritumorally with a single 
dose of 3.5 mg/kg HA-DOX solution. The injection site and location of the primary tumor were 
also labeled on each figure. Drainage of HA-DOX to the locoregional lymphatics in the axilla, 
was characterized after a s.c. needle injection near a nodal breast tumor.  
Mice were imaged, and the images of the primary tumor and lymphatic metastases were 
captured from day 1 to day 9 after drug administration. The distribution characteristics of HA-
DOX were monitored, and percentage of DOX released calculated by spectrally unmixing of the 
tumor GFP, DOX, and skin autofluorescent signals, using the Maestro software. After one day, 
10% of the initial HA-DOX drained to the tumor, and 66% drained to the tumor lymphatics and 
local tissues. After a week, 4% of original dose remained in the primary tumor, with 10% of the 
157 
 
initial dose in the surrounding area and adjacent lymph nodes. Clearance of drug from the tumor 
was 80% slower than from the surrounding tissues and lymphatics (Figure 7). Intravenous DOX 
could not be detected in the tumor or surrounding tissues by in vivo imaging at any time point 
(data not shown).  
 
9. Anticancer efficacy in breast cancer bearing nude mice 
Nude mice were injected with into the first mammary fat pad on the right side with 10
7
 
MDA-MB-468LN cells, and were randomly divided into four groups including:  saline, HA, 
DOX, and HA-DOX (n=5/group). Animals of the saline and HA control groups were euthanized 
once their tumor size reached 2000 mm
3
. Animals in the DOX or HA-DOX treatment groups 
were euthanized once their tumor reached 1000 mm
3
 in size or 24 weeks after tumor cells were 
injected. In addition, animals were euthanized during the study if tumors ulcerated, or the 
animals acquired opportunistic infections. Mammary tumors were observed three weeks after 
tumor cells were implanted. All treatments were administered in the 3
rd
 and 4
th
 weeks after tumor 
cell implantation. Two doses of 3.5 mg/kg DOX or physiological saline were administered i.v. 
via the tail vein; whereas two doses of 3.5 mg/kg of HA-DOX (on DOX basis) or HA were 
administered s.c. 2-3 mm from the tumor margins. The size of the primary tumors was measured 
weekly. 
Animals treated with saline or HA had an average tumor size of approximately 2000 mm
3
 
in nine weeks, which indicated that HA does not alter the natural progression of breast cancer.  
On the other hand, the animals that were treated with three weekly doses of i.v. DOX developed 
a tumor with an average size of 1000 mm
3
 after approximately ten weeks. In contrast, animals in 
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Figure 7.  Imaging of HA-DOX in the primary tumor and the surrounding lymphatics (day 1-9). 
HA-DOX was injected peritumorally (white arrows) with most of the carrier draining to the 
adjacent nodes (blue arrow). After spectrum unmixing and false coloring, the total DOX (within 
the red circle) and tumoral DOX (within black circle) were integrated and normalized to day 0. 
Doxorubicin is falsely colored white-yellow-red with decreasing intensity. 
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the s.c. HA-DOX treated group (three weekly equivalent doses of HA-DOX) reached an average 
tumor size of around 300 mm
3
 ten weeks after the tumor cell injection (Figure 8A). In addition, 
100% animal death occurred 18 weeks after the tumor cell injection for DOX treated group 
(Figure 8B). In contrast, 50% of HA-DOX treated animals lived for the duration of the study (24 
weeks) with an average tumor delay of 4 weeks. Overall, the result of the tumor model suggests 
that HA-DOX conjugates achieved a higher anti-cancer efficacy relative to the conventional i.v. 
DOX therapy. HA-DOX conjugates delayed the tumor progression by approximately 10 weeks 
and increased the survival of the animals relative to the i.v. DOX treatment (p<0.05). We believe 
the carrier slowly released the active form of the drug, which subsequently drained to the 
adjacent axilla lymph nodes and the surrounding lymphatic regions. 
In conclusion, HA-DOX by weekly subcutaneous injections would have great benefits 
over standard or metronomic dosing regimens, both in terms of patient compliance and tolerance, 
but also with regard to potential improved toxicity and efficacy. Further translational efforts will 
focus on optimizing the dosing frequency and completing preclinical proof of concept. 
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A.                                                                  B. 
 
Figure 8.  (A) Measurement of tumor volume and (B) survival curve of the tumor bearing 
animals. 
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1. Introduction 
Cancer cells undergo random and uncontrolable mutations, it is quite common for them 
to become resistant to a single type of chemotherapy. Usually the most successful cancer 
chemotherapy regimens involve the administration of multiple anti-cancer drugs simultaneously. 
Because different chemotherapies may have different mechanisms of action; it is difficult for 
cancer cells to become resistant to combination therapy. For instance, cisplatin crosslinks the 
DNA in cancer cells; doxorubicin inhibits protein biosynthesis in cancer cells; and taxane 
stabilizes microtubules, thus preventing cancer cells from entering mitosis.  
Many cancer patients experience high initial cisplatin responsiveness during their 
treatment; however, the majority of the patients eventually develop cisplatin-resistant disease, 
either at the late stage of their cancer or when their cancer relapses. The mechanism of cisplatin 
resistance has been investigated extensively over the past decades. It is believed that cisplatin 
resistance is a complex process, in which many mechanisms are involved, such as:  increased 
DNA repair of cancer cells [1], decreased intracellular drug accumulation [2], enhanced cisplatin 
efflux [3], and activated drug detoxification pathways [4]. 
To overcome chemoresistance, a number of combination therapy regimens have been 
investigated in clinical trials and preclinical studies. The first-line combination therapies for head 
and neck cancer include:  combination of cisplatin, docetaxel and 5-FU, combination of cisplatin 
and cetuximab, and combination of 5-FU and carboplatin. Commonly used combination 
therapies for breast cancer include:  combination of doxorubicin and cyclophosphamide, 
combination of cyclophosphamide, adriamycin and fluorouracil, and combination of carboplatin 
and paclitaxel.  
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Built upon the results of chapter 2, this chapter focuses on the development and 
evaluation of locoregional cisplatin-based combination chemotherapy for the treatment of breast 
cancer and head and neck cancer. As discussed in chapter 2, subcutaneous hyaluronan-cisplatin 
(HA-Pt) conjugates demonstrated a similar anti-cancer efficacy and survival rate as the 
conventional cisplatin therapy in a murine xenograft model of breast cancer. Based on a study 
conducted at Dr. Cohen’s laboratory, when the HA-Pt conjugates were subcutaneously co-
administered with the hyaluronan-doxorubicin (HA-DOX) conjugates, the anti-cancer 
effectiveness and survival rate were significantly improved compared to the intravenous 
combination therapy of doxorubicin and cisplatin. Efficacy results for breast tumor bearing mice 
treated with HA-conjugated doxorubicin/cisplatin (DOX/CDDP) at 50% MTD include:  
[complete responses (CR)=5, partial responses (PR)=2, and stable disease (SD)=1]. In 
comparison, mice given standard DOX/CDDP (50% MTD) demonstrated:  [progressive disease 
(PD)=6,  SD=1, and PR=1]. The results suggested that subcutaneous nanocarrier-delivery of 
doxorubicin and cisplatin significantly improved efficacy compared to standard agent 
combination therapy. Based on the success of this localized combination therapy, we sought to 
develop combination regimens of cisplatin and nitric oxide-producing prodrugs with the goal of 
improving the cytotoxicity and overcoming the chemoresistance of cisplatin therapy. 
Recent investigations have discovered that nitric oxide (NO) may be involved in the 
reversal of cisplatin resistance in head and neck cancer [5], ovarian cancer [6-7] and lung cancer 
[8], via mechanisms of survivin modulation, depletion of cellular thiols, and inhibition of Bcl-2 
ubiquitination, respectively. Similar re-sensitizing effects of nitric oxide were also reported in the 
reversal of doxorubicin chemo-resistance in human colon cancer [9]. Previously, a series of nitric 
oxide-producing prodrugs were synthesized in the Forrest laboratory. Herein, we sought to 
170 
 
develop combination chemotherapy regimens that utilize nitric oxide donors to regulate the cell 
sensitivity to cisplatin therapy in two cell culture models:   head and neck squamous cell cancer 
cell line MDA-1986 and breast cancer cell line MDA-MB-468LN. 
 
2. Synthesis of sugar star polymer-nitric oxide prodrug conjugates 
A series of nitric oxide-releasing JS-K prodrug analogues (NO1 - NO4, Figure 1A) and a 
4-arm sugar star polymer carrier [4-arm star poly-(1,2:3,4-Di-O-isopropylidene-6-O-
methacryloyl-α-D-galactopyranose), Figure 1B] were previously synthesized in the Forrest 
laboratory. Subsequently, sugar star polymer-nitric oxide prodrug conjugates (Figure 1C and 1D) 
were developed by the formation of an ester bond between the nitric oxide-releasing prodrug and 
sugar star polymer, to deliver gaseous nitric oxide chemotherapy to cancer cells. The synthetic 
steps are presented in the Appendix. 
 
3. In vitro release of nitric oxide 
In order to better simulate in vivo drug release conditions, a series of in vitro nitric oxide 
release studies were carried out in cell culture media (DMEM with 10% bovine serum albumin 
and 1% L-glutamine) with human head and neck cancer cells, MDA-1986. The nitric oxide 
release kinetics were determined in 96-well plates with 3,000 cells per well. The concentration of 
nitrite, the breakdown product of gaseous nitric oxide, was measured using the Griess assay as an 
indirect measurement of the nitric oxide concentration in cell culture media. The assay is based 
on the reaction between sulfanilamide, N-1-napthyethylenediamine dihydrochloride and nitrite,   
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Figure 1. (A) Chemical structures of nitric oxide-releasing prodrugs 1-4 (NO1-NO4); (B) 
synthesis of the sugar star polymers; (C) synthesis of an acid derivative of the sugar star polymer; 
and (D) synthesis of sugar star polymer-nitric oxide prodrug 1 conjugate (sugar-NO1) 
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under acidic conditions to produce a fluorescent azo compound. A nitrite calibration curve was 
generated under the same condition using a series of nitrite solution (0, 1.56, 3.13, 6.25, 12.5, 25, 
50, and 100 µM).  
To determine the nitric oxide release from the prodrugs, MDA-1986 cells were seeded in 
six 96-well plates 24 hours prior to drug treatment (100 µL/well). On the following day, cells 
were treated with either one of the nitric oxide prodrugs (NO1, NO2 or JS-K) or the sugar 
polymer based nitric oxide prodrug conjugate number 1 (sugar-NO1) at three different 
concentrations (0.2, 0.1 and 0.05 mM). Fifty microliters of cell culture media were collected 
from each plate at 10 minutes, 2, 7, 22, 48 and 96 hours, post treatment to determine the nitrite 
content (N=5). The Griess reaction was performed according to the manufacturer’s suggestions. 
The fluorescence intensity was measured between 520 nm and 550 nm using a fluorescence 
microplate reader. Thus, the nitrite concentration and the corresponding nitrite oxide levels were 
determined using the nitrite standard curve previously generated.  
All three nitric oxide prodrugs, NO1, NO2 and JS-K, as well as the sugar-NO1 conjugate, 
released nitric oxide in a sustained, concentration-dependent pattern, generating half lives of 6, 7, 
3, and 10 hours, respectively (Figure 2). The sugar-NO1 exhibited the longest release half-life, 
which was 2.3-fold longer than the standard NO-releasing drug, JS-K. Therefore, if the in vitro 
drug release kinetics correctly represent the in vivo conditions, the sugar-NO1 conjugate may be 
a promising candidate for the controlled release of nitric oxide in tumor-bearing animals. 
 
4. Cytotoxicity of cisplatin-nitric oxide combination chemotherapy 
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Figure 2. In vitro release of nitric oxide from NO1, NO2, JS-K, and sugar-NO1 (0.02 mM 
starting concentration on NO basis). Release studies were performed in DMEM with the 
presence of MDA-1986 cells. Release half lives were determined to be 6, 7, 3, and 10 hours, for 
NO1, NO2, JS-K, and sugar-NO1, respectively. 
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To select a model compound out of the four nitric oxide-releasing prodrugs synthesized 
for further investigation of CDDP/NO combination therapy, the cytotoxicity of these prodrugs 
was determined in the human head and neck cancer cell line MDA-1986 and human breast 
cancer cell line MDA-MB-468LN. Free NO1 and NO2 both had slightly lower in vitro toxicity 
when compared to JS-K in MDA-1986 cells; whereas, they both showed slightly higher in vitro 
toxicity in MDA-MB-468LN cells relative to JS-K (Table 1). In addition, the IC50 of the sugar 
star polymer-based conjugate was determined in the aforementioned cell lines. Even though the 
sugar-NO1 had higher IC50 values than JS-K and unbound NO1, the sustained nitric oxide-
releasing platform may provide modified drug pharmacokinetics in vivo. NO4 had extremely 
high IC50 values; therefore, it was eliminated from the investigation in the remainder of the 
studies.  
A cisplatin-NO combination therapy strategy was designed to further evaluate the in vitro 
toxicity of the chemotherapeutics against human head and neck cancer and breast cancer. Based 
on IC50 measurements, all the combination groups (CDDP + NO prodrug) revealed similar (NO1 
and NO2) or lower (JS-K) toxicity compared to their nitric oxide prodrug counterparts. 
Interestingly, CDDP/NO1 combination ([NO1] = 5% IC50 of NO1) appeared to have an 
equivalent (MDA-1986) or improved (MDA-MB-468LN) efficacy compared to CDDP treatment 
alone. Therefore, we decided to select NO1 as our model nitric oxide-releasing compound to 
further evaluate the optimal dose, treatment schedule, and cytotoxicity of CDDP/NO1 
combination therapy, in comparison to standard cisplatin treatment in a cell culture model. 
 
5. Determination of CDDP and NO1 concentrations for cell assays 
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Treatment/Cell lines IC50: MDA-1986 IC50: MDA-MB-468LN 
CDDP 7.0 µM 17.0 µM 
NO1 32.3 µM 23.6 µM 
Sugar-NO1 86.0 µM 67.0 µM  
NO1 + CDDP (25% × [IC50]) 39.8 µM 27.5 µM 
CDDP + NO1 (5% × [IC50]) 7.0 µM 8.0 µM 
NO2 56.6 µM 26.9 µM 
NO2 + CDDP (25% × [IC50]) 41.7 µM 35.9 µM 
NO3 (JS-K) 15.8 µM 42.1 µM 
NO3 + CDDP (25% × [IC50]) 316.2 µM 203.7 µM 
NO4 2.8 mM 4.4 mM 
NO4 + CDDP (25% × [IC50]) 891 µM 631 µM 
 
Table 1. IC50 values of CDDP, nitric oxide prodrugs (NO1-NO4), and combination treatments 
(NO1&CDDP and NO2&CDDP). Cell viability was determined in MDA-1986 and MDA-MB-
468LN cell lines 72 hours post drug treatment (SD<15%). 
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Three concentrations of CDDP (0.01, 0.04 and 0.1 mM), three concentrations of NO1 
(0.01, 0.03 and 0.1 mM), and two concentrations of sugar-NO1 (0.01 and 0.03 mM) were tested 
to determine the optimal dose ranges of each drug for cell viability assays. The highest 
concentrations of CDDP (0.1 mM) and NO1 (0.04 mM) both caused a large percentage (> 80%) 
of cell death, thus they were eliminated from the remainder of the experiments. The percentage 
of cell death was estimated by visual comparison of the surface area of the cell culture flask that 
was covered with the adherent cells between pre-treatment and post-treatment conditions. Three 
low concentrations of cisplatin, 0.01, 0.02 and 0.03 mM, which induced less than 20% cell death, 
were determined to be the working drug concentrations. Similarly, one relatively low 
concentration of NO1, 0.02 mM, which led to less than 10% death of MDA-1986 cells, was 
selected for further experiments. 
 
6. Evaluation of CDDP/NO1 combination therapy in head and neck cancer cells 
To compare the cytotoxicity of CDDP/NO1 combination therapy to cisplatin treatment 
alone, the post-treatment cell viability was assessed using resazurin assay. Resazurin is a non-
fluorescent molecule that is converted to a highly fluorescent molecule, resorufin, once it is 
reduced in mitochondria, making it an indicator of the metabolic activity of cells (Figure 3). 
MDA-1986 cells were trypsinized and seeded into 96-well plates (10,000 cells/well) 24 hours 
before drug treatment. On day one, NO1 was added (0.02 mM), and on day two, CDDP was 
added (0.01, 0.02 and 0.03 mM). The dosing schedule was based on the study conducted by Fetz 
et al., which investigated the synergistic effect between nitric oxide-producing prodrugs and 
cisplatin [5]. On the third day, resazurin blue in 10 μL of phosphate-buffered saline was added to  
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Figure 3.  Conversion of resazurin to resorufin. 
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each well (final concentration of 5 µM). After 4 hours, the well fluorescence was measured (λex 
560 nm, λem 590 nm) using a fluorescent plate reader (SpectraMax Gemini; Molecular Devices, 
Sunnyvale, CA). The fluorescence intensity was then normalized against the untreated control. 
The results of the resazurin assay indicate that all drug treatments caused reduced 
metabolic activity of the head and neck cancer cells compared to the untreated group (Figure 4). 
The CDDP/NO1 combination treatment resulted in a statistically significant reduction of cellular 
metabolic activity compared to cisplatin treatment alone ([CDDP]=0.02 and 0.03 mM, p<0.05). 
The improved effectiveness of the combination therapy over cisplatin treatment alone could be 
due to one of the two reasons:  first, increased cell death; or second, improved suppression of 
cellular metabolic activity without causing cell death. 
To determine the degree of cell death and understand the reduced metabolic activity 
generated by CDDP/NO1 combination therapy, trypan blue exclusion assay was conducted using 
an equivalent concentration of each drug and an identical dosing schedule as the previous 
resazurin assay (day 1:  NO1 addition; day 2:  CDDP addition; and day 3:  assay). Trypan blue is 
a diazo dye that selectively stains dead cells by passing through the damaged or disrupted 
cellular membrane (Figure 5). Live cells have intact cellular membranes that are impermeable to 
trypan blue. Therefore, live and dead cells can be differentiated under a microscope. The trypan 
blue exclusion assay enables a direct evaluation of cell viability post drug treatment; whereas, 
the resazurin assay mainly measures the mitochondrial metabolic activity of cells. Reduced 
metabolic activity may not be directly correlated with cell death. The results of the trypan blue 
assay demonstrate that the CDDP/NO1 combination treatment caused significantly higher degree 
of cell death compared to cisplatin treatment alone at all concentrations (p<0.05), which is 
consistent with the results of the metabolic assay (Figure 6). 
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Figure 4.  Measurement of metabolic activity in MDA-1986 cells using resazurin assay. 
Treatment groups included untreated control, NO1 alone (0.02 mM), CDDP alone (0.01, 0.02 
and 0.03 mM), and CDDP/NO1 combination treatments ([NO1]=0.02 mM; [CDDP]=0.01, 0.02 
or 0.03 mM). p<0.05 for [CDDP]=0.02 and 0.03 mM (N=4). 
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Figure 5.  Chemical structure of trypan blue. 
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Figure 6.  Determination of post-treatment cell counts using trypan blue exclusion assay. 
Treatment groups included untreated control, NO1 alone (0.02 mM), CDDP alone (0.01, 0.02 
and 0.03 mM), and CDDP/NO1 combination treatments ([NO1]=0.02 mM; [CDDP]=0.01, 0.02 
or 0.03 mM). p<0.05 for all CDDP concentrations (N=4). 
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The findings from the two assays (resazurin and trypan blue) led us to ask our next 
question:  by which mechanism was the cell death caused in the combination therapy? Three of 
the known mechanisms of cell death include:  apoptosis, necrosis and autophagy [10]. Apoptosis, 
also known as type I programmed cell death, is a process in which cells initiate intracellular 
suicide in response to stress, such as cytotoxic drug exposure. Apoptosis results in distinct 
morphological changes of cells including:  cell membrane disruption, nuclear fragmentation and 
chromatin condensation. Unlike apoptotic suicide, necrosis is an “accident”-induced cell death 
pathway, which usually causes inflammatory response of the surrounding cells. The 
morphological changes involved in a necrotic pathway consist of the loss of plasma membrane 
integrity and leakage of cytoplasm [11]. Autophagy is another mechanism of programmed cell 
death (type II), which is characterized by the self-digestion of intracellular components via 
autolysosomal machinery. Autophagy can be induced by nutrient deprivation as well as insult by 
cytotoxic agents [12]. The underlying mechanisms of autophagy pathway are not yet clearly 
understood, but it is believed to be an alternative approach of cell death when apoptotic signaling 
fails. In a review article written by Edinger et al., a series of representative TEM images were 
provided to demonstrate the characteristic changes of cellular morphology during apoptosis-, 
necrosis-, or autophagy-mediated cell death (Figure 7) [10]. 
To decipher the specific mechanisms that contribute to the enhanced cytotoxicity of 
CDDP/NO1 combination therapy, apoptosis-mediated cell death mechanism was first 
investigated by the determination of caspase-3 activity of drug treated cells. Caspase-3 belongs 
to a family of cysteine-requiring aspartate proteases that mediate cell death in the process of 
apoptosis. In vitro caspase-3 activity can be determined using a fluorimetric assay that measures 
the fluorescent moiety 7-amido-4-methylcoumarin (AMC) that is released after the hydrolysis of 
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Figure 7. “Morphological features of autophagic, apoptotic and necrotic cells. (a) Normal, (b) 
autophagic, (c) apoptotic (d) and necrotic cells. Whereas the morphologic features of apoptosis 
are well defined, the distinction between necrotic and autophagic death is less clear. The 
bioenergetic catastrophe that culminates in cellular necrosis also stimulates autophagy as the cell 
tries to correct the decline in ATP levels by catabolizing its constituent molecules. Thus, 
vacuolation of the cytoplasm is observed in both autophagic cells (b) and in cells stimulated to 
undergo programmed necrosis (d). By contrast, ATP levels are maintained in normal (a) and 
apoptotic cells (c) consistent with the limited number of autophagic vacuoles in their cytoplasm. 
The scale bar represents 1 mm.” Reviewed in [10]. 
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a peptide substrate (Ac-DEVD-AMC) by caspase-3 (Figure 8). The excitation and emission 
wavelengths of AMC are 360 nm and 460 nm. To evaluate the combination therapy, first, a 
series of cisplatin and NO1 concentrations were tested in MDA-1986 cells to identify the optimal 
dosing windows for apoptosis induction for each drug. If the drug concentration is too high, it 
may kill the majority of the cells during incubation and before the caspase-3 activity can be 
measured. On the other hand, if the drug concentration is too low, the drug-induced production 
of caspase-3 may not be detectable using the commercially available apoptosis detection kit. 
The apoptosis assay was conducted using an identical dosing schedule as the two 
previous assays (day 1:  NO1 addition; day 2:  CDDP addition; and day 3:  assay). Measurements 
of caspase-3 activity in each treatment group were normalized against the untreated control. The 
results suggest that increasing the CDDP concentration produced elevated caspase-3 activity in 
MDA-1986 cells (Figure 9). In contrast, treatment with NO1 alone did not induce any 
statistically marked increase in caspase-3 activity. Since the NO1 concentrations employed were 
verified to cause cell death, this indicates that NO1 may trigger cell death through a mechanism 
other than apoptosis. In addition, all combination treatment groups demonstrated increased levels 
of caspase-3 activity with elevated CDDP concentrations. However, the degree of caspase-3 
activity generated in cells that were treated with the CDDP/NO1 combination was similar or 
even lower than cisplatin treatment alone. In other words, the presence of nitric oxide did not 
seem to accelerate the apoptotic process of MDA-1986 cells in the timeframe of the experiment. 
If a comparison is made between cisplatin treatment alone (i.e. [CDDP]=0.03 mM) and 
cisplatin/NO1 combination treatment (i.e. [NO1]=0.02 mM; and [CDDP]=0.03 mM), a reduction 
of caspase-3 activity was observed for the combination group. It is likely that the combination 
therapy caused an increase in cell death; therefore, a lower number of apoptotic cells are present  
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Figure 8. Hydrolysis reaction of the peptide substrate by caspase-3, producing a fluorescent 
molecule, AMC. 
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Figure 9.  Measurement of caspase-3 activity in MDA-1986 cells. Treatment groups included 
untreated control, NO1 alone (0.02 mM), CDDP alone (0.01, 0.02 and 0.03 mM), and 
CDDP/NO1 combination treatments ([NO1]=0.02 mM; [CDDP]=0.01, 0.02 or 0.03 mM). 
p<0.05 for [CDDP]=0.03 mM (N=4). 
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that are able to produce caspase-3.  
In conclusion, NO1, a new nitric oxide-producing prodrug, demonstrated similar anti-
proliferative activity as the standard JS-K against HNSCC cells. The NO1/CDDP combination 
therapy exhibited enhanced cytotoxicity compared to cisplatin treatment alone in vitro ([NO1] 
=0.02 mM). The improved effectiveness of combination treatment was independent of cisplatin 
concentration; whereas, it was noted that the concentration of NO1 played a role in increasing 
the anti-cancer activity of the combination therapy. Namely, combination therapy with a high 
NO1 concentration (0.02 mM) resulted in enhanced cytotoxicity against HNSCC cell; in contrast, 
combination therapy with lower NO1 concentrations (0.002 and 0.005 mM) did not exert a toxic 
effect. This is consistent with the results from a study conducted by Fetz et al., in which the 
authors investigated CDDP/NO combination therapy using two nitric oxide-releasing prodrugs, 
SNAP and SNP [5]. They demonstrated the upregulation of survivin expression in HNSCC cells 
treated with a low concentration of the NO-donors. Because survivin expression is known to be 
associated with chemoresistance, this may provide an explanation to the lack of efficacy of the 
combination therapy. In addition, they reported forced overexpression of inducible NO synthase 
in HNSCC cells that were treated with a high concentration of the NO-donors, which triggered 
cell death and ultimately led to enhanced cytotoxicity of the combination therapy. 
The effectiveness of CDDP/NO1 combination therapy may be further improved by 
incorporating the carrier-based sugar-NO1 conjugate in our future studies. Sugar-NO1 and NO1 
demonstrated NO in vitro release half lives of 10 and 6 hours, respectively. According to a study 
conducted by Azizzadeh et al., NO-producing prodrugs with a longer release half life may be 
more potent inhibitors of DNA synthesis and mitotic activity in the S-phase compared to short-
lived NO-prodrugs [13]. With carrier-based NO1 and cisplatin conjugates (sugar-NO1/HA-Pt), 
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we could achieve locoregional delivery of highly concentrated CDDP/NO combinational agents, 
further improving the efficacy of HA-Pt therapy in HNSCC xenograft model by incorporating 
the additional benefits of NO-prodrugs. 
A number of studies reported that JS-K activated apoptotic signaling via a caspase-
dependent pattern in cancer cells [14-15]. However, based on our preliminary studies, NO1 
triggered cell death via a non-apoptotic pathway, because the caspase-3 activity of NO1-treated 
cells was shown to be similar to the untreated cells. Additionally, the caspase-3 activity after 
combination treatment even demonstrated a marked reduction relative to the cisplatin alone. In a 
recent study conducted by McMurtry et al., autophagic cell death was reported in breast cancer 
cells treated with JS-K [16]. The TEM images of JS-K treated cells revealed characteristic 
changes of cell morphology such as the formation of vesicle organelles suggesting the 
occurrence of autophagic cell death. To determine the mechanism of CDDP/NO-induced cell 
death, future studies will examine alternative mechanisms such as necrosis and autophagy.  
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1. Introduction 
The mechanism of how cisplatin enters cancer cells is poorly defined. The two most 
common interpretations include passive diffusion [1-2] and carrier-mediated transport [3-5], both 
of which act via a transcellular route. The passive diffusion mechanism of cisplatin 
internalization is based on the evidence that the cellular accumulation of cisplatin is proportional 
to the drug concentration. It is driven by a concentration gradient, following Fick’s Law. In 
addition, cellular accumulation of cisplatin was determined to be unsaturable, thus supporting the 
passive diffusion pathway. However, recent observations revealed that cisplatin may enter cells 
through an ion channel, supporting the carrier-mediated pathway. One of the possible 
transporters involved in cisplatin influx is believed to be the human copper transporter 1, which 
is the primary transporter responsible for the internalization of copper and silver [6]. Once 
cisplatin gains access into the cells, the intracellular disposition has not been fully described. 
Studies have shown that besides plasma membrane, cisplatin is present in the cytoplasm and 
nuclear matrices [2]. 
Our previous findings suggested that the hyaluronic acid-cisplatin (HA-Pt) conjugate had 
improved in vivo efficacy in head and neck cancer compared to the free cisplatin. In order to 
understand the enhanced anti-proliferative activity, herein we would like to examine the cellular 
localization and the mechanism of internalization of polymer-based cisplatin conjugates. By 
labeling HA with a very small gold nanoparticle, both the carrier and the drug may be detected 
using transmission electron microscopy, as both gold and platinum are electron-dense elements. 
In addition, a similar approach will be taken to evaluate the internalization and localization of 
hyaluronic acid-doxorubicin (HA-DOX) conjugates using a far-red dye tagged HA polymer. 
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2. Determination of  hyaluronic acid-cisplatin cellular internalization using TEM 
 
2.1 Sample preparation for TEM 
A solution of cisplatin (CDDP) or hyaluronic acid-cisplatin (HA-Pt) conjugate was 
prepared prior to TEM viewing, with a concentration of approximately 1 mg/mL on a platinum 
basis. Ten microliters of the solution was coated onto the surface of a lacey carbon coated nickel 
TEM grid. Representative TEM images showed 5-nm cisplatin particles (Figure 1A), which were 
precipitated from 1 mg/mL cisplatin solution during drying, and 25-nm platinum-based HA-Pt 
conjugates (Figure 1B). Bound platinum on the side chains of HA formed hydrophobic regions 
during dehydration, leading to the formation of platinum clusters. 
 
2.2 In vitro localization of cisplatin 
MDA-1986 cells were seeded in 75 cm
2
 cell culture flasks. Cisplatin treatment (0.1 mM) 
was added once the cells became adherent. Twenty-four or forty-eight hours post treatment, cells 
were harvested and fixed to make TEM cell pellets. Typically, cell culture fluid was removed 
from the flask and PBS was added and incubated for 3 minutes at room temperature. Once the 
PBS was removed, 2% gluteraldehyde in 0.1 M sodium cacodylate (pH 7.4) was added into the 
cell culture flask. After incubating the cells in the fixative for 15 minutes, the cells were scraped 
from the surface of the flask into a centrifuge tube. Subsequently, the cell suspension was 
centrifuged at 500 rpm for 5 minutes. The cell pellets were then rinsed in twice with 0.1 M 
sodium cacodylate buffer at pH 7.4 to remove the excess glutaraldehyde.  
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Figure 1.  TEM images of (A) 5-nm cisplatin particles (precipitated during drying), and (B) 25-
nm HA-Pt clusters. 
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Cells were post-fixed in 1% osmium tetroxide and 0.3% potassium ferricynide buffered 
in 0.1 M sodium cacodylate (pH 7.4) for one hour in a fume hood. Pellets were then rinsed three 
times with de-ionized distilled water. After rinsing, the pellets were dehydrated in a series of 
ethanol, as follows:  30%, 70%, 80%, 95%, 100% and 100%, for 10 minutes each step. 
Subsequently, pellets were placed in propylene oxide for 10 minutes in a fume hood and then 
were infiltrated overnight in a 50% propylene oxide and 50% Embed 812 resin medium mixture 
(5 mL of Embed 812, 4 mL of DDSA, 2 mL of NMA and 190 µL of DMP-30, purchased from 
Electron Microscopy Sciences, Hatfield, PA). The next day, cell pellets were placed into fresh 
100% Embed 812 resin mixture for 30 minutes. The resin containing the cells was placed into 
tube with cells and placed into a 60 °C oven overnight to polymerize. The next day, the cell 
pellets were removed and oriented in a flat embedding mold, the mold was placed in a 60 °C 
oven overnight.  
Samples were sectioned with a diamond knife (Leica Ultrtome) into 80-90 nm sections. 
The sections were then contrasted with 3% uranyl acetate for 15 minutes and rinsed, followed by 
Sato’s modified lead citrate solution for 3 minutes. Finally, the sections were rinsed with water 
five times (one minute each time) and air dried for viewing by TEM. 
Figure 2 is a representative TEM image of an untreated MDA-1986 cell. Cellular 
organelles were permanently fixed and darkly stained. The cell exhibited an intact cellular 
membrane, nucleus, mitochondria, vesicles, Golgi apparatus and endoplasmic reticulum (Figure 
2). The dark wavy lines were caused by the wrinkling of the embedding material during drying. 
It was noted that the cellular compartments of untreated, healthy cells were evenly stained, thus, 
no enhanced contrast was observed. 
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Figure 2.  A representative TEM image of an untreated MDA-1986 cell. 
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Figure 3 shows a group of TEM images of cisplatin treated MDA-1986 cells. The cells 
were incubated in the presence of 1-µg/mL cisplatin for 48 hours before fixation. Cellular 
organelles such as mitochondria, Golgi apparatus, and vesicles, were clearly stained. Particulate-
like enhancement was detected on the surface of the plasma membrane, in the cytoplasm, and 
surrounding vesicles [2], presumably because the electron-dense platinum was localized in these 
organelles. Interestingly, dark staining was also observed in the mitochondria, which is 
consistent with a number of recent discoveries of cisplatin mitochondria toxicity in head and 
neck cancer cells [7]. Future work will further explore the localization and mechanism of 
internalization of cisplatin and carrier-based cisplatin conjugates in cancer cells. 
 
2.3 In vivo localization of HA-Pt conjugates  
A mouse was inoculated with MDA-1986 cells to induce squamous cell carcinoma of the 
head and neck. HA-Pt was administered as a subcutaneous injection peritumorally with a dosage 
of 3.5 mg/kg. Twenty-four hours post dosing, the animal was euthanized by isoflurane overdose. 
The cervical lymph nodes draining the injection site were collected, fixed in formalin, and 
embedded in paraffin. Subsequently, the embedded lymph node tissues were sectioned into 4-µm 
sections using an ultratome and imaged with TEM. Platinum accumulation was detected in 
lymph node tissues, indicated by the red arrows highlighting the signal enhancement (Figure 4). 
Small particulates were in the size range of 100-200 nm; whereas, larger aggregates measured 
approximately 400-500 nm in size. The presence of platinum in HA-Pt treated tissue was verified 
by comparing it with tissue from an untreated animal using an energy dispersive x-ray detector 
(Figure 5). The results indicated that the conjugate drained and was retained in the surrounding  
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Figure 3.  Representative TEM images of CDDP treated MDA-1986 cells. 
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Figure 4. TEM image showing platinum accumulation in the cervical lymph node tissues of a 
HNSCC bearing mouse post s.c. injection of HA-Pt (3.5 mg/kg). 
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Figure 5.  Elemental spectra of (A) untreated and (B) HA-Pt treated lymph node tissues of nude 
mice, generated by an energy dispersive x-ray detector. 
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lymphatics within 24 hours after subcutaneous injection. However, without organelle specific 
staining, the cellular localization of the conjugate remains unknown and is worth further 
investigation. 
 
2.4 Synthesis of gold tagged HA-Pt conjugates 
Colloidal gold nanoparticles were synthesized by quickly adding solution B (50-60 °C), 
which contained 4 mL of 1% w/v trisodium citrate·2H2O, 5 mL of 1% w/w tannic acid, 5 mL of 
25 mM K2CO3, and 6 mL of water, into solution A (60 °C), which contained 79 mL of water and 
1 mL of 1% HAuCl4, with continuous stirring. Addition must be rapid in order to form colloid 
nanoparticles with uniform size. The solution mixture was stirred rapidly, heated to a simmer, 
and then allowed to react until the color of the solution turned brown. Once the color change was 
complete, the solution was heated to a full boil and then allowed to cool to room temperature. 
Subsequently, a small amount of H2O2 was added into the colloidal gold solution to a final 
concentration of 0.1%. The solution was covered and stored at 4 °C until further use. Two 
representative TEM images of 3-nm gold colloidal nanoparticles are shown in Figure 6; the scale 
markers are 100 nm and 20 nm, respectively. An X-ray backscattering map was generated with 
an energy dispersive x-ray detector (Figure 7). 
HA-ADH was synthesized as previously described (chapter 3.2). 2,5-dioxopyrrolidin-1-yl 
5-(1,2-dithiolan-3-yl)pentanoate was then conjugated to HA-ADH in a H2O/THF mixture (1:2) 
with 5% TEA (Figure 8). The reaction was allowed to proceed for 48 hours. The resulting HA-
thioctic ester was purified via dialysis for 24 hours and lyophilized overnight. The next day equal  
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Figure 6.  TEM images of 3-nm colloidal gold nanoparticles on a copper mesh TEM grid. 
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Figure 7.  Elemental spectrum of 3-nm colloid gold nanoparticles. 
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Figure 8.  Synthetic scheme of gold tagged HA-Pt. 
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volumes of HA-thioctic ester solution in 20 mM HEPES at pH 7.4, and the colloidal gold 
solution were mixed, covered and stirred at room temperature for 24 hours. Finally, the resulting 
HA-Au conjugate was centrifuged to remove aggregates, dialyzed against water for 24 hours and 
lyophilized to obtain the gold tagged HA conjugate. Subsequently, cisplatin was attached to the 
carboxylic acid groups of HA, as described in chapter 2.2, leading to the formation of gold 
labeled HA-Pt.  
The substitution degree of the cisplatin and gold was determined by atomic absorption 
spectroscopy and UV-Vis spectroscopy, respectively. No apparent peak shifts were observed on 
the UV spectrum of gold tagged HA compared to HA. This is likely due to the limited binding 
efficiency between the gold nanoparticles and the thiol moieties of the linker, leading to a very 
low conjugation degree. Thus the gold concentration could not be determined by UV-Vis 
spectroscopy. Future work will focus on the selection of gold binding linkers to produce stable 
gold tagged HA-Pt conjugates with an optimized loading degree of both the drug and the gold 
label. Further, the selection of heavy-metal staining and contrasting agents will be optimized. 
The metals used in this study include osmium, lead and uranium, all of which have similar 
electron densities as the targeted platinum and gold. They are very likely to cause signal 
overlapping under TEM, making identity assignment difficult. Hence, contrasting agents such as 
molybdenum derived materials will be investigated in future studies. 
 
3. Determination of hyaluronic acid-doxorubicin cellular internalization using 
fluorescent microscopy 
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3.1 Synthesis of IR820 tagged hyaluronic acid-doxorubicin conjugates 
Near-IR dye molecules, including IR820 (Figure 9A), have been used in our laboratory as 
a fluorescent tag of a variety of nanocarriers for in vivo whole body imaging as they produce 
minimum background fluorescence, facilitating spectra deconvolution in data analysis. 
Doxorubicin was conjugated to HA-IR820 (Figure 9B) via a dihydrazine linker. The synthesis 
was described in the “Synthesis and characterization of hyaluronan-doxorubicin (HA-DOX) 
conjugates” section in chapter 3. The resulting IR820 labeled HA-DOX conjugate (IR820-HA-
DOX) had approximately 1% (wt/wt) of each of the two fluorophores (IR820, DOX). A 
minimum amount of DOX/IR820 substitution is desired because high degree of conjugation may 
yield more hydrophobic HA conjugates that could affect the cellular internalization of the drug 
as well as the carrier.  
 
3.2  Cellular uptake of IR820 labeled hyaluronic acid-doxorubicin (IR820-HA-DOX) 
A human head and neck squamous cell carcinoma cell line, MDA-1986, was employed to 
evaluate the internalization and cellular distribution of the drug bound vehicles (HA-DOX), by 
incorporating a fluorescent tag, IR820, to determine the cellular trafficking of the carrier as free 
HA cannot be detected by fluorescence microscopy. First, cells were treated with a series of 
concentrations of unbound doxorubicin (final concentration of 0.5, 1 and 5 µg/mL) and HA-
IR820 (final concentration of 0.5, 1 and 1.7 µg/mL on IR820 basis) for 6 hours as control groups 
to determine the optimal working concentrations. Post treatment, cells were rinsed with PBS and 
imaged by fluorescence microscopy using the Texas red (DOX) and Cy5 (HA-IR820) filter sets. 
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Figure 9. Chemical structures of (A) IR820 and (B) HA-IR820. 
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Doxorubicin has an excitation and an emission wavelength of 480 nm and 590 nm, 
respectively. IR820 is a laser dye, and HA-IR820 has an excitation and an emission wavelength 
of 675 nm and 730 nm, respectively. Thus, the fluorescent signals of doxorubicin and IR820 
could be captured simultaneously using Texas red and Cy5 filter sets, respectively. In Figure 10, 
the cellular internalization of both doxorubicin (Images A, B and C) and HA-IR820 (Images D, 
E and F) are shown at three different concentrations. The intensity of the fluorescent signal was 
proportional to the concentration. Because the highest concentrations of doxorubicin (5 µg/mL) 
and IR820 (1.7 µg/mL) appeared to saturate the images, they were eliminated from further 
experiments. In addition, MDA-1986 cells are sensitive to doxorubicin treatment, thus prolonged 
exposure or elevated concentrations may lead to cell death, which is undesirable in this study. In 
order to minimize doxorubicin-induced cytotoxicity, which may alter the morphology of cells, 
MDA-1986 cells were only exposed to doxorubicin or IR820 labeled HA-DOX for one hour 
prior to imaging for the rest of the experiments. 
In the non-overlaid fluorescent images, it was noticed that after entering the cell, 
doxorubicin was mainly localized in the nucleus with a smaller amount of drug remaining in the 
cytoplasm (Figure 11); whereas HA-IR820 had a greater cytoplasmic distribution compared to its 
nuclear accumulation (Figure 12). In addition, as a control, cells were treated with HA-DOX to 
demonstrate that HA-DOX can enter cells, before the experiments using IR820-HA-DOX were 
conducted (Figure 13). Similar to the free doxorubicin, cleaved doxorubicin (from the carriers) 
was mainly localized within the nucleus. Because large polymer conjugates, such as 35 kDa HA- 
DOX, may not be able to enter the nucleus, this suggests the cleaved doxorubicin was 
internalized into the nucleus. Therefore, it is possible that the conjugates release the free drug, 
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Figure 10. Uptake of doxorubicin (captured using a Texas red filter set; A: 0.5 µg/mL, B: 1 
µg/mL, C: 5 µg/mL) and HA-IR820 (captured using a Cy5 filter set; D: 0.5 µg/mL, E: 1 µg/mL, 
F: 1.7 µg/mL) into MDA-1986 cells. 
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Figure 11. Cellular internalization of doxorubicin (A:  overlaid cellular phase contrast/DOX 
fluorescent images, B:  non-overlaid fluorescent DOX image). MDA-1986 cells were treated 
with a final concentration of 100 ng/mL doxorubicin for an hour prior to imaging. The 
representative images were taken using a Texas red filter set. The red color indicates the 
internalization of doxorubicin. 
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Figure 12. Cellular internalization of HA-IR820 (A:  overlaid cellular phase contrast/HA-IR820 
fluorescent images, B:  non-overlaid HA-IR820 fluorescent image). MDA-1986 cells were 
treated with a final concentration of 100 ng/mL IR820 for an hour prior to imaging. The 
representative images were taken using a Cy5 filter set. The red color indicates the 
internalization of HA-IR820. 
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Figure 13. Cellular internalization of HA-DOX (A:  overlaid cellular phase contract/HA-DOX 
fluorescent images, B:  non-overlaid HA-DOX fluorescent image). MDA-1986 cells were treated 
with a final concentration of 100 ng/mL doxorubicin for an hour prior to imaging. The 
representative image was taken using a Texas red filter set. The red color indicates the 
internalization of HA-DOX. 
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and then the free drug enters the cells via mechanisms, such as, passive diffusion or active uptake. 
The other possibility is that the conjugates are internalized via receptor-mediated endocytosis (i.g. 
CD44, the primary receptor of HA), followed by the intracellular drug release, and the further 
nuclear uptake.  
In order to simultaneously examine the cellular trafficking of the carrier and the drug, 
cells were treated with IR820 tagged HA-DOX prior to imaging. Unfortunately, due to the 
instability of the doubly labeled conjugate (IR820-HA-DOX), no fluorescent signal of IR820 
was detected in cells, suggesting the degradation of the dye or the complex releases the dye from 
the carriers during the process of conjugating DOX onto HA-IR820 (Figure 14). This assumption 
led to the evaluation of the release kinetics of IR820 from HA. In order to determine its release 
half life, HA-IR820 solution was placed in dialysis tubing in a PBS bath at 37 °C. Aliquots of 
HA-IR820 solution were collected at 0, 1, 2, 4, 6, 24 and 30 hours, and the amount of IR820 was 
determined using a spectrophotometer. The release half-life was calculated to be approximately 
18 hours (Figure 15). Because the time frame for conjugation of doxorubicin onto HA-IR820 and 
the subsequent dialysis lasted one to two days, it was not surprising that the majority of the dye 
may have been degraded or cleaved from the carriers, before the cell assay was conducted.  
In future studies, three alternative approaches may be investigated. First, the order of the 
two conjugation reactions could be altered, which means a HA-DOX conjugate would be 
synthesized, followed by the conjugation of IR820. This approach may solve the previous issue 
because HA-DOX was determined to be more stable than HA-IR820 indicated by their release 
half lives (HA-IR820: t1/2=18 hours, HA-DOX: t1/2=172 hours). The second approach is to select 
a more stable dye with excitation and emission wavelengths differentiable from doxorubicin  
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Figure 14. Cellular internalization of IR820 labeled HA-DOX conjugate (A:  Texas red channel 
showing cellular internalization of doxorubicin, B:  Cy5 channel showing cellular internalization 
of HA-IR820). MDA-1986 cells were treated with IR820 tagged HA-DOX for an hour prior to 
imaging. The red color in image A indicates the internalization of doxorubicin. No IR820 signal 
was detected in the Cy5 channel in image B, suggesting the degradation or release of the dye. 
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Figure 15. Release of IR820 from the carrier HA. The release study was conducted in PBS at 
37 °C. The concentration of IR820 was determined using a spectrophotometer. 
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under a fluorescent microscope, preventing early degradation of the dye molecule. Another 
alternative method is to replace the current linker (Figure 16A) with a molecule that has two 
primary amines at both ends (Figure 16B), thus maximizing the release half life of the dye and 
improving the stability of the conjugates. 
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Figure 16. Chemical structures of A) the linker used in HA-IR820 conjugation reaction, B) 
modified linker for future study. 
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1. Development of combination therapy 
Our preliminary results of CDDP/NO1 combination chemotherapy demonstrated 
improved anti-proliferative activity against human head and neck cancer cells and human breast 
cancer cells. Therefore, further evaluation of a series of dose regimens will be conducted to 
identify the most efficacious drug combination and treatment schedule for each cancer cell line 
of interest. These cell lines include, but are not limited to the human head and neck squamous 
cell cancer cell line MDA-1986 (CDDP sensitive and CDDP resistant), human breast cancer cell 
lines MDA-MB-468LN, MDA-MB-231 and MCF-7, as well as human melanoma cell line A375.  
To understand nitric oxide-induced mechanism of cell death, the apoptotic status of 
CDDP/NO1 treated cells were tested. The results suggest that the additive cytotoxicity of the 
combination treatment was not mediated via an apoptotic pathway. Therefore, future studies will 
investigate alternative cell death mechanisms such as necrosis and autophagy using lactate 
dehydrogenase release assay and Cyto-ID
TM
 autophagy detection kit, respectively; to determine 
the primary pathway of drug-induced cell death. 
In addition, carrier-based nitric oxide prodrugs including sugar-NO1 will be tested in 
combination with cisplatin, to determine the efficacy of the controlled-release drug delivery 
platform in vitro and to determine the most responsive cancer type to this treatment. 
Subsequently, a corresponding xenograft model will be utilized to examine the in vivo toxicity 
and efficacy of the most promising combination regimen. If both equivalent or reduced toxicity 
and improved in vivo efficacy are observed post combination treatment, the concept will be 
adapted to other treatment regimens such as doxorubicin/NO-prodrugs. 
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2. In vivo evaluation of sugar star polymer-based NO prodrugs: pharmacokinetics, 
toxicity and anti-cancer efficacy 
A series of star polymer-nitric oxide prodrug conjugates have been synthesized and 
characterized in our laboratory. In our preliminary studies, I have determined the in vitro release 
kinetics and toxicity of the formulations. In an on-going anti-cancer efficacy study, a sugar star 
polymer-NO1 conjugate was administered as a weekly subcutaneous injection in HNSCC 
bearing nude mice. The conjugate demonstrated 100% tumor inhibition effectivity, leading to a 
complete cure and prolonged survival of the animals (Figure 1). The next step of this study is to 
examine the pharmacokinetics, bio-distribution, and drug-induced toxicity, of the conjugates in 
Sprague-Dawley rats, and the anti-tumor activity and survival rate in tumor-bearing mice.  
 
3. Determination of the cellular distribution of gold tagged HA-Pt and Cy7 tagged HA-
DOX conjugates 
In order to determine the tumor cell distribution of the carried-based chemotherapy, I 
synthesized a gold-tagged HA-CDDP conjugate via a disulfide bond between the 3-nm gold 
nanoparticle and the carrier HA. Transmission electron microscopy (TEM) will be used to 
determine the co-localization of the gold-tagged carrier as well as the platinum-based anticancer 
drug. In my initial studies, I characterized the conjugate using atomic absorption spectroscopy 
and UV-visible spectroscopy. Subsequently, the sample preparation procedures were optimized 
by examining a variety of drug concentrations, treatment durations, and staining/contrasting 
agents, in MDA-1986 cells. Finally, the TEM operation conditions were also optimized using 
TEM grids made of different materials, to minimize the background interference with the target  
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Figure 1. Locoregional chemotherapy with star polymer nanoparticles releasing NO (NP-star-
NO) were highly efficacious, increasing mean survival by >10 weeks in xenografts of HNSCC. 
Dosing was 10 mg/kg NO-prodrug. 
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metals (Au and Pt). Future work will be conducted to determine the compartment-specific 
cellular localization and distribution of the polymer backbone and the cleaved active drug. Based 
on the information collected, we will be able to answer the questions:  has the drug been released 
from the carrier before it enters the cell and are the carriers incorporated into the cell via 
endocytosis? 
An alternative approach to investigate the cellular distribution of the carrier-based 
chemotherapy is to use fluorescently labeled HA-DOX. Because of the distinct fluorescence 
spectra of the Cy7 fluorophore and doxorubicin, the signals can be separated and analyzed using 
fluorescence microscopy. Further, Cy 7 is a more stable fluorescent dye than IR820 for the use in 
fluorescence microscopy. Therefore, the same goal may be accomplished and the questions of 
interest can be answered. 
 
 
 
 
 
 
 
 
 
 
Appendix 
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1. Synthetic schemes of a sugar star polymer and nitric oxide prodrugs 
1.1. Synthetic scheme of a sugar star polymer 
 
 
 
 
 
 
Scheme 1.  Synthesis of MADIX/RAFT agents 
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Scheme 2. Synthesis of 1,2;3,4-Di-O-isopropylidene-6-O-acryloyl-α-D-galactopyranose 
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Scheme 3. Synthesis of a sugar star polymer 
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1.2. Synthetic scheme of nitric oxide prodrugs 
 
 
 
 
 
 
 
Scheme 4. Synthesis of JS-K 
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Scheme 5. Synthesis of JS-K analogues 
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2. Release of nitric oxide from JS-K, JS-K analogues and carrier-based prodrugs 
 
A. 
 
B. 
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C. 
 
D. 
 
Figure 1. In vitro release of nitric oxide from (A) NO1, (B) NO2, (C) JS-K, and (D) sugar-NO1. 
Release studies were performed in DMEM with the presence of MDA-1986 cells. Release half 
lives were determined to be 6, 7, 3, and 10 hours, for NO1, NO2, JS-K and sugar-NO1, 
respectively. 
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3. Dosing schedule and results of caspase-3, resazurin and trypan blue assays in MDA-
1986 cells 
 
Experiment # Cell line Cells/well Dose on day 1 Dose on day 2 
1 MDA-1986 10,000 NO1 NO1+CDDP 
2 MDA-1986 10,000 NO1 CDDP 
3 MDA-1986 10,000 CDDP NO1+CDDP 
4 MDA-1986 10,000 CDDP NO1 
5 MDA-MB-468LN 5,000 NO1 NO1+CDDP 
6 MDA-MB-468LN 5,000 NO1 CDDP 
7 HUVEC 3,000 NO1 NO1+CDDP 
8 HUVEC 3,000 NO1 CDDP 
 
Table 1. Dose regimens of single drug treatment and combination therapy in three cell lines. 
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Figure 2. Measurement of caspase-3 activity in MDA-1986 cells (experiment #1). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 3. Measurement of caspase-3 activity in MDA-1986 cells (experiment #2). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 4. Measurement of caspase-3 activity in MDA-1986 cells (experiment #3). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 5. Measurement of caspase-3 activity in MDA-1986 cells (experiment #4). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 6.  Measurement of metabolic activity in MDA-1986 cells (experiment #1). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p<0.001 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p<0.05 for 0.02 
mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p<0.05 for 0.01 mM CDDP vs. 0.01 mM 
CDDP+0.02 mM NO1 (N=5). 
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Figure 7.  Measurement of metabolic activity in MDA-1986 cells (experiment #2). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p=0.26 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p=0.19 for 0.02 
mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.015 for 0.01 mM CDDP vs. 0.01 mM 
CDDP+0.02 mM NO1 (N=5). 
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Figure 8.  Measurement of metabolic activity in MDA-1986 cells (experiment #3). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p=0.0006 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p<0.0001 for 
0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.005 for 0.01 mM CDDP vs. 0.01 mM 
CDDP+0.02 mM NO1 (N=5). 
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Figure 9.  Measurement of metabolic activity in MDA-1986 cells (experiment #4). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p<0.0001 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p=0.0029 for 
0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.0026 for 0.01 mM CDDP vs. 0.01 
mM CDDP+0.02 mM NO1 (N=5). 
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A. 
 
B. 
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Figure 10.  Determination of live cell ratio in MDA-1986 cells (experiment #1, 2 trials (1
st
 trial: 
(A), 2
nd
 trial: (B)). Treatment groups included untreated control, DMSO control, CDDP, NO1, 
and a variety of combination treatments. p=0.053 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 
mM NO1, p=0.0005 for 0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.068 for 0.01 
mM CDDP vs. 0.01 mM CDDP+0.02 mM NO1 (N=4). 
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4. Results of caspase-3, resazurin and trypan blue assays in MDA-MB-468LN cells 
 
 
 
 
 
Figure 11. Measurement of caspase-3 activity in MDA-MB-468LN cells (experiment #5). 
Treatment groups included untreated control, DMSO control, CDDP, NO1, and a variety of 
combination treatments (N=5). 
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Figure 12. Measurement of caspase-3 activity in MDA-MB-468LN cells (experiment #6). 
Treatment groups included untreated control, DMSO control, CDDP, NO1, and a variety of 
combination treatments (N=5). 
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Figure 13.  Measurement of metabolic activity in MDA-MB-468LN cells (experiment #5). 
Treatment groups included untreated control, DMSO control, CDDP, NO1, and a variety of 
combination treatments. p=0.0026 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, 
p=0.0043 for 0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.0004 for 0.01 mM 
CDDP vs. 0.01 mM CDDP+0.02 mM NO1 (N=5). 
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Figure 14.  Measurement of metabolic activity in MDA-MB-468LN cells (experiment #6). 
Treatment groups included untreated control, DMSO control, CDDP, NO1, and a variety of 
combination treatments. p<0.0001 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, 
p=0.0002 for 0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.0004 for 0.01 mM 
CDDP vs. 0.01 mM CDDP+0.02 mM NO1 (N=5). 
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Figure 15.  Determination of live cell ratio in MDA-MB-468LN cells (experiment #5). 
Treatment groups included untreated control, DMSO control, CDDP, NO1, and a variety of 
combination treatments. p=0.0003 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, 
p<0.0001 for 0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.0003 for 0.01 mM 
CDDP vs. 0.01 mM CDDP+0.02 mM NO1 (N=4). 
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5. Results of caspase-3, resazurin and trypan blue assays in HUVEC cells 
 
 
 
 
 
Figure 16. Measurement of caspase-3 activity in HUVEC cells (experiment #7). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 17. Measurement of caspase-3 activity in HUVEC cells (experiment #8). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments (N=5). 
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Figure 18.  Measurement of metabolic activity in HUVEC cells (experiment #7). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p=0.0028 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p<0.0001 for 
0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p<0.0001 for 0.01 mM CDDP vs. 0.01 
mM CDDP+0.02 mM NO1 (N=5). 
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Figure 19.  Measurement of metabolic activity in HUVEC cells (experiment #8). Treatment 
groups included untreated control, DMSO control, CDDP, NO1, and a variety of combination 
treatments. p<0.0001 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p<0.0001 for 
0.02 mM CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.0008 for 0.01 mM CDDP vs. 0.01 
mM CDDP+0.02 mM NO1 (N=5). 
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Figure 20.  Determination of live cell ratio in HUVEC cells (experiment #7). Treatment groups 
included untreated control, DMSO control, CDDP, NO1, and a variety of combination treatments. 
p=0.0003 for 0.03 mM CDDP vs. 0.03 mM CDDP+0.02 mM NO1, p=0.0039 for 0.02 mM 
CDDP vs. 0.02 mM CDDP+0.02 mM NO1, p=0.003 for 0.01 mM CDDP vs. 0.01 mM 
CDDP+0.02 mM NO1 (N=4). 
 
